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Abstract 
 
PP2A (protein serine/threonine phosphatase 2A), a conserved protein found in 
different species, was involved in various cellular processes including cell cycle, 
signal transduction, DNA  replication, transcription, protein synthesis and 
apoptosis. Deregulation of PP2A methylation is linked to Alzheimer's disease 
and increased susceptibility to pathogen infection. PP2A was identified as to be 
an important tumour suppressor protein and hence a potential target for cancer 
therapeutic strategies. PP2A comprises a core structure of a 65 kDa scaffolding 
subunit A (PP2AA) and a 36 kDa catalytic subunit C (PP2AC), which associates 
with a variable regulatory subunit B to form a heterotrimeric holoenzyme. 
Different heterotrimeric compositions influence the enzyme's cellular location 
and substrate specificity. 
 
Leucine carboxyl methyltransferase 1 (LCMT1) and protein phosphatase 
methylesterase 1 (PME1) are involved in PP2A's methylation and 
de-methylation respectively. Recent research has demonstrated that 
methylation of PP2A subunit C at the carboxyl-terminus, residue Leu309, by 
LCMT1 is related to the selection of the regulatory subunit to form a triple 
complex with the PP2A AC core enzyme (PP2AD). In contrast, PME1 is thought 
to associate with and stabilize the inactivated form of PP2A complex.  
 
The crystallographic structure of PME1-PP2A complex was solved in 2008 and 
was suggested that PME1 only associates with the catalytic subunit of PP2A; 
however, both PME1 and PP2A scaffolding subunit are not native form. In this 
~  ~ 
 
3 
study, we used isothermal titration calorimetry (ITC) and surface plasmon 
resonance (SPR) methods to verify the association of PME1 and PP2AA and 
measured thermodynamic parameters of PME1-PP2AA interaction.  
 
Finally, we have solved an X-ray crystal structure of human LCMT1 protein in 
complex with the co-factor S-adenosylmethionine (AdoMet) to resolution of 2 Å.   
The structure enables us to postulate a mode of interaction with protein 
phosphatase PP2A and it provides a platform for further functional studies of 
the methylation regulation of PP2A. 
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1.1  Protein Phosphatase 2A 
 
1.1.1 Classification of Protein Phosphatases 
 
Protein phosphatases and kinases represent almost 3 % of human genome, including 
518 putative protein kinases, 107 putative protein tyrosine phosphatases (PTPs) and 
far fewer other protein phosphatases. Together, these proteins regulate almost 30 % of 
the cellular proteins via reversibly protein phosphorylation [1-3].  
 
Protein phosphatases (PPs), primary effectors of dephosphorylation, can be grouped 
into two major superfamilies, protein tyrosine phosphatases (PTPs) and protein 
serine/threonine phosphatases (PSPs), based on distinct substrates, amino acid 
sequences, three dimensional structures, and the catalysis mechanisms [4]. 
According to amino acid sequence of the catalytic domain, the PTPs superfamily can 
be further grouped into four families, Class I Cys-based PTPs (classical PTPs and 
dual specificity phosphatases (DSPs)), Class II Cys-based PTPs (18 kDa low 
molecular weight tyrosine phosphatase (LMPTP)), Class III Cys-based PTPs 
(CDC25a, CDC25b and CDC25c), and Asp-based PTPs (Eya) [5;6]. The PSPs 
superfamily contains the phosphoprotein phosphatases (PPPs) family, the metal 
dependent protein phosphatases (PPMs) family and the aspartate-based 
phosphatases, represented by FCP/SCP (TFIIF-associating component of RNA 
polymerase II CTD phosphatase/small CTD phosphatase). The FCP/SCP subfamily 
uses the aspartate-based catalytic mechanism to de-phosphorylate the C-terminal 
domain of RNA polymerase II. There are seven members in the PPPs family 
 22 
comprising PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7. The catalytic subunit of each 
member associates with various regulatory subunits. The metal dependent protein 
phosphatases (PPMs) family comprises PP2C and pyruvate dehydrogenase 
phosphatases (PDPs), which rely on Mg2+ and Mn2+ activation. Unlike the PPPs family, 
the members of PPMs family have no regulatory subunits but contain additional 
domains and conserved motifs which are related to their substrate specificity (Figure 
1-1) [4;6]. This thesis focuses on the structure and methylation regulation of protein 
serine/threonine phosphatase 2A (PP2A) which belongs to the PPPs family of PSPs 
superfamily.  
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Figure 1-1. Classification of Protein Phosphatase Members. Protein phosphatases comprise two superfamilies, protein tyrosine 
phosphatases (PTPs) and protein serine/threonine phosphatases (PSPs). PP2A is classified into the phosphoprotein phosphatases 
(PPPs) family of PSPs superfamily [4-6].
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1.1.2 Structure of PP2A 
 
The core enzyme of PP2A is a dimer (PP2AD) that consists of a highly conserved 65 
kDa scaffolding subunit A (PP2AA) and a 36 kDa catalytic subunit C (PP2AC).  Each 
subunit has two isoforms, α and β, which share high sequence similarity [7-9]. The 
core enzyme combines with one of the variable regulatory subunits to form a triple 
complex (PP2AT). The regulatory subunits, at least 17 of them, belong to four families, 
B (PR55), B’ (PR61), B” (PR48/PR59/PR72/PR130), and B’” (PR93/PR110) [10;11]. 
The regulatory B subunits will determine substrate specificity, cellular location and 
enzymatic activity of PP2A. In addition, the expression levels of the various regulatory 
subunits are highly diverse among different cell types and tissues [10;11].  
 
1.1.2.1 Scaffolding Subunit A (PP2AA) 
 
The PP2A scaffolding subunit A exists in two forms, Aα and Aβ, which are 86% 
identical and consists of 15 tandem repeats, Huntingtin-Elongation-A subunit-TOR 
(HEAT) motifs, which are organized into a horseshoe shape [12]. A HEAT repeat is a 
loosely conserved sequence motif that has been identified in the huntingtin protein, 
elongation factor 3, the PP2A scaffolding subunit, lipid kinase (TOR), the nuclear pore 
transport protein importin β, and the splicing factor SAP155 [13-16]. Each HEAT 
repeat is composed of about 39 amino acids that are folded into a pair of anti-parallel α 
helices connected by an intra-repeat loop. Adjacent HEAT repeats are connected by 
inter-repeat turns. Left-handed rotations at several inter-repeat interfaces generate an 
L-shaped super helical conformation (Figure 1-2a [12]). When the scaffolding subunit 
 25 
A interacts with the catalytic subunit C and regulatory subunit, significant bending of 
HEAT repeats 12-15 toward the amino terminus of the scaffolding subunit A was 
observed (Figure 1-2b [17]). Assembly of PP2AD results in significant changes in 
HEAT repeat 13 of the scaffolding subunit A [18]. The additional conformational 
rearrangement in the scaffolding subunit A, caused by the breakage of a hydrogen 
bond in HEAT repeat 11, is present in the PP2AT but not PP2AD. The flexible structure 
of the PP2A scaffolding subunit A may be an important feature for the PP2AD to 
accommodate multiple families of regulatory subunits [19]. The scaffolding subunit A 
interacts with the catalytic subunit C via the intra-repeat loops of HEAT repeats 11-15 
(Figure 1-2c [17;19]). The interaction between the subunit A and C is dominated by an 
extensive hydrogen bonds network that probably explains the high affinity of this 
interaction. Eight mutants of subunit A are linked to lung and colon cancers and all 
mutations in subunit A are defective in binding either subunit B or C [20]. With the 
reference to the crystal structures it could be noted that the amino acids related to 
these cancer-associated mutations directly participate in subunit interactions. This 
observation could be used to postulate that loss of normal regulation of PP2A activity 
might be caused by disruption of PP2AT formation and thus contributing to 
carcinogenesis [17-19]. 
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d.  
 
 
 
Figure 1-2. The Structure of PP2AA and PP2Ac. (a) Ribbon diagram of PP2AA generated with PyMOL viewer (DeLano Scientific 
LLC). PP2AA is composed of 15 HEAT repeats and forms a horse-shoe shaped fold [12]. (b) The structure superimposition of PP2AA  
(blue) (PDB: 1B3U) and PP2AT (green) (PDB: 2IAE) using Coot 0.6.1. and presented by PyMOL viewer. The association of regulatory 
subunit and catalytic subunit with PP2AA will cause the conformational change of PP2AA [17]. (c) Interface of PP2AA (green) and 
PP2AC (yellow) generated with PyMOL viewer. PP2AA interacts with PP2AC through hydrogen bonds at the intra-repeat loops of HEAT 
repeat 11-15 [17;19]. Dashed black lines represent hydrogen bonds. (d) The structure of PP2AC (PDB: 2IE3) generated with PyMOL 
viewer shows the active site of the enzyme and the substrate binding pocket located above the two manganese atoms [18].
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1.1.2.2 Catalytic Subunit C (PP2AC) 
 
PP2A catalytic subunit C, composed of 309 amino acids, also contains two closely 
related iso-forms, Cα and Cβ, which share 97% sequence identity [21]. PP2AC 
contains an α/β fold catalytic domain and two manganese ions at the active site and 
shows high sequence identity to the catalytic subunit of PP1 (43% sequence identity) 
(Figure 1-2d [18]). Moreover, the residues participating in catalysis are highly 
conserved exhibiting similar catalytic mechanisms [21;22]. The active site is 
positioned away from the ridge of PP2AA and tilted toward the regulatory subunit B 
binding site of PP2AA. Although the overall structure of PP2AC is conserved to other 
serine/threonine phosphatases in PPPs family, the local conformation of the solvent 
exposed surface loops are quite different. These differences might explain the 
functional diversity between PP2A and other protein phosphatases [17;19].  
 
The carboxyl terminal residues 294-309 of PP2AC play an important role in the 
regulation of PP2A of subunit C and are highly conserved among all other 
serine/threonine phosphatases. Thus, the mechanism of regulation may be similar in 
all other serine/threonine phosphatases [17;19]. 
 
1.1.2.3 Regulatory Subunits (PP2AB, PP2AB’, PP2AB”, and PP2AB”’) 
 
In contrast to subunit A or C, members of the four families of the PP2A regulatory 
subunits exist in several isoforms (Figure 1-3 [10;11]). Each type of the regulatory 
subunit imparts specific functions to the PP2A holoenzymes. In recent reports it was 
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suggested that the role of the PP2A regulatory subunits is to tether the PP2AT to its 
substrate rather than modify the catalytic site to accommodate different substrates 
[23]. 
 
1.1.2.3.1 Regulatory Subunit B (PP2AB) 
 
Regulatory subunit B family is involved in the dephosphorylation of Tau protein related 
to Alzheimer’s disease [24]. In mammalian cells there are four isoforms encoded by 
four related genes in this family, PR55α, PR55β, PR55γ and PR55δ. PR55α and 
PR55δ have a widespread tissue distribution, whereas PR55β and PR55γ are 
enriched in the brain [25-27]. According to molecular structure the B family adopts a 
seven-bladed β-propeller fold, also known as tryptophan-aspartate (WD) repeats 
containing an acidic, substrate-binding groove located in the centre of the propeller [24] 
(Figure 1-4a). WD repeats are commonly found in proteins which engage in multiple 
protein-protein interactions [28]. For example, PR55α and PR55δ have been shown to 
interact with transforming growth factor-β (TGF-β) receptors and suppress and 
activate signaling pathway, respectively [29;30]. In addition to the core structure of 
β-propeller fold, PR55α also contains two β hairpins and two α helices which extend 
out of the β-propeller fold and form a β hairpin arm that grabs on to the A subunit 
(Figure 1-4a [24]). Unlike the B’ family, there are very few interactions between B 
family and PP2AC.  The only contact is via residue Leu87 of PR55α, which interacts 
with PP2AC residues Val126 and Tyr127 via van der Waals (Figure 1-4b [24]) type of 
interactions. In addition, there is no interaction between C-terminal tail of PP2AC and 
PR55α.  However, the association of PP2AA and PR55α are more extensive and 
stable. The β hairpin arm makes interactions with HEAT repeat 1 and 2 of PP2AA 
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through van der Waals and the β-propeller fold also associates with PP2AA at the ridge 
of HEAT repeat 3 to 7 (Figure 1-4b [24]). All amino acids in PR55α forming H-bond to 
residues in PP2AA are highly conserved in other isoforms of regulatory subunits B 
family and share an identical mode of interaction with PP2AA [24]. 
 
1.1.2.3.2 Regulatory Subunit B’ (PP2AB’) 
 
Five distinct mammalian genes encode members of the B’ (PR61) family, called 
PR61α, β, γ, δ, and ε, generating at least eight isoforms [31-35]. All members of the 
family B’ contain a highly conserved sequence in the central region (80% identity) but 
diverge at the C- and N-terminal portions suggesting that the conserved region is 
required for interaction with the A-C (PP2AD) complexes, whereas the C- and 
N-terminal sequences may be responsible for different purposes, such as regulation of 
substrate specificity and subcellular targeting [35]. The PR61α and PR61γ1–γ3 are 
mainly expressed in the heart and skeletal muscle [34;36], whereas PR61β and δ are 
mainly expressed in the brain [32;33].  
 
The two structures of the PP2AT reveal that the regulatory subunit B’(PR61γ1) is 
composed of eight pseudo-HEAT repeats and forms a solenoid-shaped structure 
similar to the HEAT repeats [17;19]. However, the protein sequence of PR61γ1 does 
not share apparent sequence similarity to any other HEAT-repeats-containing proteins. 
PR61γ1 interacts with subunit C near the active site and can determine the substrate 
specificity of PP2A by shielding a substantial surface of the PP2AC to provide a new 
surface. There are three main interfaces formed between PP2AC and PR61γ1 (Figure 
1-5a [17]). The conserved residue Arg268 in the β12-β13 loop of PP2AC make 
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interactions with acidic residues in the intra-repeat loop 2 of PR61γ1 and form the first 
interface. The helical subdomain of PP2AC forms the second interface with the 
intra-loop of pseudo-HEAT repeats 6-8 of PR61γ1. The third interface is formed 
between the C-terminal tail of PP2AC and pseudo-HEAT repeats 4-6 of PR61γ1. The 
interactions of PR61γ1 with PP2AA are between the intra-repeat loops of the HEAT 
repeats 2–8 of PP2AA and the convex side of the PR61γ1 pseudo-HEAT repeats 2, 4, 
and 5 (Figure 1-5b [17]). 
 
1.1.2.3.3 Regulatory Subunit B” (PP2AB”) 
 
The B” family contains two Ca2+ binding sites formed by an E-F hand motif. Two 
different isoforms have been described, PR72 and PR130, which are the splicing 
products from the same gene. Previous studies demonstrated that the family B” (PR72) 
is expressed exclusively in the heart and skeletal muscle, whereas PR130 was 
detected in almost all of the tissues analyzed, with the highest levels observed in the 
heart and muscle [37]. A recent report shows that the PR72 subunit is highly 
expressed in striatal tissue and possibly plays a role in the regulation of 
dopaminoceptive neurons, dopamine- and cAMP-regulated protein (DARPP-32) 
dephosphorylation by PP2A [38]. 
 
A regulatory subunit PR59, identified as an interaction partner of the 
retinoblastoma-related p107 protein, shares 56% identity with PR72; however the 
expression patterns of the two proteins differ completely. When PR59 and p107 were 
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co-expressed, overexpression of PR59 resulted in inhibition of cell cycle progression 
in the G1 phase.  This observation may be related to an increase in the amount of the 
hypo-phosphorylated p107 contributing to the activation of p107 [39]. 
 
PR48 shares 68% sequence similarity with PR59 and was found to interact with Cdc6, 
a protein required for the initiation of DNA replication [40;41]. Over-expression of 
PR48 causes a G1 arrest suggesting that PP2A keeps the Cdc6 in the 
dephosphorylated form, a prerequisite for binding to the origins of DNA replication 
[42]. 
 
1.1.2.3.4 Regulatory Subunit B’” (PP2AB’”) 
 
Striatin (PR110) and S/G2 nuclear autoantigen (SG2NA/PR93) were observed to form 
a stable complex with PP2A and were also identified as new members of a potential 
B’’’ family. Like the family B (PR55), they all contain the WD40 repeats and the 
association of striatin and SG2NA with PP2AD is independent of the C subunit 
carboxyl terminus. Striatin has been reported to associate with the post-synaptic 
densities of neurons, whereas SG2NA has been reported to be a nuclear protein 
expressed primarily during the S and G2 phases of the cell cycle [43;44]. Both proteins 
also bind to calmodulin in a calcium-dependent manner, suggesting that these 
proteins that form PP2A triple-complexes may be involved in calcium-dependent 
signaling pathways and cellular events [45-48].  
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Figure 1-3. The Four Families of Regulatory Subunits. Based on the protein sequence, multiple B subunits, which have been 
grouped into four individual families (B (PR55), B' (PR61), B" (PR48/59/72/130) and B'" (PR93/110)), exist to target PP2A to distinct 
cellular compartments and/or substrates [10;11].
 35 
 
 
 
 
 
Figure 1-4. The Interaction of PP2AD and PR55. (a) The figure orginated from 
reference [24]. PR55 contains a seven-bladed β-propeller fold forming a highly acidic 
top face and additional a/β hairpin arm that interacts with the A subunit. (b) Ribbon 
diagram of PP2AD-PR55 (PDB: 3DW8) generated with PyMOL viewer (DeLano 
Scientific LLC). The interaction between the hairpin arm of PR55 and HEAT repeats 1 
and 2 of PP2AA is dominated by van der Waals, whereas the recognition between the 
a 
b 
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bottom face of PR55 and HEAT repeats 3-7 is dominated by hydrogen bonds (black 
dashed line). In addition, the residue Leu87 of PR55α contacts PP2AC residues 
Val126 and Tyr127 via van der Waals interactions [24]. 
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Figure 1-5. Interface of the PR61 with PP2AC and PP2AA.  Ribbon diagram of 
PP2AD-PR61 (PDB: 2IAE) [17] represented by PyMOL viewer (DeLano Scientific LLC). 
(a) Three main interfaces formed between PP2AC and PR61γ1contain a mixture of 
hydrogen bonds (black dashed line) and van der Waals contacts. (b) The interface of 
PP2AA and PR61γ1is dominated by van der Waals interactions [17]. 
a 
b 
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1.1.3 Regulation of PP2A 
1.1.3.1 Phosphorylation 
 
PP2A can be phosphorylated by the epidermal growth factor (EGF), insulin receptor, 
and the tyrosine kinases including leukocyte-specific protein tyrosine kinase (LCK) 
and viral sarcoma (V-SRC) kinases [49]. The phosphorylation of the C-terminal tail of 
PP2A at Tyr307 will result in the inactivation of PP2A [50-53]. In addition to 
phosphorylation of PP2AC, regulatory subunit B’ family can also be phosphorylated. In 
vitro, phosphorylation of PR61δ by protein kinase A (PKA) regulates the activity and 
changes the substrate specificity of PP2A [54]. Phosphorylaton of PR61α by the 
double-strand-RNA-dependent protein kinase (PKR) promotes the activity of PP2A to 
associate with PKC-phosphorylated myelin basic protein and PKR-phosphorylated 
eukaryotic translation initiation factor 2α, in vitro [55].   
 
1.1.3.2 Methylation 
 
In addition to Tyr307 for phosphorylation, the T304PDYFL309 motif of PP2AC also 
contains a target site for methylation by a novel carboxyl methyltransferase [56-58]. All 
PP2AC sequences share this highly conserved motif at their C-terminal and the 
reversible methylation occurs on the carboxyl group at Leu309 [59;60]. In 
Saccharomyces cerevisiae, loss of the protein phosphatase methyltransferase 1 
(PPM1), a homolog of leucine carboxyl methyltransferase 1 (LCMT1), results in loss of 
PP2A methylation, indicating that yeast PPM1 is probably the major methyltransferase 
responsible for methylating PP2A [61]. In parallel, it was demonstrated that the 
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mammalian LCMT1 and protein phosphatase methylesterase 1 (PME1) were also the 
major mammalian methyltransferase and methylesterase of PP2A [62;63]. Although 
many hypotheses were generated regarding the cellular function of the reversible 
methylation of PP2A, definitive description of a role that methylation of PP2A plays 
remained elusive.  
 
Initially, the main function of methyltransferase was thought to be to methylate and 
further activate PP2A [64], with methylesterase reverse role to de-methylate and 
inactivate PP2A [63]; however, this hypothesis was soon disputed by two other groups 
which obtained opposing data with respect to the effect of PP2AC methylation. One 
group suggested that the methylation was not related to the activity of PP2AC [62] 
while others indicated that methylation leads to a decrease in PP2AC activity [65]. 
Therefore, methylation of PP2AC may impact on other properties of PP2A rather than 
catalytic activity directly.   
 
After it was shown that methylation of Leu309 is necessary for PP2AD to associate with 
regulatory subunit PR55, in vitro [66] further evidence for the role of methylation in 
heterotrimeric assembly emerged. For example, it was demonstrated that 
fully-methylated PP2AT recruits B” (PR72) or B’” subunit in vivo. In a separate study 
though PP2AT was not always fully methylated when associated with B subunit (PR55) 
[62]. This result was soon confirmed by others that showed that the loss of carboxyl 
methyltransferase activity decreases but does not eliminate the formation of the 
PP2AT with PR55 [67;68]. Furthermore, an additional player in PP2A assembly and 
activation was identified – the protein phosphatase 2A activator (PTPA) protein, a 
peptidyl-prolyl cis/trans-isomerase.  In vitro Studies have shown that the inactivated 
 40 
PP2AC forming a complex with PME1 can only be reactivated by PTPA but not by 
methyltransferase [69;70] thus creating an even more complex picture of PP2A 
regulation and the specific function that methylation step plays in this process.  
 
In 2006, the crystal structure of the PP2A holoenzyme was determined by two groups 
independently. Based on the PP2A three dimensional structure, the methylation of the 
C-terminal tail of subunit C at Leu309 was predicted to neutralize the negatively 
charged surface present at the A-C interface and thus recruit subunit B’ (PR61) to form 
a stable holoenzyme [17] (Figure 1-6). This result might explain how methylation could 
assist in the formation of the PP2A holoenzyme and why methylation is always 
required for PP2A to recruit B’ subunit (PR61). In 2007, another research group 
supported the view that methylation of the C-terminal tail of the PP2A subunit C is not 
required for either catalytic activity or the binding of the B subunit (PR55), in vitro [71]. 
In contrast a recent work indicated that methylation of the PP2A subunit C is not 
absolutely required for the binding of B’ (PR61) or B” (PR72) family, but necessary for 
the binding of B (PR55) family, in vivo [72]. Taken everything together, it could be 
concluded that the methylation state of the catalytic subunit imparts on and regulates 
holoenzyme assembly. However due to the contradictory evidence it remains unclear 
how the methylated status of PP2AC results in an acquired selectivity for binding of 
regulatory subunit B, B’ or B’”. 
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Figure 1-6. Methylation of PP2AC. Qualitative representation of surface 
electrostatic potential of PP2AA (PDB: 2IAE) as generated in PyMOL viewer 
(DeLano Scientific LLC). The C-terminal tail of PP2AC is positioned in the middle 
of negatively charged region (red) of PP2AA. When the C- terminal tail of PP2AC 
is methylated by LCMT1, charge repulsion is neutralized and the methylated 
C-terminal tail can settle down on the A-B interface [17;18]. 
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1.1.4 Biological Role of PP2A 
 
Protein serine/threonine phosphatase 2A (PP2A) is a conserved protein found in many 
different species and it constitutes 1% of total cellular proteins.  Together with protein 
phosphatase 1 (PP1), PP2A contributes to 90% of all Serine/Threonine phosphatase 
activity in tissues and cells [73]. PP2A plays an important role in various cellular 
processes [10;74;75] including cell cycle regulation [76-80], DNA replication [42;81;82], 
mRNA translation [83-86], signal transduction [87-89] and apoptosis [90-95]. The 
deregulation of PP2A methylation is linked to Alzheimer’s disease and increased 
susceptibility to pathogen infections [96-98]. PP2A was identified as an important 
tumour suppressor protein and hence a potential target for cancer therapeutic 
strategies [99;100]. In addition, okadaic acid (OA), a PP2A non-specific inhibitor, is the 
main marine toxin implicated in the diarrhetic shellfish poisoning (DSP) in humans 
after consumption of contaminated bivalve molluscs. Therefore, PP2A could be used 
in an inhibitor assay for assessing okadaic acid contamination [101]. 
 
1.1.4.1 The Role of PP2A in Cell Cycle Regulation 
 
The cell cycle, composed of four distinct phases (G1, G2, interphase and mitosis), 
takes place in a cell leading to its division and duplication [102]. M Phase promoting 
factor (MPF) composed of the cell division cycle 2 (Cdc2) kinase and cyclin B is 
involved in the G2/M transition [103]. In the cell cycle progression, PP2A negatively 
regulates Cdc2 kinase forming a complex with cyclin B in G2/M transition [104-107]. 
The activity of Cdc2 kinase relies on phosphorylation at residue Thr161, and PP2A is 
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related to its de-phosphorylation and inactivation [108;109]. In addition, 
phosphorylation at two other sites, Thr14 and Tyr15 of Cdc2 kinase is controlled by 
Wee1 kinase while the Cdc25 dual-specificity phosphatase activates the activity of the 
Cdc2 kinase. PP2A indirectly inactivates the Cdc2 by both the activation of the Wee1 
kinase, which phosphorylates the cdc2 kinase at Tyr15, and by the inactivation of the 
Cdc25 dual-specificity phosphatase, which remove s phosphate from both Thr14 and 
Tyr15 of the Cdc2 kinase [78;110;111] (Figure 1-7). 
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Figure 1-7. The Role of PP2A in Cell Cycle. In early G2 phase, PP2A is required to keep cyclin B-Cdc2 complex in its inactive form 
by inhibiting CAK (Cdc2 activating kinase) and activating Wee1 kinase. In addition, PP2A inhibits Cdc25 phosphorylation. Finally, 
PP2A is implicated in the exit from mitosis where PP2A participate in cyclin B degradation and in dephosphorylation of mitotic 
substrates of active cyclin B-Cdc2 complex [78;104-111]. 
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1.1.4.2 The Role of PP2A in DNA replication 
 
Previous studies indicated the relationship between PP2A and viral DNA replication, in 
vivo or in vitro. The Simian vacuolating virus 40 (SV40) large T antigen possesses 
site-specific DNA binding, ATPase and DNA unwinding activities [112]. The 
association of the various PP2A complexes with large T antigen is related to the 
activity of large T function. PP2AC and PP2AD-B” family or -B’ family are involved in 
SV40 large T antigen dephosphorylation at Ser120, Ser123, Ser677, and Ser679 sites 
that stimulates large-T-dependent origin unwinding and DNA replication [113;114]. In 
contrast, PP2AD and PP2AD-B family will inactivate large T antigen by 
dephosphorylating the Cdc2 target site, Thr124 site [115].  
 
In eukaryotic cells, cell division cycle 6 protein (Cdc6) is a member of the 
pre-replication complex together with the origin recognition complex, chromatin 
licensing and DNA replication factor 1 (Cdt1) and the mini-chromosome maintenance 
(MCM) complex. Cdc6 is recruited for loading MCM proteins onto the DNA [116;117]. It 
was demonstrated that PP2AD-B” family interacts with Cdc6 and modulates DNA 
replication. The phosphorylation of Cdc6 by cyclin-dependent kinase 2 (Cdk2) is 
necessary for DNA replication and export of Cdc6 from the nucleus. PP2AD-B family, 
existing in the cell nucleus, has a role in maintaining levels of dephosphorylated Cdc6 
until replication is triggered by Cdk2 [42;82]. 
 
1.1.4.3 The Role of PP2A in mRNA Translation 
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1.1.4.3.1 The Initiation of Translation 
 
The target of rapamycin (TOR), a serine/threonine kinase, is highly conserved from 
yeast to mammals [118;119]. TOR regulates the cell growth and metabolism in 
response to growth factors, nutrients and stress conditions [120-122]. In eukaryotic 
cells, there are two distinct multimeric complexes, TORC1 and TORC2. TORC1, 
sensitive to rapamycin, regulates temporal processes of cell growth while TORC2, 
which is insensitive to rapamycin, controls spatial aspects of cell growth such as yeast 
actin polarization, the membrane-localized actin patching concentrate at a previously 
selected and marked bud site after the initiation of a new cell cycle [120;123;124]. In 
yeast, Tap42 is a direct target of TORC1 phosphorylation that binds to PP2AC without 
A subunit and B subunit [125]. When nutrients are abundant phosphorylated 
Tap42-PP2AC localizes to the cell membrane and interacts with TORC1. Under this 
condition, Tap42-PP2AC will not dephosphorylate and activate Maf1, a repressor of the 
RNA Polymerase III. In addition, TORC1 will also phosphorylate Sch9 and promote 
ribosome biogenesis via the expression of Ribi and RP regulons [126]. However, in 
response to nutrient deprivation or rapamycin treatment, Sch9 phosphorylation is 
inhibited and ribosome biogenesis is turned off. At the same time, the Tap42-PP2AC 
will be disrupted and PP2AC will dephosphorylate Maf1, leading to inhibition of RNA 
Polymerase III [127].  
 
In mammalian cells, an α4 protein, a homologue of Tap42, also binds to PP2AC 
independently of PP2AA and regulatory subunit [128-130]. The function of mTOR is 
related to the phosphorylation of the translation inhibitor, eukaryotic initiation factor 4E 
binding protein 1 (4E-BP1), and p70 S6 kinase and eventually causes the 
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phosphorylation of the 40 S ribosomal protein S6 and initiation of the translation [131].  
Like yeast, the nutrient deprivation or rapamycin treatment also leads to the 
dissociation of α4 and PP2AC. Free PP2AC can dephosphorylate mTOR- 
phosphorylated 4E-BP1 and finally inhibit translation [132]. 
 
1.1.4.3.2 The Termination of Translation 
 
In addition to the importance of the initiation of translation, PP2AC also participates in 
the termination of translation via the association with a translation termination factor, 
eukaryotic release factor 1 (eRF1), which cooperates with eukaryotic release factor 3 
(eRF3) to terminate protein synthesis in ribosomes [84;133;134]. 
 
1.1.4.4 The Role of PP2A in Signal Transduction 
 
In signal transduction, PP2A can negatively modulate the activities of several protein 
kinase cascades, in particular protein kinase B (PKB) [135], protein kinase C (PKC) 
[136], p70 S6 kinase [137], Ca2+ calmodulin dependent kinases [138-140], mitogen 
activated protein kinases (MAPK), nuclear factor-κB (NF-κB) [141] and the B cell 
CLL/lymphoma 2 family [142]. 
 
1.1.4.4.1 Protein Kinase B (PKB) and p70 S6 kinase 
 
Protein kinase B (PKB) is involved in cellular survival pathways by inhibiting apoptosis 
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processes [143] and also in the induction of protein synthesis [144]. Phosphoinostide 
3-kinase (PI 3-kinase) is related to an extraordinarily diverse group of cellular 
functions and generates lipid secondary messengers phosphatidylinositol 
3,4-bisphosphate (PtdIns(3,4)P2) and phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)P3). Both of these two messengers bind to the PH domain of PKB and 
bring about recruitment of PKB to the membrane. Under these conditions, 
3-phosphoinositide dependent protein kinase-1 (PDK1) and Ser473 kinase will 
phosphorylate and activate PKB [145]. PP2A de-phosphorylates and thus inactivates 
PKB [135].   
 
P70 S6 kinase is also activated by PDK1 but without the assistance of any lipid 
secondary messengers and inactivated by PP2A. P70 S6 kinase, a serine/threonine 
kinase, participates in the phosphorylation of S6 ribosomal protein and then induces 
protein synthesis [137;146-148]. 
 
1.1.4.4.2 Protein Kinase C 
 
Protein kinase C (PKC) superfamily plays key roles in a multitude of cellular processes 
including control of fundamental cellular autonomous activities such as cell 
proliferation and organismal functions such as memory [149].  PKC contains several 
isoforms which share three highly conserved phosphorylation sites. One is required 
for its activity and the others are related to maintenance of the enzyme stability. The 
activated PP2A which contains PR55 will interact with PKC leading to its inhibition 
[136;150;151]. 
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1.1.4.4.3 Ca2+-Calmodulin-Dependent Kinase (CaM Kinase) 
 
The CaM kinase cascade is composed of three kinases: CaM-kinase kinase (CaMKK); 
and the CaM kinases CaMKI and CaMKIV. CAMKI and CAMKIV are phosphorylated 
and activated by CaMKK [152]. This cascade plays an important role in many cellular 
processes and has been implicated in various diseases. These processes include cell 
proliferation, apoptosis, neuronal growth, synaptic plasticity, proper function of the 
immune system including the inflammatory response, activation of T lymphocytes and 
hematopoietic stem cell maintenance, and the central control of energy balance that 
can lead to obesity and diabetes [153-155]. 
 
PP2A can not only dephosphorylate CaM kinase I, II and IV in vitro, but also CaM, 
which exists in several forms activating variety of target proteins [87]. Therefore, PP2A 
might indirectly or directly control the activity of CaM kinase by binding to CaM kinases 
or modulating interactions between CaM and CaM kinases [156]. 
 
1.1.4.4.4 B Cell CLL/Lymphoma 2 Family (Bcl2)  
      
The PP2A is also linked to various mechanisms of apoptosis [157-159]. The 
Bcl-2-associated death promoter protein (Bad) and Bcl-2-associated X protein (Bax) 
are all pro-apoptotic molecules of the B cell CLL/lymphoma 2 family (Bcl2 family) 
[160-162]. Recently, it was shown that PP2A may function as the physiological Bax 
and Bad regulatory phosphatase that dephosphorylates Bax and Bad and further 
activates their pro-apoptotic functions [90;95]. The induction of neutrophil apoptosis is 
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an important event in the inflammatory process. PP2A promotes neutrophil apoptosis 
through two actions, firstly by dephosphorylating and inactivating p38 
mitogen-activated protein kinase (p38 MAPK), a neutrophil survival factor, and thus 
inhibiting the phosphorylation of caspase 3 and secondly by dephosphorylating 
caspase 3, which has already been phosphorylated, thereby restoring its activity [94]. 
In addition, PP2A will dephosphorylate and inhibit the activity of Bcl2 resulting in 
activation of caspase 2 and thus triggering mitochondrial pathway of cell apoptosis 
[163]. 
 
1.1.4.4.5 Nuclear Factor-κB (NF-κB) 
 
PP2A is also a key regulator of negative feedback regulation of nuclear factor-κB 
(NF-κB) [141]. NF-κB plays a paradoxical role in apoptosis [164]. Although NF-κB 
usually inhibits apoptotic process, upon activation by interleukin-1 (IL-1) it enhances 
ultraviolet-B radiation (UVB)-induced apoptosis [165]. UVB will inactivate the activity 
of PP2A which is responsible for persistent inhibitor of κB kinase β (IKKβ) activity [166]. 
The phosphorylation of IKKβ will lead to uncontrolled NF-κB activity. Chronic NF-κB 
activation will finally lead to cell death but not survival [141]. 
 
1.1.4.4.6 Mitogen-Activated Protein Kinase (MAPK) 
 
MAPK pathways regulate a variety of physiological processes such as cell growth, 
differentiation, and apoptotic cell death [167]. Three MAPK pathways have been 
elucidated including the extracellular regulated kinase (ERK) pathway, the c-Jun 
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NH2-terminal kinase (JNK)/ stress-activated protein kinase (SAPK) and p38 pathway 
[168-171].  
 
PP2A plays both a positive and negative role in the regulation of ERK pathway [172]. 
The ERK pathway, related to cell growth, cell proliferation, and survival, is activated 
mainly in response to mitogens and growth factors [173-175]. Ras, a 
membrane-bound protein, will recruit Raf (MAPKKK), to the cell membrane for 
activation [176].  Three mammalian Raf proteins, A-Raf, B-Raf, and Raf-1, share the 
same downstream MAPKK substrate mitogen-activated protein kinase kinase 1,2 
(MEK1,2). MEK1,2 phosphorylate and activate ERK1,2 which can phosphorylate 
several cytoplasmic and nuclear kinases [177]. PP2A has not only been reported to 
negatively regulate ERK1/2 activity [178-180], but has also been identified as a 
positive regulator of Raf1 [181-183] and Ksr - kinase suppressor of Ras [184]. In 
addition, the different activities of various heterotrimeric PP2A complexes in PP2A’s 
regulation of the ERK1,2 pathway were investigated. For instance, in the human 
sympathetic neuron cell line PC6–3, overexpression of the PP2A regulatory subunit 
PR55γ induced ERK pathway activity, whereas PR55α or PR55δ directly promoted 
ERK1,2 dephosphorylation [183;185]. Recent studies also indicate that PP2A 
containing PR61β or PR61 γ could directly dephosphorylate and inactivate ERK [186].  
 
The p38 pathway can be stimulated by inflammatory cytokines and mitogens [170]. All 
p38 MAPK protein isoforms, α, β, γ, δ, are activated by dual phosphorylation of a 
threonine and a tyrosine [187]. Phosphorylated p38 proteins can activate several 
transcription factors, including ATF-2, CHOP-1, MEF-2, p53, and Elk-1, and other 
kinases, such as MNK1,2, MSK1, PRAK, PRAK, MAPKAPK-2 and MAPKAPK-3. In 
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addition, activation of p38 pathway is also required for apoptosis induction in different 
cellular models and related to the promotion of cancer cell growth and survival 
[188-191]. PP2A regulates p38 pathway by association with and dephosphorylation of 
MEK3 - the activator of p38 MAPK [192]. 
 
1.1.4.4.7  Wnt Signalling Pathway 
 
The Wnt signaling pathway comprises a complex network of proteins involved in 
embryogenesis [193;194]. The deregulation of Wnt pathway will lead to tumorigenesis 
due to the accumulation of β-catenin in the nucleus [195;196]. Like in ERK pathway, 
PP2A also plays dual role with dominant and negative effects in Wnt signaling [197]. In 
the absence of Wnt signal, β-catenin will form complex with adenomatosis polyposis 
coli (APC), Axin and GSK-3β in the cytosol [196-198]. GSK-3β will phosphorylate 
β-catenin resulting in the ubiquitination of β-catenin for degradation by proteosome. 
The binding of PR61α and PR61δ to APC or the binding of PR61α, PR61β and PR61γ 
to Axin will lead to decreased levels of β-catenin [194]. However, the mechanism of 
how PP2A negatively regulates the Wnt signaling pathway through the destabilization 
of β-catenin is still unclear.  
 
The role of PP2A in positive regulation of Wnt signaling is even more complex. PP2A 
can directly stabilize β-catenin at plasma membrane. The inhibition of PP2A 
expression results in the degradation of β-catenin which is redistributed to the 
cytoplasma [194]. The activation of Wnt will lead to the degradation of 
APC-Axin-GSK-3β through Dishevelled (Dsh). Naked, one of the downstream target 
genes of the Wnt pathway, inhibits Dsh through a negative feedback mechanism. 
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Unlike PR72, PR130 will inhibit Naked resulting in the increased Dsh expression, 
which is also positively regulated by PR61ε. Both PR61ε and PR55 will destabilize the 
inhibitory properties of GSK-3β. PR61α also interacts with p63, a member of p53 
family, and finally stabilizes β-catenin through the negative regulation of GSK-3β 
[199;200] (Figure 1-8). 
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Figure 1-8. The Role of PP2A in Wnt Pathway. In the absence of Wnt signal, β-catenin will associate with APC and Axin which form 
complex with the members of PR61 family in the cytosol. GSK-3β will phosphorylate β-catenin resulting in the ubiquitination of 
β-catenin for degradation by proteosome; however, in the presence of Wnt signal, the APC, Axin, and GSK-3β complex is degraded 
by Dsh. Unphosphorylated β-catenin will move to the nucleus leading to the activation of Wnt target genes. Here, PP2A appears to 
play a role in the stabilization of β-catenin [194;199;200]. 
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1.1.4.5 PP2A and Pathologies 
 
1.1.4.5.1 Alzheimer’s Disease 
 
Alzheimer's disease (AD) is associated with two histopathological hallmarks in the 
brain, senile plaques and neurofibrillary tangles. Senile plaques are the accumulation 
of the amyloid-beta peptides derived from the abnormal processing of amyloid 
precursor protein (APP) whereas neurofibrillary tangles consist of 
hyperphosphorylated tau protein related to the low activity of phosphatases in the AD 
brain [201].  
 
Recent research indicated elevated blood levels of the homocysteine are a significant 
risk factor for Alzheimer's disease. The PP2A catalytic subunit C can be methylated at 
Leu309 residue by the leucine carboxyl methyltransferase 1 and methylation is 
required for efficient assembly of the PP2A holoenzyme.  The LCMT1 activity is 
dependent on the S-adenosylmethionine (SAM) and inhibited by the 
S-adenosylhomocysteine (SAH). The elevated SAH levels result in decreased PP2A 
methylation and may be related to subunit B downregulation and accumulation of the 
phosphorylated tau protein [202;203].  
 
In addition, intracellular PP2A activity is regulated by two inhibitor proteins, called 
I1PP2A and I2PP2A, found in mammalian tissues. It was suggested that I1PP2A and I2PP2A 
may be involved in Alzheimer neurofibrillary pathology through the inhibition of PP2A 
activity resulting in abnormal hyperphosphorylation of the tau protein [97;204].  
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1.1.4.5.2 Carcinogensis 
 
The role of PP2A in carcinogenesis has been disputed for a long time and the protein 
was viewed as a tumour suppressor. However, there is a sufficient evidence that the 
inactivation and disruption of PP2A may be related to cancer formation [99;100;205]. 
For example, the PPP2R1B gene encoding the subunit A of the serine/threonine 
protein phosphatase was identified as a putative tumour suppressor gene in lung and 
colon cancer in the chromosome region 11q23. Four of the cancer-associated 
mutations were found and they have affected A subunit binding to other subunits. 
Moreover, a total absence or substantial reduction of the subunit A will cause the 
deregulation of PP2A and some human cancers [206;207]. In addition to subunit A, it 
was shown that truncation of the regulatory subunit B’ (PR61γ) will lead to increased 
metastasis [208]. Recent data has shown that the expression of PR61γ is suppressed 
in melanomas compared with non-transformed melanocytic naevi [209]. PR61α also 
plays an important role as a regulator of c-myc. The dephosphorylation of Ser62 of 
c-myc by PR61α is modulated by a human oncoprotein, the cancerous inhibitor of 
PP2A (CIP2A) [210]. In addition, PR61α acts as both a negative and positive regulator 
of the tumor suppressor p53. The cyclin G, a p53 target, will recruit PP2A containing 
either PR61α or PR61β to form a quaternary complex with the E3 ligase MDM2 and 
activate the protein. Finally, MDM2 binds to p53 and ubiquitinates p53 leading to its 
degradation [211;212].   Although this discovery would not support that notion that 
PP2A is a tumor suppressor, PP2A is also a positive regulator of p53 signaling 
pathway. Namely, it was shown that PP2A directly dephosphorylates p53 at Ser37 or 
Thr55.  While dephosphorylation of Ser37 decreases p53 transcriptional activity 
dephosphorylation of Thr55 stabilizes p53 protein resulting in increased apoptosis 
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[213;214]. PP2A containing PR55α was also implicated in dephosphorylation and 
inactivation of protein kinase B that has an important role in tumor-promoting 
pathways [215]. 
 
In another example, the SV40 small t antigen (ST) is an oncoprotein that disrupts the 
function of PP2A by binding to PP2AA and displacing the regulatory subunit [216]. 
Recently, the crystal structure of the SV40 small t antigen with the mouse PP2AA was 
determined.  The small t antigen contains an N-terminal J domain and a unique 
C-terminal domain, formed by two zinc-binding motifs. Both the J domain and second 
zinc-binding motif interact with the intra-repeat loops of the HEAT repeats 3–7 of 
PP2AA, whereas the first zinc-binding motif may directly interact with and inactivate 
the catalytic subunit PP2AC [217].  
   
1.2  Protein Phosphatase Methylesterase 1 (PME1) 
       
PME1, the first methylesterase found in humans, is a highly conserved protein found 
in different species [63]. In human cells, PME1 is most abundant in the nucleus, 
whereas the leucine carboxyl methyltransferase 1 (LCMT1) is mainly found in the 
cytoplasm. The subcellular localization of LCMT1 and PME1 is related to the 
methylation state of the PP2A subunit C [218].  
 
Earlier studies indicated that PME1 is a PMSF-resistant, okadaic acid-sensitive PP2A 
methylesterase belonging to a functional family of serine carboxylesterases containing 
Ser-Asp/Glu-His triad; this triad is also found in lipases [60;63]. According to the 
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3D-PSSM fold recognition program [219] and the Pfam domain prediction database 
[220], PME1 contains an esterase domain (residue position from 47-238) thought to 
catalyze the demethylation of carboxylmethylester of Leu309 from PP2A.  
 
In addition, inactive PP2A was found to tightly interact with PME1 and could only be 
re-activated by PP2A phosphatase activator (PTPA) but not by LCMT1, in vitro [69;70]. 
This discovery hints to a wider function of PME1 in PP2A regulation rather than just a 
hydrolysis of a methylester bond. Recently, structural studies suggested that the 
association of PME1 to PP2A results in inactivation of PP2A through removal of 
catalytic metal ions [221]. 
 
1.2.1 The Structure of PME1 
 
Although PME1, composed of 386 amino acids, has been purified and well 
characterized more than10 years ago, only recently, its three dimensional structure 
forming complex with PP2AD was solved [221]. Based on the structure, PME1 was 
classified into α/β hydroxylase superfamily. This domain is composed of a nine 
stranded β sheet surrounded by six α helices, two on one side and four on the other 
side of the β core. The active site pocket containing catalytic residue Ser156 is located 
between the cap domain, composed of four additional α helices, and the α/β fold. This 
structural arrangement suggests that PME1 must undergo an activation process that 
might be mediated by binding to the PP2A core enzyme. This observation also 
explains why PME1 cannot interact with carboxyl-methylated peptide T304PDYFL309 
and shows no reduction of methylesterase activity toward PP2A core enzyme when 
treated with a conventional a serine protease inhibitor, PMSF [221]. 
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In the reported structure of PME1-PP2AD complex, PME1 only binds to PP2AC but not 
PP2AA (Figure 1-9 [221]). PME1 and PP2AC stack closely against each other and form 
an S-shaped interface, which is dominated by three networks of hydrogen bonds 
(Figure 1-9 [221]). The first network includes residue Arg214 of PP2AC which provides 
two intermolecular hydrogen bonds to the carbonyl oxygen atoms of residues 334 and 
335 in PME1, and two intramolecular hydrogen bonds, one to Asp202 and the other to 
carbonyl oxygen of residue 241 in the PP2AC. Two other hydrogen bonds networks 
stabilize both ends of the S-shaped interface. The residue Arg268 of the PP2AC forms 
three hydrogen bonds with several residues at the N-terminal of helix α9 in PME1. The 
other network was composed of a water molecule mediating hydrogen bonds between 
residue 213 in PP2AC and the side chains of Gln340, Arg369, and His370 in PME1 
[221].  
 
The interaction between PME1 and PP2A leads to marked conformational changes of 
active site in PME1 resulting in the widening of the active site pocket for PME1 to 
accommodate the C-terminal tail of PP2AC and the rearrangement of the catalytic triad 
residues, Ser156, His349, and Asp181, into an active conformation. On the other hand, 
the binding of PME1 to PP2A displaces the manganese ions from the active site of the 
PP2AC resulting in the inactivation of PP2A [221]. 
 
The crystal structure of PME1-PP2AD suggests that PME1 only interacts with PP2AC.  
However the PME1 protein used in the study contains only residues 39-238 linked 
through a small EGK tripeptide to remaining protein residues 284-376 while and 
PP2AA subunit was engineered such that it included only HEAT repeats 1 and 11-15. 
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Even though this study showed the methylesterase activity of truncated form PME1 as 
only slightly different from that of full length PME1 the three dimensional arrangement 
of interaction between PME1 and PP2A may not be fully accounted for in the structure.
 61 
 
 62 
Figure 1-9. Interface between PME1 and PP2AC. Ribbon diagram of PP2AD-PR61 
(PDB: 3C5W) represented by PyMOL viewer (DeLano Scientific LLC). The structure of 
PP2AD-PME1 complex shows that PME1 (orange) only associates with PP2AC 
(green). In addition, PME1 and PP2AC form and S-shaped interface and the 
interaction between PME1 and PP2AC is dominated by hydrogen bonds (black dashed 
line) [221]. 
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1.2.2 Biological Role of PME1 
 
Although overexpression of PME1 causes a significant change in the methylation 
status of the PP2A subunit C, there is no significant effect on normal cell functioning 
[72].  However, knock-out of LCMT1 protein and co-overexpression of PME1 are 
associated with the hyper-phosphorylation of tau protein and cause a G1 arrest and 
ultimately apoptosis [222]. 
 
1.3  Leucine Carboxyl Methyltransferase 1 (LCMT1) 
 
The gene for human leucine carboxyl methyltransferase 1 (LCMT1) encoding 334 
amino acid residues has been sequenced and cloned [62]. Recently, it was shown that 
LCMT1 is important for normal progression through mitosis in mammalian cells and is 
necessary for embryonic development in mice [222]. Inhibition of LCMT1 expression 
will disrupt the formation of PP2AD-PR55 and further induce cell apoptosis. With 
reference to these mechanisms, methylation of PP2A by LCMT1 may play an 
important role in cell functions [222]. 
 
 
1.3.1 The Structure of Protein Phosphatase Methyltransferase 1 
 
Although the structure of human mammalian leucine carboxyl methyltransferase 1 
was still unsolved, the three dimensional structure of protein phosphatase 
methyltransferase 1 found in Saccharomyces cerevisiae was solved in 2004 [223] and 
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demonstrated a leucine carboxyl methyltransferase domain involved in 
carboxy-methylation of the PP2AC. PPM1 shares 28% sequence identity to the 
mammalian leucine carboxyl methyltransferase 1 based on the pairwise sequence 
alignment through ClustalW (EMBL-EBI). The core domain of PPM1 containing 
AdoMet and PP2A binding sites is characterized by alternate α/β secondary structure 
elements forming a central sheet containing seven β-strands (β1-β7). The six 
α-helices (αZ and αA-αE) are oriented roughly parallel and surrounding the β-strands 
(Figure 1-10a) [223]. The structure of the core domain is highly conserved among 
methyltransferases such as L-isoaspartate-O-methyltransferase, chemotaxis receptor 
methyltransferase, phenylethanolamine N-methyltransferase, glycine 
N-methyltransferase and Yeco methyltransferase (Figure 1-10b). However, their 
substrates are very diverse due to additional insertions and variations to the core 
domain [223]. In Saccharomyces cerevisiae PPM1, helix α1, helix α5, helix α8 and 
helix αZ of the core domain form the funnel-shaped cavity for the methyl donor group 
to situate at and specify the acceptor substrate which needs to penetrate deeply inside 
the cavity  (Figure 1-10c) [223]. 
 
Based on the 3D-PSSM fold recognition program and sequence alignment, human 
LCMT1 shares the core domain and insertions with Saccharomyces cerevisiae PPM1. 
In addition, the Saccharomyces cerevisiae methyltransferase PP2A binding site and 
AdoMet binding site residues are highly conserved in methyltransferases of different 
species (Figure 1-10d). For that reason, we could propose that human LCMT1 has the 
same PP2A binding site and a similar function to Saccharomyces cerevisiae 
methyltransferase, and thus we could design human LCMT1 DNA constructs based on 
Saccharomyces cerevisiae methyltransferase structure using this structure as our 
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model for further studies. 
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d 
                             α 1                             α 2 
                  --HHHHHHHHHHHHHHHHHHHH------------HHHHHHHHHHHHHHHHHHHHH-HHHH 
S.cerevisiae      MERIIQQTDYDALSCKLAAISVGYLPSSGLQRLSVDLSKKYTEWHRSYLITLKKFSRRAF 60 
H.sapiens         ---------MATRQRESSITSCCSTSSCDADDEGVRGTCEDASLCKRFAVSIGYWHDPYI 51 
M.musculus        ---------MASSSRESSFSSCS--SSCDLDDEGVRGTCEDASLCKRFAVSIGYWHDPYI 49 
A.thaliana        ---------MAESRS---------------NRAAVQATNDDASASKLSCVKKGYMKDDYV 36 
C.elegans         ----MDSEAVSSDSHVAAAIATRRRSNSVSDDYSVQRTNDDATQCKYFATQKGYWKDEFI 56 
 
                   α 3                        α z                β 1        
                  HHHHHHHH--------HHHHHHHHHHHHHHHHHHHHHHHH-----SSSSSS------HHH 
S.cerevisiae      GKVDKAMR-----SSFPVMNYGTYLRTVGIDAAILEFLVA--NEKVQVVNLGCGSDLRML 113 
H.sapiens         QHFVRLSK----ERKAPEINRGYFARVHGVSQLIKAFLRK-TECHCQIVNLGAGMDTTFW 106 
M.musculus        EHLVRQSK----ERKAPEINRGYFARVHGVSQLIKAFLRK-TECHCQILNLGAGMDTTFW 104 
A.thaliana        HLFVKRP-----VRRSPIINRGYFSRWAAFRKLMSQFLLSGTSSKKQILSLGAGFDTTYF 91 
C.elegans         SRFANSSSNVSEARRFPEISMGYWARTAAIEKYVRDFLNE-FDGNAQVVSLGCGFDTLFW 115 
 
                   α A       β 2        α B        α 4                  
                  HHHHH----SSSSSSS-HHHHHHHHHHHHH-HHHHHH---H-----------SSSSS--S 
S.cerevisiae      PLLQMFP-HLAYVDIDYNESVELKNSILRESEILRIS---LGLSKEDTAKSPFLIDQGRY 169 
H.sapiens         RLKDEDLLPSKYFEVDFPMIVTRKLHSIKCKPPLSSPILELHSEDTLQMDGHI-LDSKRY 165 
M.musculus        KLKDEGLLPNKYFEVDFPMIVTRKLLTIKSKPLLFRPIMELHPEDTLQMDSHM-LDSKRY 163 
A.thaliana        QLLDEGNGPNLYVELDFKEVTSKKAAVIQNSSQLRD---KLGANASISIDEGQ-VLSDHY 147 
C.elegans         RLVSSGAKLVKYVEVDFSSVTSKKIRHILKPIGPNSVDLKKSFESDAVVSHHADLHAGNY 175 
 
                  β 3         α C              β 4           α D                 
                  SSSS-----HHHHHHHHH---------SSSSSS—-HHH—HHHHHHHHHHHHHH----SSS 
S.cerevisiae      KLAACDLNDITETTRLLDVCTKR-EIPTIVISECLLCYMHNNESQLLINTIMSKFSHGLW 228 
H.sapiens         AVIGADLRDLSELEEKLKKCNMNTQLPTLLIAECVLVYMTPEQSANLLKWAANSFERAMF 225 
M.musculus        AIIGADLRDLSELEEKLKKCNMNTQLPTLLITECVLVYMTPEQSANLLKWAASSFETAMF 223 
A.thaliana        KLLPVDLRDIPKLRDVISFADMDLSLPTFIIAECVLIYLDPDSSRAIVNWSSKTFSTAVF 207 
C.elegans         HLIGADLRQANELDQKLATCQLSHDIPTIFIAECVLVYMSADSSTALLKQIVSQFKQPAF 235 
 
                  β 5                α 5                   α E           β 6 
                  SSSSS--------HHHHHHHHHHHHHH------------HHHHHHH-------SSSSSSH 
S.cerevisiae      ISYDPIGGSQPNDRFGAIMQSNLKESRNLEMPTLMTYNSKEKYASRWSAA--PNVIVNDM 286 
H.sapiens         INYEQVN---MGDRFGQIMIENLR-RRQCDLAGVETCKSLESQKERLLSNGWETASAVDM 281 
M.musculus        INYEQVN---MDDRFGQIMIENLR-RRSCDLAGVETCKSLESQKERLLLNGWETASAVNM 279 
A.thaliana        FLYEQIH---PDDAFGHQMIRNLE-SRGCALLSIDASPTLLAKERLFLDNGWQRAVAWDM 263 
C.elegans         VNYEQFR---TSDAFTKVMEQNLG-DRGIQLHGLEMCESAEKQEERFRNAGFKEVKVMDM 291 
 
                   α 7       α 8             α 9       β 7 
                  HHHHHHH—HHHHHHHHH-------HHHHHHHHH-SSSSSSSS 
S.cerevisiae      WEIFNAQIPESERKRLRSLQFLDELEELKVMQTHYILMKAQW------------------ 328 
H.sapiens         MELYNRLPRAEVS-RIESLEFLDEMELLEQLMRHYCLCWAT---------------KGGN 325 
M.musculus        MELYSGLPRAEVN-RIESLEFLDEMELLEQLMRHYCLCWAT---------------RGGQ 323 
A.thaliana        LKVYGSFVDTQEKRRIERLELFDEFEEWHMMQEHYCVTYAVNDAMGIFGDFGFTREGGGE 323 
C.elegans         NQIFNNFLDQKEVSRIREIEMLDEMELLQQLFAHYCVVSARI------------------ 333 
 
 
 
 
 
Figure 1-10. The Structure of PPM1 in Saccharomyces cerevisiae. (a) The core 
domain structure of PPM1 represented by ribbon diagram [223]. (b) A superimposition 
of MT core domain of yeast leucine carboxyl methyltransferase 1 (PDB code 1RJD, 
purple), L-isoasparate-o-methyltransferase (PDB code 1JG3, blue), Yeco 
methyltransferase (PDB code 1IM8, red) and Phenylethanolamine 
N-methyltransferase (PDB code 1HNN, green) shows that β strands are conserved 
[223].  (c) Sliced representation of the PPM1 surface originated from reference [223]. 
A conformational change is necessary for AdoMet to enter or for AdoHCys to exit the 
cavity. The methyl group is accessible through the second cavity perpendicular to the 
AdoMet binding cavity, which may constitute the binding site for the PP2A C-terminal 
tail. (d) Based on the multiple sequence alignment of LCMT1 from different species by 
ClustalW, the yeast PPM1 PP2A binding site residues (blue), and AdoMet binding site 
residues (red) are highly conserved in methyltransferases of different species. 
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1.3.2 Biological Role of LCMT1 
 
Although LCMT1 and PP2A regulatory subunits are important in mammalian 
cells for the spindle checkpoint, which ensures proper spindle formation and 
chromosomal attachment prior to progression from M phase to G1 phase, the 
precise role of various regulatory subunits in spindle checkpoint and mitosis still 
need to be elucidated [224]. The latest research indicated that both B family 
isoform PR55δ and the B’ family isoform RR61γ are the negative regulators of 
sister chromatid separation. PR55δ is involved in stabilizing securin, which 
protect cohesins from the degradation by separase, a cohesion protease. 
PR61γ was also found to protect cohesion by binding to shugoshin and 
maintain cohesins in a more stable state [225;226]. LCMT1 knockdown in 
mammalian cells reduces both PP2AC methylation and the formation of PP2A 
heterotrimers and further influence the mitotic progression, in vivo [222]. 
 
In addition, B, B’ regulatory family and LCMT1 play important roles in 
anti-apoptosis. The knockdown by small hairpin RNAs and monoclonal 
antibodies of both B subunit and LCMT1 in HeLa cells induced apoptosis and 
this phenotype was partially rescued by thymidine treatment. This study also 
indicates that LCMT1 is essential for development. Homozygous knockout of 
LCMT1 in mice will cause embryonic lethality, but the details of mechanism are 
still unclear [222]. 
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Chapter Two 
 
Materials & Methods 
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2.1 Informatics 
 
2.1.1 Gene Annotation 
 
2.1.1.1 Bioinformatic Prediction 
 
In order to identify domains, protein secondary structure and related proteins, 
the full length sequences of Leucine carboxyl methyltransferase 1 (LCMT1) 
and Protein phosphatase methylesterase 1 (PME1) were submitted to the 
following webservers, SMART (simple modular architecture research tool [227], 
Pfam (protein families database of alignments and hidden Markov models) [220] 
and PSIPRED second structure prediction [228;229].  
 
2.1.1.2 The Limited Proteolysis 
  
Limited proteolysis is a commonly used method for probing conformational 
features of a protein. This method can be used to identify the most stable 
fragment or a domain in a protein structure, thus providing useful information 
that could direct choices in designing protein expression gene constructs [230]. 
 
Two proteases, trypsin and chymotrypsin (Sigma), were chosen for the 
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experiment. For the first experiment, the amount of protease should be about 
1000 times less than the amount of target protein in mass units. For example, 1 
µg of trypsin or chymotrypsin was added to the 1 mg of target protein. The 
sample was incubated at room temperature and the aliquots of the sample were 
removed for SDS-PAGE analysis at 10, 30, and 60 minutes, then at hourly 
intervals until the reaction has ended. 
 
To identify the most stable fragment or domain in target protein for protein 
construct design, the sample after protease digestion was immobilised on a 
PVDF membrane (GE Healthcare) via transfer buffer (10 mM CAPS pH 11.0, 
10% methanol) with a constant voltage of 250 milliamps (mA) for 2 hours and 
the target band of membrane, stained by CBB stain (0.025% Comassie Blue 
R-250, 40% methanol), was sent to Protein & Nucleic Acid Chemistry Facility 
(PNAC) of Cambridge University for the N-terminal protein sequence analysis 
(six residues).  The molecular weight of a target segment or a domain, from the 
solution at the concentration of 1 mg/ml of the protein sample in 10mM 
ammonium acetate buffer pH 6.4, was determined by Mass Spectrometry 
analysis at the Institute of Structural and Molecular Biology (ISMB). 
 
2.1.2 Protein Modeling 
 
In order to study the catalytic mechanism and the putative three dimensional 
structure, human LCMT1 model was generated and assessed based on yeast 
protein phosphatase methyltransferase 1 (PPM1) (PDB: 1RJG) by Modeller 
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9v2 [231, 232]. The initial model of LCMT1 for molecular replacement covered 
~75 % of the amino acid residues, including residues 62-108, residues 114-137, 
residues 157-231 and residues 258-321, present in the polypeptide chain used 
to obtain crystals. Further structural comparisons were accomplished by CCP4 
Molecular Graphics v1.0 [233] and PyMOL Viewer (DeLano Scientific LLC).  
 
2.2 Bacterial Strains 
 
Escherichia coli DH5α or Escherichia coli XL1-blue were used for cloning of 
DNA expression vectors while Escherichia coli BL21 (DE3) pLysS, Escherichia 
coli Rosetta (DE3) pLysS, Escherichia coli BL21 (DE3), and Escherichia coli 
C41 (DE3) were used for the expression of proteins. 
 
2.2.1 Growth Medium and Culture Conditions 
 
Luria-Bertani (LB) growth medium (10 g/L tryptone, 5 g/L yeast extract and 5 g/L 
NaCl) was produced using deionised water from an Elga Maxima Ultra-pure 
water purification system and sterilized by autoclaving and used for liquid 
cultivation of E. coli strains. LB agar plates consisted of LB medium 
supplemented with 15 g/L agar. 
 
LB medium for the cultures of E. coli DH5α, E. coli XL1-blue, E. coli BL21 (DE3) 
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and E. coli C41 (DE3) strains containing any pET30aTEV or pET28a 
expression vector (Novagen) was supplemented with 50 µg/ml kanamycin 
while the media for the growth of the cells containing any pET442b (Birkbeck 
College) or pGEX4T2 (GE Healthcare) expression vector was supplemented 
with 100 µg/ml ampicillin. In addition, 30 µg/ml chloramphenicol was included in 
media for the growth of any pLysS-containing E. coli strains. 
 
2.2.2 Competent E. coli Cells for Cloning 
 
One single colony of E. coli DH5α or E. coli XL1-blue cells was inoculated into 5 
ml LB media and incubated at 37 oC with shaking at 200 revolutions per minute 
(rpm) for overnight until the culture becomes cloudy. 1 ml of the overnight 
culture was transferred to 100 ml LB and incubated at 37 oC with shaking at 200 
rpm until mid log phase (OD600nm = 0.45). The cells were put on ice for 5 
minutes and then spun down by centrifugation at 3440 g for 5 minutes at 4oC. 
The supernatant was decanted and the cell pellet was resuspended in 15 ml of 
cold, sterile Transformation Buffer 1 (TFB1) (30 mM potassium acetate pH 5.8, 
100 mM RbCl, 50 mM MnCl2, 10 mM CaCl2, 15 % glycerol). The cells were 
incubated on ice for 2 hours and then spun down by centrifugation at 3440 g for 
5 minutes at 4 oC. The TFB1 was decanted and the cell pellet was resuspended 
in 3 ml of cold, sterile Transformation Buffer 2 (TFB2) (10 mM MOPS pH 6.8, 10 
mM RbCl, 75 mM CaCl2, 15 % glycerol). The competent cells were aliquoted 
into 100 µl samples and then placed at -80 oC. 
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2.2.3  Competent E. coli Cells for Protein Expression 
 
One single colony of E. coli BL21 (DE3) pLysS, or E. coli Rosetta (DE3) pLysS 
or E. coli C41 (DE3) or E. coli BL21 (DE3) cells was inoculated into 5 ml LB 
media and incubated at 37 oC with shaking overnight at 200 rpm until the 
culture becomes cloudy. The LB media contained 30 µg/ml chlorampheniol for 
the competent E. coli Rosetta (DE3) pLysS and E. coli BL21 (DE3) pLysS cells. 
1 ml of the overnight culture was transferred to 100 ml LB and incubated at 37 
oC with shaking at 200 rpm until OD600nm = 0.6. The cells were spun down by 
centrifugation at 860 g for 10 minutes at 4 oC. The cell pellet was resuspended 
in one-half volume (50 ml) of cold, sterile 100 mM CaCl2 and incubated on ice 
for 2 hours. The cells were spun down as before and gently resuspended in 4 
ml of cold sterile 100 mM CaCl2 containing 15 % sterile glycerol. The competent 
cells were aliquoted into 50 µl samples and then placed at -80 oC. 
 
2.2.4 Nucleic Acid Methods 
 
2.2.4.1 Purification of Plasmid DNA 
 
A single colony from freshly transformed DH5α or XL1-blue cell culture was 
inoculated into 5 ml LB media containing antibiotics and grown at 37 oC with 
vigorous shaking at 200 rpm for overnight. Purification of plasmid was 
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performed using a QIAprep Spin Miniprep Kit (Qiagen). The bacterial cells were 
spun down and lysed in alkaline buffer. The lysate was subsequently 
neutralised and adjusted to high-salt binding conditions.  The spin columns 
contain a unique silica membrane specific to the adsorption of DNA. Salts are 
removed by a wash buffer containing 80 % ethanol and then the plasmid eluted 
from the QIAprep spin column using elution buffer (Tris containing buffer, pH 
7.0 – 8.5). 
                
2.2.4.2 Agarose Gel Electrophoresis 
 
For separation and identification of digested DNA fragments, DNA fragments 
were resolved on 1 % agarose gel using electrophoresis. Agarose was 
dissolved in TAE buffer (40 mM Tris-acetate and 1 mM 
ethylene-diamine-tetraacetic acid (EDTA)) containing 0.5 µg/ml ethidium 
bromide (EtBr) to detect the DNA. Gels were cast and set in the apparatus 
provided. DNA samples were prepared by the addition of 1x Orange Loading 
Dye Solution (Fermentas). The Quick-Load 100 bp and 1 kb DNA ladders (New 
England Biolabs) were used as molecular weight standards. Electrophoresis 
was carried out in TAE buffer at 100 V for 20-30 minutes and the resolved DNA 
bands were analyzed on UV-transilluminators. 
 
2.2.4.3 Extraction of DNA from Agarose Gels 
 
DNA fragments were extracted from the gel using the QIAquick Gel Extraction 
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Kit (Qiagen). The appropriate salt concentration and pH for adsorption of DNA 
to the silica-membrane of the spin column were provided by binding buffers. 
Salts are washed away by the ethanol-containing PE buffer. The DNA is 
subsequently eluted with buffer EB (10mM Tris, pH 8.5).   
 
2.2.5 Manipulation of Constructs  
 
Appropriate oligo-nucleotide primers were designed to amplify specific gene 
targets by polymerase chain reaction (PCR). The primers were designed to be 
at least 16 base pairs long with similar melting temperatures and included a 
stop codon in the reverse primer.  
 
The DNA sequence for all constructs of LCMT1 was amplified by polymerase 
chain reaction (PCR) using human’s full length LCMT1 as a template. PCR for 
all LCMT1 variants except LCMT17-334 and LCMT1SD20-334 was 
accomplished using primers designed to introduce the restriction site PciI 
(ACATGT) at the 5’ end of the PCR fragments and a HindIII (AAGCTT) 
restriction site and stop codon at the 3’ end. In order to generate DNA 
constructs for LCMT17-334 and LCMT1SD20-334, nested PCR protocol with 
two pairs of primers was used. The restriction site PciI was introduced at the 5’ 
end of the PCR fragments while the reverse primer 
(5’-CTGTGACTCTAATGATTTGCCTTCGTTCACCTGTTCGTA-3’) 
corresponded to complementary DNA strand of the amino acid sequence 
YEQVN-EG-KSLE, where YEQVN sequence comprises residues 228-232 of 
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LCMT1.  The second pair of primers consisted of a forward primer 
(5’-TACGAACAGGTGAACGAAGGCAAATCATTAGAGTCACAG-3’) coding for 
YEQVN-EG-KSLE amino acid sequence and a reverse primer that introduced 
HindIII restriction site and a stop codon at the 3’ end of the fragment.  
Combination of the two fragments yielded a PCR amplicon encoding residues 
20-232 linked through the EG dipeptide to residues 259-334 of the human 
LCMT1. The amplified PCR products were cloned into a pET30aTEV 
expression vector (Novagen) with an N-terminal six histidine affinity tag and a 
tobacco etch virus (TEV) protease cleavage site to allow the removal of the 
affinity tag.  
 
For constructs of PME1, majority of PCR products were designed to contain the 
NcoI (CCATGG) restriction site at the 5’ end and a HindIII (AAGCTT) restriction 
site and the stop codon at the 3’ end. However for the production of 
PME1_GE239-283 and PME1_ET239-283 constructs, PCR primers were designed 
to incorporate the restriction site BamHI (GGATCC) at the 5’ end of the PCR 
fragments and a NotI (GCGGCCGC) restriction site and the stop codon at the 3’ 
end. All methods and protocols for molecular cloning of PME1 variant were 
similar except for PME139-376 which contains residues 39-238, a small linker 
EGK, followed by PME1 residues 284-376 (1). Nested PCR protocol with two 
pairs of primers was used to generate this construct. Two primers for residues 
39-238 of PME139-376 were designed to introduce the restriction site PciI 
(ACATGT) at the 5’ end of the PCR fragments and KQC-EGK-PYT site 
(GGTGTATGGTTTGCCTTCACACTGTTT) at the 3’ end and another two 
primers for residues 284-376 of PME139-376 were set up to apply the 
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KQC-EGK-PYT site  (AAACAGTGTGAAGGCAAACCATACACC) at the 5’ end 
of the PCR fragments and the HindIII (AAGCTT) restriction site and stop codon 
at the 3’ end. All PCR products were digested and cloned into pET30aTEV 
vector except PME1_GE239-283 and PME1_ET239-283 which were cloned 
into pGEX4T2 and pET442b vector respectively. In addition, few PME1 
expression constructs, designed for isothermal titration calorimetry 
measurements, included a BamHI (GGATCC) site at the 5’ end and a NotI 
(GCGGCCGC) site at the 3’ end and these PCR amplicons were cloned into a 
pET442b (Birkbeck College) with E. coli NusA protein tag (NusA tag) or 
pGEX4T2 (GE Healthcare) with glutathione-S-transferase tag (GST tag). 
 
PCR amplification of the A subunit of Protein phosphatase 2A (PP2AA) was 
carried out with the primers that introduced NdeI (CATATG) and NotI 
(GCGGCCGC) restriction sites at the 5’ and 3’ ends of the amplified fragment 
respectively. The amplified PCR product was cloned into a pET28a expression 
vector with thrombin cleavage site and an N-terminal six-histidine affinity tag. 
The names of all expression constructs that were produced and described in 
this thesis, and the primers used to generate them are shown in Table 1. 
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Construct name Vector 5’ to 3’ Forward Primer 3’ to 5’ Reverse Primer 
LCMT161-334 pET30a 
CGCGACATGTCTAGGAAAGCCCCTGAAATC CGCGAAGCTTTTAATAAGTTATCTCC 
LCMT11-321 pET30a 
GGCGCGACATGTCTATGGCCACTAGGCAGAGG GCTCATTAAGCTTCTAGGTTGCCCAGCAAAG 
LCMT19-321 pET30a 
GGGAGGGACATGTCTATCACCTCCTGCTG GCTCATTAAGCTTCTAGGTTGCCCAGCAAAG 
LCMT116-321 pET30a 
CACCTCCTACATGTCTACCTCGAGCTG GCTCATTAAGCTTCTAGGTTGCCCAGCAAAG 
LCMT120-321 pET30a 
GTATTTCAGGGCGCCATGGACGAGAACGACGAGGGCGTG GCTCATTAAGCTTCTAGGTTGCCCAGCAAAG 
LCMT120-334 pET30a 
GTATTTCAGGGCGCCATGGACGAGAACGACGAGGGCGTG ACCCGACTTCCTCTATTGAATAATTTTAAGCACGAGGCAG 
LCMT11-334 pET30a 
GGCGCGACATGTCTATGGCCACTAGGCAGAGG ACCCGACTTCCTCTATTGAATAATTTTAAGCACGAGGCAG 
LCMT17-334 pET30a 1. CCGGCAACATGTCTGAATCCTCTATCACCTCC 
2.       TACGAACAGGTGAACGAAGGCAAATCATTAGAGTCACAG 
1. CTGTGACTCTAATGATTTGCCTTCGTTCACCTGTTCGTA 
2. GGTTCAAGCTTTTAATAAGTTATCTCCTTCAG 
LCMT1SD20-334 pET30a 1.      CCGGCAACATGTCTGACGCAGACGACGAGGGC 
2.       TACGAACAGGTGAACGAAGGCAAATCATTAGAGTCACAG 
1. CTGTGACTCTAATGATTTGCCTTCGTTCACCTGTTCGTA 
2. GGTTCAAGCTTTTAATAAGTTATCTCCTTCAG 
LCMT17-232 pET30a CCGGCAACATGTCTGAATCCTCTATCACCTCC GGTTCAAGCTTTTAGTTCACCTGTTCGTAGTT 
PME151-370 pET30a 
GAGTCCATGGAGTCCATGGAAGATGTAGAA GATGGGTTCAAGCTTCTAGTGCCGGAT 
PME153-370 pET30a 
GAGTCCATGGAAGATGTAGAAGTAGAGAAT GATGGGTTCAAGCTTCTAGTGCCGGAT 
PME156-370 pET30a 
GAGTCCATCCATGGTAGAAGTAGAGAATG GATGGGTTCAAGCTTCTAGTGCCGGAT 
PME165-370 pET30a 
GAATGAAACCCATGGATACTTTTCGAGTCTAC GATGGGTTCAAGCTTCTAGTGCCGGAT 
PME188-370 pET30a 
CATGTAGGCCATGGCGTCTGCCCTTTC GATGGGTTCAAGCTTCTAGTGCCGGAT 
PME151-386 pET30a 
GAGTCCATGGAGTCCATGGAAGATGTAGAA CTAACAAAGCTTCTAACAGCCAGGAAACAC 
PME153-386 pET30a 
GAGTCCATGGAAGATGTAGAAGTAGAGAAT CTAACAAAGCTTCTAACAGCCAGGAAACAC 
PME11-382 pET30a 
CGCGCCATGGGTATGTCGGCCCTC CTAACAAAGCTTCTACACACACTGGAATCCACC 
PME124-382 pET30a 
CCGGCACCATGGGCAGTCAGAGC CTAACAAAGCTTCTACACACACTGGAATCCACC 
PME126-382 pET30a 
GCAGCGCCATGGGTCAGAGCGGA CTAACAAAGCTTCTACACACACTGGAATCCACC 
PME144-382 pET30a 
ACTTTTCCATGGTTCCTTGGAGTCAGTATTTTGAG CTAACAAAGCTTCTACACACACTGGAATCCACC 
PME11-386 pET30a 
CGCGCCATGGGTATGTCGGCCCTC CTAACAAAGCTTCTAACAGCCAGGAAACAC 
PME1_ET239-283 pET442b CGCGGATCCGAAGGAATTACAAGTCCAGAA TTCCTTTTGCGGCCGCTCAATGGTCTTTCTTGGTCTCCAT 
PME1_GE239-283 pGEX4T2 CGCGGATCCGAAGGAATTACAAGTCCAGAA TTCCTTTTGCGGCCGCTCAATGGTCTTTCTTGGTCTCCAT 
PME139-376 pET30a 1. CCGGCAACATGTCTCGGGATTTTCCCCT 
2.       AAACAGTGTGAAGGCAAACCATACACC 
1. GGTGTATGGTTTGCCTTCACACTGTTT 
2. GGTTCAAGCTTTCAGATGGGTTCTGCAAA 
PP2AA_Full pET28a 
GGAATTCCATATGGCGGCGGCCGACGGC CGCGGAATGCGGCCGCTCAGGCGAGAGACAGAACAGTCA 
Table 2-1. The Forward and Reverse Primers of all PME1, LCMT1 and PP2AA Constructs for E. coli Strains.
 81 
 
2.2.5.1 Amplification of Genes Using Polymerase Chain Reaction 
 
PCR amplification was performed in 50 µl reaction volumes containing 1x  
Phusion HF buffer (FINNZYMES), 3 % DMSO, 1 µM of forward primer, 1 µM of 
reverse primer, 0.5 µg DNA template and 0.02 units (U) Phusion DNA 
Polymerase (FINNZYMES). The cycling conditions of PCR reactions were 
carried out using the guideline (FINNZYMES) as follows: initial denaturation at 
98 oC for 5 minutes was followed by performing 30 cycles that consisted of 
denaturation step at 98 oC for 1 minute, 1 min annealing step at the appropriate 
temperature and an extension step at 72 oC that lasted for 30 seconds per 1000 
base pairs to amplify the required stretch of DNA. Annealing temperatures were 
chosen based on the melting temperature value (Tm) of primers. Final 
extension step was carried out at 72oC for 10 minutes and the reactions were at 
the end held at 4 oC. The PCR amplified products were analysed on an agarose 
gel, and extracted using QIAquick gel extraction kit (Qiagen). 
 
2.2.5.2 Restriction Enzyme Digestion 
 
All restriction enzymes were purchased from New England Biolabs. The 
plasmid pET30aTEV was double digested with NcoI and HindIII while the 
double cleavage of pET28a plasmid was carried out using NdeI and NotI 
enzymes. The pET442b and pGEX4T2 vector were digested with BamHI and 
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NotI enzymes. All LCMT1 PCR products were double digested with PciI and 
HindIII while PME1 PCR fragments were double digested with NcoI or PciI and 
HindIII except for those PCR amplicons that were subsequently cloned into 
pET442b and pGEX4T2 vectors which were double digested with BamHI and 
NotI. The PCR fragments of PP2AA were double digested with NdeI and NotI. 
All DNA digestion reactions were performed using the protocol guideline. 
Reactions were performed in 20-50 µl volumes and incubated at appropriate 
temperature based on the optimal activity of enzymes used for overnight 
reactions. Cleavage products were electrophoresed on an agarose gel and 
subsequently extracted and purified using QIAquick Gel Extraction Kit 
(Qiagen). 
 
2.2.5.3 DNA Ligations and Transformations 
 
Ligations were carried out in 10 µl or 20 µl volumes using insert:vector molar 
ratios of  3:1 or 5:1, 1x T4 DNA ligation buffer (New England Biolabs) (50 mM 
Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol (DTT), 1 mM ATP, 25 µg/ml 
bovine serum albumin (BSA)) and 400 U of T4 DNA ligase (New England 
Biolabs) at 25 oC, overnight.  
 
100 µl aliquots of competent cells were thawed on ice. 10 µl of ligation mixture 
or 1 µl of constructed plasmid were added to the thawed cells and left on ice for 
30 minutes. The cells were then heat shocked at 42 oC for 45 seconds and then 
left on ice for at least 2 minutes. 500 µl of LB broth were subsequently added to 
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the cells that were then incubated at 37 oC and 200 rpm for 1 hour. 200 µl of 
transformation mixture was plated onto agar plate with the appropriate 
antibiotic and incubated overnight at 37 oC. 
 
Constructed plasmids were verified by restriction enzyme digestion to confirm 
the presence and size of an insert and by sequencing via Eurofins MWG 
Operon Company.  
 
2.2.5.4 Preparation of Glycerol Stocks 
 
A single colony from an agar plate was inoculated into 5 ml of LB with the 
appropriate antibiotic. Cells were incubated overnight at 37 oC with shaking at 
200 rpm. 1 ml of each culture was transferred into a cryogenic vial along with 
700 µl of 70 % glycerol and stored at -80 oC. 
 
2.2.6 Protein Expression   
 
The summary of all LCMT1, PME1 and PP2AA variants protein expression 
results are listed in Table 2-2. 
 
2.2.6.1 Small Scale Protein Expression Tests in 100 ml LB Medium 
 
A single colony selected from an agar plate of freshly transformed E. coli BL21 
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(DE3) pLysS or E. coli Rosetta (DE3) pLysS or E. coli C41 (DE3) or E. coli BL21 
(DE3) was inoculated in 5 ml of LB media containing antibiotics and the culture 
was incubated overnight at 37 ºC and 200 rpm. 1 ml of overnight culture was 
transferred to 100 ml of LB medium containing antibiotics and incubated at 37 
ºC and 200 rpm until OD600nm = 0.6. The expression of protein was initiated by 
addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration 
of 1 mM and the protein expression was carried out at 37 ºC for further 4 hours. 
The cell cultures were spun down at 20000 g in a Sorvall SS-34 rotor and the 
pellets were resuspended with Tris buffer (25mM Tris pH 8.0) to obtain an OD of 
0.6. The cells were disrupted by mild sonication and then spun down at 20000 g 
in a Sorvall SS-34 rotor. Finally, supernatant and cell debris/insoluble fraction of 
each sample were analysed by SDS polyacrylamide gel electrophoresis to 
assess protein expression and its solubility.   
 
2.2.6.2 Large Scale Protein Expression of all LCMT1 Constructs 
 
In order to enhance production of soluble protein, E. coli C41 (DE3) cells were 
cotransformed with pBADESL plasmid containing GroES/GroEL (chaperonin) 
genes in addition to various LCMT1 recombinant clones [234]. Alternatively, 
LCMT1 expression clones were expressed in BL21 (DE3) pLysS cells. Protein 
expression in C41 (DE3) cells was carried out in batches of 6 L LB medium 
containing kanamycin (50 µg/ml) and ampicillin (100 µg/ml) and L-arabinose (2 
mg/ml) for induction of GroES/EL expression. For protein expression in BL21 
(DE3) pLysS cells, 50 µg/ml kanamycin and 30 µg/ml chloramphenicol were 
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added to the media. The cells were incubated at 37 oC and 200 rpm and grown 
to an OD600nm of 0.6. The cultures were then supplemented with 1 mM IPTG for 
protein induction. After 5 hours of induction, the cells were harvested at 4 oC 
and 5000 g in a Sorvall SLA-3000 rotor for 15 minutes. The cell pellets were 
stored at -20 oC. 
 
2.2.6.3 Large Scale Protein Production of all PME1 Constructs 
 
The transformed E. coli BL21 (DE3) pLysS, E. coli Rosetta (DE3) pLysS or E. 
coli BL21 (DE3) cells from glycerol stock were inoculated into 100 ml of fresh 
medium containing suitable antibiotics and incubated overnight at 37 oCt. The 
cell cultures were then aliquoted into 6 L LB medium and grown at 37 oC until 
OD600nm = 0.6 when protein expression was induced by 0.5 mM IPTG at 30 oC 
and 180 rpm for 5 hours.  After 5 hours of induction, the cells were harvested at 
4 oC by centrifugation at 5000 g in a Sorvall SLA-3000 rotor for 15 minutes. The 
cell pellets were stored at -20 oC until the time of protein purification. 
 
2.2.6.4 Large Scale Protein Expression of the PP2AA Construct 
 
Large scale protein expression from transformed E. coli BL21 (DE3) cells was 
performed in batches of 6 L LB medium containing kanamycin (50 µg/ml). Cell 
cultures were incubated at 37 oC with shaking at 180 rpm and grown to an 
OD600nm of 0.6. For induction of protein expression, the cultures were then 
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supplemented with 0.1 mM IPTG at 18 oC. After 18 hours of induction, the cells 
were harvested by centrifugation at 4 oC and 5000 g in a Sorvall SLA-3000 rotor 
for 15 minutes [12;17]. The cell pellets were stored at -20 oC until the time of 
protein purification. 
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Construct Name Protein Sequence Protein Expression Protein Expression 
Temperature (oC) 
Ammount of Protein Purified from 
1 L of E. coli Cell Culture (mg) 
LCMT161-334 residues 61-334 Soluble 37 10 
LCMT11-321 residues 1-321 Insoluble - - 
LCMT19-321 residues 9-321 Insoluble - - 
LCMT116-321 residues 16-321 Insoluble - - 
LCMT120-321 residues 20-321 Insoluble - - 
LCMT120-334 residues 20-334 Soluble 37 1.5 
LCMT11-334 residues 1-334 Soluble 37 2.5 
LCMT17-334 residues 7-232, a linker EG, 
and residues 259-334 
Soluble 37 4 
LCMT1SD20-334 residues 20-232, a linker EG, 
and residues 259-334 
Soluble 37 4 
LCMT17-232 residues 7-232 Insoluble - - 
PME151-370 residues 51-370 Insoluble - - 
PME153-370 residues 53-370 Insoluble - - 
PME156-370 residues 56-370 Insoluble - - 
PME165-370 residues 65-370 Insoluble - - 
PME188-370 residues 88-370 Insoluble - - 
PME151-386 residues 51-386 Insoluble - - 
PME153-386 residues 53-386 Insoluble - - 
PME11-382 residues 1-382 Insoluble - - 
PME124-382 residues 24-382 Soluble 30 2 
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PME126-382 residues 26-382 Soluble 30 2 
PME144-382 residues 44-382 Insoluble - - 
PME11-386 residues 1-386 Soluble 30 2 
PME1_ET239-283 NusA and residues 239-283 Soluble 30 3 
PME1_GE239-283 GST and residues 239-283 Soluble 30 2.5 
PME139-376 residues 39-238, a small 
linker EGK, and residues 
284-376 
Soluble 30 2.5 
PP2AA_Full Residues 1-589 Soluble 18 1 
 
Table 2-2. Summary of LCMT1, PME1, and PP2AA Protein Expression and Production. 
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2.3  Baculovirus Expression System 
 
Baculovirus expression systems are powerful systems for high-level, 
recombinant protein expression in insect cells. Target genes placed under the 
transcriptional control of the strong polyhedrin promoter of the Autographa 
california nuclear polyhedrosis virus (AcNPV) are expressed during the late 
stages of infection. Bac-to-bac baculovirus expression system (Invitrogen) and 
BacMagic transfection system (Novagen) were used for the expression of the 
full length C subunit of protein phosphatase 2A (PP2AC). 
 
2.3.1 Insect Cell Lines 
 
Two insect cell lines were used for baculovirus expression system. Sf9 cells 
(Novagen) are derived from pupal ovarian tissue of Spodoptera frugiperda and 
used for the transfection, amplification and quantification of virus. High Five 
cells (Invitrogen) that are commonly recommended for protein expression, 
originate from the ovarian cells of the cabbage looper Trichoplusia ni. Sf9 cells 
were grown in protein-free Insect-Xpress medium (Lonza) while High Five cells 
were grown in protein-free EX-CELL 405 medium containing L-glutamine 
(Sigma). 
 
2.3.1.1 Initiation of Cell Culture from Frozen Stock 
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A vial of cells from liquid nitrogen was incubated in a water bath at 37 oC until 
cells were all thawed. The vial was decontaminated outside using 70 % ethanol 
and placed on ice. 4 ml of Insect-Xpress medium or EX-CELL 405 medium was 
added to a 25 cm2 tissue culture flask (Sigma). 1 ml of cells was transferred into 
the flask and incubated at 27 oC for 30 minutes. After the cells were attached 
the medium was replaced with 5 ml of fresh medium and the cells were further 
incubated at 27 oC for 24 hours. The health of the cells was assessed by 
viability which should be greater than 70 %. The cells were incubated until they 
formed a confluent monolayer.  
 
2.3.1.2 Suspension Cultures of Cells 
 
5 ml of the cells from tissue culture flask was transferred to 250 ml erlenmeyer 
flask with a 43 mm vent cap (Corning) containing 50 ml fresh medium with 5 % 
fetal bovine serum (FBS) (Biosera) and antibiotics and incubated in shaking 
incubator at 27 oC and 125 rpm. The cells were checked daily and split when 
the log phase cell density of Sf9 or High Five cells exceeded 4 million cells per 
ml. 
 
2.3.1.3 Long Term Storage of Insect Cells 
 
For the storage, cell viability, used to assess healthy cells content in cell 
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population, needs to be at least 90 %, as nearly 30 % of cells are lost during the 
recovery process. The freezing medium for Sf9 cells contains 60 % 
Insect-Xpress medium, 30 % FBS and 10 % DMSO and for freezing of High 
Five cells the medium includes 42.5 % old EX-CELL 405 medium from original 
cell culture, 42.5 % fresh EX-CELL 405 medium, 5 % FBS and 10 % DMSO. 
Sterile cryovials were placed on ice. The cells were spun down at 4 oC and the 
supernatant was decanted to be used later for the preparation of freezing 
medium for High Five cells. The cells were resuspended in freezing medium 
and 1 ml of the cell mixture was transferred to sterile cryovials, placed at -20 oC 
for 1 hour and then incubated at -80 oC for 24 hours. Sterile cryovials with insect 
cells were finally stored in liquid nitrogen. 
 
2.3.2 Bac-to-Bac Baculovirus Expression System (Invitrogen) 
             
To produce the baculovirus for the expression of PP2AC and improve the 
stability of protein, target gene was cloned into the pFastBacHTa vector with an 
uncleavable HA tag or 8 histidine tag and introduced D88N mutation in the 
active sites of the enzyme [235].        
              
2.3.2.1 Cloning of PP2AC 
 
Conventional molecular biology procedures and techniques were used for 
cloning and DNA constructs manipulation in bacterial strains. DNA gene 
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expression constructs and primers designed for insect cells expression system 
are shown in Table 2-3. The primers used to generate the expression 
constructs of PP2AC encompass an NcoI (CCATGG) site at the 5’ end and a 
HindIII (AAGCTT) site at the 3’ end. pFastBacHTa plasmid (Invitrogen) and the 
full length PP2AC DNA fragment were digested overnight at 37oC with NcoI and 
HindIII restriction enzymes. After ligation using T4 DNA Ligase (New England 
Biolabs) overnight at room temperature, the recombinant plasmid was 
transformed into E. coli DH5α cells. The recombinant plasmid was finally 
verified by using diagnostic restriction enzyme reaction and by DNA 
sequencing (Eurofins MWG). 
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Construct name Vector 5’ to 3’ Forward Primer 3’ to 5’ Reverse Primer 
PP2AC_Full 
with 8 His Tag 
pFastBacHTa CCGCGCCATGGCTCATCACCATCACCATCACCATCACGAGAAGGTG GGCCAAGCTTTTATTACAGGAAGTAGTCTGG 
PP2AC_Full 
with 8 HA Tag 
pFastBacHTa CCGCGCCATGGCTTACCCATACGACGTCCCAGACTACGACGAGAAGGTGT GGCCAAGCTTTTACAGGAAGTAGTCTGGGG 
PP2AC_Full 
with 8 His Tag 
pBAC4x-1 CGGGATCCATGCACCACCACCACCACCACCACCACGACGAGAAGGTGTTC GGCCGCATGCTTACAGGAAGTAGTCTGGGG 
PP2AA_Full pBAC4x-1 TCCCCCGGGATGGCGGCGGCCGAC GACTAGTTCAGGCGAGAGACAGAA 
 
Table 2-3. Forward and Reverse Primers of all PP2AC and PP2AA DNA Constructs for Baculovirus Expression System. 
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2.3.2.2 Transposition of Target Genes 
 
For transposition of target DNA, the recombinant plasmid is transformed into E. 
coli DH10Bac competent cells (Invitrogen) containing the bacmid with a 
mini-attTn7 target site and the helper plasmid (Figure 2-1). 
 
Luria agar plates containing 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml 
tetracycline, 100 µg/ml bluo-gal, and 40 µg/ml IPTG were prepared and 50 µl of 
E. coli DH10Bac competent cells were thawed on ice.  Approximately 1 ng of 
recombinant plasmid was added to the DH10Bac competent cells and 
incubated on ice for 30 minutes. The mixture was heat shocked at 42 oC for 45 
seconds and then chilled on ice for 2 minutes. 900 µl of SOC medium 
(Invitrogen) was added to the mixture and then the cells were placed in a 
shaking incubator at 37oC and 250 rpm for 4 hours. 200 µl of transformation 
mixture was plated evenly onto Luria agar plate and incubated at 37 oC for 24 to 
48 hours. 
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Figure 2-1. Bac-to-Bac Baculovirus Expression System (Invitrogen). The target gene is cloned into a pFastBac donor plasmid 
(Invitrogen), followed by transformation into DH10Bac competent cells (Invitrogen). The cells contain the bacmid with a mini-attTn7 
target site and the helper plasmid. The target gene can be transposed to the mini-attTn7 target site in the presence of transposition 
proteins provided by the helper plasmid. Bacmid with target gene can be further identified by colony’s color due to disruption of the 
lacZ gene. Bacmid was purified and used to transfect insect cells.
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2.3.2.3 Purification of Recombinant Bacmid  
 
White colonies containing the recombinant bacmid are selected from plates and 
inoculated into 5 ml LB media containing antibiotics, 50 µg/ml kanamycin, 7 
µg/ml gentamicin, and 10 µg/ml tetracycline, and grown overnight at 37 oC with 
vigorous shaking at 200 rpm. 1 ml of each sample was transferred into a 
cryogenic vial along with 500 µl of 70 % glycerol and stored at -80 oC. 
 
The cells were spun down at 3440 g for 10 minutes and the supernatant was 
decanted. The pellet was resuspended using 0.3 ml of solution I (15 mM Tris pH 
8.0, 10 mM EDTA, and 100 µg/ml RNase A) and lysed upon addition of 0.3 ml of 
solution II (0.2 M NaOH, and 1 % SDS). The lysate was gently mixed and 
incubated at room temperature for 5 minutes. 0.3 ml of solution III (3 M 
potassium acetate pH 5.5) was added for precipitating protein and isolating 
genomic DNA. The sample was placed on ice for 10 minutes and then spun 
down at 16060 g for 10 minutes. The supernatant was transferred to the tube 
containing 0.8 ml of absolute isopropanol. The sample was mixed gently and 
placed on ice for 10 minutes. After incubation, the mixture was spun down for 
10 minutes, the supernatant was removed, and the pellet was washed with 0.5 
ml of 70 % ethanol. The pellet was air dried for 10 minutes and dissolved in 40 
µl of TE buffer (10 mM Tris pH 8.0, and 1 mM EDTA). The bacmid was stored at 
4 oC. 
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2.3.2.4 Transfection of Sf9 Insect Cells (Novagen) 
 
1 million Sf9 cells in 2 ml of Insect-Xpress protein-free medium (Lonza) 
containing 7 µg/ml gentamicin were seeded in 2 ml cell dish and allowed to 
attach at 27 oC for 1 hour. For each transfection, solution A (100 µl 
Insect-Xpress protein-free medium without antibiotics, and 10 ng of bacmid 
DNA) and solution B (100 µl Insect-Xpress protein-free medium without 
antibiotic, and 6 µl CellFECTIN Reagent (Invitrogen)) were prepared and mixed 
thoroughly. Two solutions were combined and incubated at room temperature 
for 45 minutes. The cells were washed once using 2ml of Insect-Xpress 
protein-free medium without antibiotics. Solution C was formed such that 0.8 ml 
of Insect-Xpress protein-free medium without antibiotics was added to tube 
containing the mixture of solution A and B. Wash medium was removed from 
the cell dish and then 1 ml of solution C was overlaid over the cells. The cells 
were incubated at 27 oC for 5 hours. After incubation, the tansfection mixture 
was decanted and 2 ml of the fresh Insect-Xpress protein-free medium 
containing 7 µg/ml gentamicin was added. The cells were incubated at 27 oC for 
72 hours. After 72 hours transfection, the viruses were harvested from the cell 
culture medium containing 2 % FBS and stored at 4 oC, protected from light.  
   
2.3.2.5 Amplification and Quantification of Viruses  
 
2 million cells per ml in 50 ml suspension culture were infected using 100 µl of a 
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viral stock and incubated in shaking incubator at 27 oC for 72 hours. The cells 
were spun down at 860 g and 4 oC. 50 ml of the supernatant containing viruses 
were filtered and supplemented with 1 ml FBS for further quantification of 
viruses.  
 
For efficient titer of viral inoculum, the FastPlax Titer Kit (Novagen) utilizing a 
monoclonal antibody specific to an external epitope of baculovirus glycoprotein 
64 (GP64) was used. The GP64 envelope fusion protein is an integral 
membrane protein which could be detected on the surface of the infected cells 
at 8-24 hours post-infection.  
 
Following the manufacturer protocol, infected cells are fixed after 20-30 hours 
post-infection by serial diluted viral stock (10-5, 10-6, and 10-7) and FastPlax 
antibody is added to the cells for GP64 detection. Goat Anti-Mouse IgG 
β-Galactosidase Conjugate and X-Gal/NBT were used for colorimeric antibody 
detection. The cells infected by baculovirus are distinguished by their dark blue 
color. The number of well isolated dark blue cell was count for the calculation of 
the viral titer. The titer was calculated with the following formula: 
 
Plaque-forming unit per ml = 5 x (# infected cells and foci) x (dilution factor) 
(2.1) 
           dilution factor = dilution of viral stock (10-5, 10-6, and 10-7) 
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2.3.2.6 Optimization of Infection Conditions for High Five Cells 
  
For multiplicity of infection (MOI) optimization and the time course of infection, 2 
million cells per ml in 50 ml suspension culture were infected at varying MOIs 
and 5 ml of cells from each MOI sample were harvested at the following time 
intervals: 24, 36, 48, 60 and 72 hours. 
 
Each sample of different MOI and time intervals was lysed using 1 ml of 
FastBreak Cell Lysis Reagent (Promega) and incubated on ice for 30 minutes. 
The cell lysate was pelleted at 16060 g and 4 oC. The supernatant of each 
sample was analyzed using SDS-PAGE electrophoresis and verified by His-Tag 
AP Western Reagent Kit (Novagen). 
 
2.3.3 BacMagic Transfection System (Novagen) 
  
BacMagic DNA is a faster method than bac-to-bac baculovirus expression 
system for generating recombinant baculoviruses by eliminating the steps of 
bacmid generation and purification. The BacMagic DNA (Novagen) and 
pBAC4x-1 plasmid with target gene were co-transfected into insect cells 
through GeneJuice transfection reagent (Novagen). The homologous 
recombination of the pBAC4x-1 plasmid and BacMagic DNA takes place in 
insect cells thus restoring the function of virus (Figure 2-2). 
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Figure 2-2. The BacMagic System (Novagen). The BacMagic DNA, an 
AcNPV genome, contains a portion of the open reading frame (ORF) 1629 and 
a bacterial artificial chromosome (BAC) in place of the polyhedrin (polh) coding 
region. The target gene is cloned into pBAC transfer plasmid and further 
co-transfected with BacMagic DNA into insect cells. Homologous 
recombination within the cells restores the function of the virus ORF1629 while 
the target coding sequence replaces the BAC sequence. 
 
2.3.3.1 pBAC4x-1 with PP2AC  
 
To improve the stability of PP2AC protein, target gene was cloned into the 
pBAC4x-1 plasmid (Novagen) with uncleavable 8 His tag and D88N mutation 
was introduced in the active site of the enzyme. The primers for constructs of 
PP2AC include a BamHI (GGATCC) site at the 5’ end and a SphI (GCATGC) site 
at the 3’ end. For cleavage of DNA, pBAC4x-1 plasmid and the full length 
PP2AC DNA fragment were both digested overnight at 37oC by BamHI and SphI 
(New England Biolabs). The pBAC4x-1 and the full length PP2AC DNA 
fragments were ligated using T4 DNA Ligase (New England Biolabs) at and the 
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recombinant plasmid was transformed into E. coli DH5α. The recombinant 
plasmid was finally verified using restriction enzyme digestion and sequencing 
(Eurofins MWG). 
 
2.3.3.2 pBAC4x-1 with PP2AA and PP2AC 
 
The pBAC4x-1 vector contains four promoters and cloning sites for a large 
scale expression of multiple target genes in the same cell. For co-expression of 
PP2AC and PP2AA protein, pBAC4x-1 plasmid containing PP2AC sequence 
was used.  For PCR amplification of PP2AA sequence, pET28a plasmid 
containing PP2AA sequence (PP2AA_Full), described in section 2.2.5, was used 
as a template and the primers were introduced SmaI (CCCGGG) and SpeI 
(ACTAGT) restriction sites at the 5’ and 3’ ends of the amplified fragment 
respectively. Both PP2AC-containing pBAC4x-1 plasmid and the PCR product 
were digested overnight at 25 oC using restriction enzyme, SmaI and SpeI (New 
England Biolabs).  The plasmid and the insert were ligated overnight using T4 
DNA Ligase (New England Biolabs) at room temperature and the recombinant 
plasmid was transformed into E. coli DH5α. The DNA sequence was verified by 
restriction enzyme digestion and through sequencing (Eurofins MWG). 
 
2.3.3.3 Transfection of Sf9 Cells 
 
1 million Sf9 cells in 2 ml of Insect-Xpress protein-free medium (Lonza) 
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containing 7 µg/ml gentamicin were seeded in 2 ml cell dish and incubated at 27 
oC for 1 hour. During incubation period, transfection mixture containing 1 ml 
Insect-Xpress protein-free medium without antibiotics, 5 µl Insect GeneJuice 
(Novagen), 100 ng of BacMagic DNA, and 500 ng of recombinant plasmid were 
prepared and gently mixed. To allow lipid complexes formation, the mixture was 
incubated at room temperature for 30 minutes. The medium was removed from 
the cells and 1 ml of the transfection mixture was added drop by drop to the 
centre of cell dish. The cells were incubated overnight at 27 oC. After the initial 
incubation period, 1 ml Insect-Xpress protein-free medium with 7 µg/ml 
gentamicin was added to the cell dish and incubated at 27 oC for another five 
days after which, the medium containing recombinant baculovirus was 
harvested and filtered. 
 
2.3.3.4 Amplification of Recombinant Virus 
 
2 million Sf9 cells per ml in 100 ml suspension culture were infected using 500 
µl of a viral stock and incubated in shaking incubator at 27 oC for 5 days. The 
cells were spun down and the supernatant containing viruses were filtered and 
supplemented with 5 ml FBS for further quantification of viruses using the 
FastPlax Titer Kit (Novagen). 
 
2.4  Detection of Protein 
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2.4.1. Western Blot  
 
The western blot analysis was carried out with the His Tag AP Western Reagent 
Kit (Novagen). Proteins were separated on a 10 % SDS-PAGE gel and 
PageRular Prestained Protein Ladder (Fermentas) was used for approximating 
molecular weight of proteins. Hybond-P Polyvinylidene Difluoride (PVDF) 
membrane (GE Healthcare) was activated in 100 % methanol for 10 seconds 
and then washed in distilled water for 10 minutes. The SDS-PAGE, PVDF 
membrane, filters and sponge were rinsed in western transfer buffer (25 mM 
Tris-HCl, pH 8.3, 190 mM glycine, and 20 % methanol) for 5 minutes and then 
the electroblotting cassette was assembled in western transfer buffer. Proteins 
were transferred to a PVDF membrane in Mini Protean II (Bio-Rad) by 
electroblotting in transfer buffer with a constant voltage of 250 milliamps (mA) 
for 2 hours. Membranes were washed using 30 ml of TBS buffer (10 mM Tris pH 
7.5 and 150 mM NaCl) and then incubated for 1 hour in 15 ml of blocking buffer 
(10 mM Tris pH 7.5, 150 mM NaCl and 3 % BSA) to block the remaining protein 
binding sites on the membrane. After the blocking step, the membrane was 
washed in 40 ml of TBSTT buffer (20 mM Tris pH 7.5, 500 mM NaCl, 0.2 % 
Triton X-100, 0.05 % Tween -20) and then 15 ml of TBS buffer. 
 
The primary mouse Anti His-tag monoclonal antibody (Clontech) was added at 
a dilution of 1:1000 to 10 ml of blocking buffer. Alternatively, mouse anti-PP2AC 
antibody (BD Biosciences) was used as primary antibody at a dilution of 
1:20000 to 10 ml of blocking buffer for PP2AC detection. After incubation for 2 
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hours with primary antibody, membranes were washed with 40 ml of TBSTT 
buffer and15 ml of TBS buffer and then incubated in blocking buffer with 1:5000 
Goat Anti-Mouse IgG AP Conjugate (Novagen) for 1 hour. Following the final 
washing step in 100 ml of TBSTT buffer the membranes were incubated in a 
developing solution at room temperature until colour developed. Developing 
solution was prepared by adding 60 µl NBT (42 mg/ml in 100 % 
dimethylformamide) and 60 µl BCIP (83 mg/ml in 100 % dimethylformamide) to 
1x Alkaline phosphatase (AP) buffer.  
 
2.4.2. Sodium Dodecyl Sulphate – Polyacrylamide Gel 
Electrophoresis (SDS-PAGE)  
 
SDS-PAGE separates proteins based on their molecular weights. SDS disrupts 
the folded structure of proteins by forming complexes with proteins through 
binding to hydrophobic patches of a polypeptide chain SDS-PAGE composed 
of a 5 % stacking layer and a 10 % or 15 % resolving layer was used in all 
experiments. Electrophoresis was carried out using the MiniProtean II gel 
apparatus (BioRad) connected to a PowerPac 300 power supply (BioRad). 
SDS loading dye (0.5 M Tris-HCl pH 6.8, 0.5 % bromophenol blue, 10 % SDS, 
and 50 % glycerol) was added to each sample which were then heated to 95 oC 
for 5 minutes and centrifuged at 16060 g for 1 minute. Unstained Precision Plus 
Protein standards (BioRad) were used as molecular weight markers. 
Polyacrylamide gels were electrophoresed at a constant voltage of 100 V 
through the stacking layer and 150 V through the resolving layer. 
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Following electrophoresis the gel was stained in a solution containing a 
Coomassie dye (0.25 % brilliant blue R Coomassie, 40 % methanol, 7 % acetic 
acid and 52 % H2O). Protein bands were visualized by washing the gel in a 
de-staining solution (40 % methanol and 10 % acetic acid in distilled water) for 
30 minutes. 
 
2.4.3. Silver Staining Method 
  
There are two types of silver staining methods: those based on silver amine 
complex and those using silver nitrate solutions as the silvering agent. Silver 
amine method depends on the formation of silver diamine complexes with 
ammonium hydroxide. These complexes bound to proteins are subsequently 
reduced to metallic silver with formaldehyde in acidic environment. Silver nitrate 
method involves the reaction of silver ions with protein under weak acidic 
conditions, followed by the reduction of silver ion to metallic silver by 
formaldehyde under alkaline conditions [236]. 
 
ProteoSilverTM Kits (Sigma) based on silver nitrate method which detects at 
least 0.1 ng of protein per mm2 was used for the visualization of protein bands.  
 
2.5  Purification of Protein  
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2.5.1 LCMT1 and PME1 with an N-terminal Histidine Tag 
 
2.5.1.1 Metal Affinity Chromatography  
 
The cells were defrosted on ice and resuspended in a sonication buffer (50 mM 
Tris pH 8.0, 50 mM NaCl, 3 mM β-mercaptoehanol, and complete EDTA-free 
cocktail inhibitor (Roche)) and then lysed by sonication (20 x 30 seconds bursts 
with 1 minute intervals). The lysate was spun down at 20000 g for 30 minutes. 
The supernatant (soluble fraction) was incubated with 0.5 – 2 ml Ni Sepharose 
6 Fast Flow (GE Healthcare) by rolling for 2 hours. The beads were washed 7 
times with 30 resin volumes of wash buffer (50 mM Tris pH 8.0, 50 mM NaCl, 
3mM β-mercaptoethanol, and 25 mM imidazole). The protein was eluted in 
elution buffer (50 mM Tris pH 8.0, 50 mM NaCl, 3 mM mercaptoehanol, and 300 
mM imidazole) and the eluted samples were analysed by SDS-PAGE. 
Histidine-tagged TEV protease was added in a 1:10 dilution of the total amount 
of protein present and the solution left to dialyse overnight at 4oC in dialysis 
buffer (50 mM Tris pH 8.0, 50 mM NaCl, and 3 mM β-mercaptoehanol). In order 
to remove the cleaved six histidine tag and TEV protease, the dialysed samples 
were incubated with Ni-NTA agarose (Qiagen) by rolling at 4 oC for 2 hours and 
then spun down at 2600 g. The supernatant was stored at 4 oC for further 
purification. 
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2.5.1.2 Size Exclusion Chromatography 
 
Further purification of proteins based on protein size was carried out using Hi 
Load 16/60 Superdex 200 Prep Grade column (GE Healthcare) and ÄKTA 
FPLC system (Amersham Biosciences) at 4 oC. The column was 
pre-equilibrated with buffer C (50 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT). 
Upon concentrating protein solution using concentrator (10,000 Da cutoff 
membrane), the protein samples (1-5 ml) were injected into the pre-equilibrated 
column at a flow rate of 2 ml per minute with 2 ml fractions collected. Total 
volume for an elution was approximately 160 ml. Eluted protein was detected 
using UV absorbance at 280 nm and verified by SDS-PAGE analysis. 
 
2.5.2 PME1 with GST Tag or NusA Tag 
 
2.5.2.1 Purification of PME1 with GST Tag 
 
The cells were defrosted on ice and resuspended in phosphate buffered saline 
(PBS) and then lysed by sonication (20 x 30 seconds bursts with 1 minute 
intervals). The lysate was spun down at 20000 g for 30 minutes. The 
supernatant (soluble fraction) was incubated with suitable amount of 
Glutathione Sepharose™ 4 Fast Flow beads (GE Healthcare), with the binding 
capacity of approximately 10 mg GST tag protein per ml medium, by rolling for 
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one hour. The glutathione beads were washed 6 times with 30 resin volumes of 
PBS buffer. The protein was eluted in elution buffer (50 mM Tris pH 8.0, 50 mM 
NaCl, and 10 mM reduced glutathione) and the eluted samples were analysed 
by SDS-PAGE and prepared for isothermal titration calorimetry experiments.  
 
2.5.2.2 Purification of PME1 with NusA Tag 
  
Although there are no commercial beads especially for NusA protein, the 
pET442b plasmid also includes the six hisitidine tag sequence; therefore, the 
same procedure of histidine tag protein purification for LCMT1/PME1 variants 
can also be used in the purification of PME1 with NusA tag. In addition, anion 
exchange chromatography on Q FF Fast Flow column (Amersham Pharmacia) 
was included in the procedure for further purification. The method was 
described in section 2.5.3.2. 
 
2.5.3 PP2AA  
 
2.5.3.1 Metal Affinity Chromatography 
 
The frozen cells were thawed on ice and resuspended in a sonication buffer (50 
mM Tris pH 8.0, 50 mM NaCl, 3 mM β-mercaptoehanol, and complete 
EDTA-free cocktail inhibitor (Roche)) followed by the sonication (20 x 30 
seconds bursts with 1 minute intervals). The cell lysate was centrifuged at 
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20000 g for 30 minutes. The supernatant was incubated with 0.5 – 2 ml Ni 
Sepharose 6 Fast Flow (GE Healthcare) by rolling for 2 hours. Non-specifically 
bound proteins were removed, by washing the beads 7 times with 30 resin 
volumes of wash buffer (50 mM Tris pH 8.0, 50 mM NaCl, 3mM 
β-mercaptoethanol, and 25 mM imidazole). The protein was eluted in elution 
buffer (50 mM Tris pH 8.0, 50 mM NaCl, 3 mM mercaptoehanol, and 300 mM 
imidazole) and the eluted samples were analysed by SDS-PAGE. Due to the 
irregular cleavage of PP2AA by thrombin protease (Sigma), six histidine tag of 
PP2AA was not removed. 
 
2.5.3.2 Anion Exchange Chromatography 
  
Separation and purification of proteins using ion exchange chromatography is 
based on differences in the ionic properties of surface amino acids. At a given 
pH that is below its pI value, a protein exhibits more positive overall net charge 
that becomes more negative at a higher pH above the protein’s pI. Target 
protein containing a positive or negative net charge displaces a low molecular 
weight ion from an ion exchange matrix and binds to the matrix. An increase in 
the counter-ion concentration or a decrease in the protein net charge by change 
in a buffer pH causes the bound protein to be released from the ion exchange 
matrix in favour of the counter-ion.  
 
Anion exchange chromatography with HiTrap Q FF Fast Flow column 
(Amersham Pharmacia) at the buffer pH of 8.0, was selected as the isoelectric 
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point (pI) of PP2AA is 5.6 The column was equilibrated with 10 bed column 
volumes of buffer A (50 mM Tris pH 8.0, 1 mM DTT) and the protein samples (5 
ml) were then injected into the pre-equilibrated column. Total volume for a salt 
gradient elution was approximately 50 bed column volumes. The gradient 
elution was carried out using the lower ionic strength buffer A and higher ionic 
strength buffer B (50 mM Tris pH 8.0, 1 M NaCl, 1 mM DTT) on an ÄKTA FPLC 
system (Amersham Biosciences). The fractions were analyzed by SDS-PAGE 
electrophoresis. 
 
2.5.3.3 Size Exclusion Chromatography 
 
Further purification of PP2AA was achieved by using Hi Load 16/60 Superdex 
200 Prep Grade column (GE Healthcare) and ÄKTA FPLC system (Amersham 
Biosciences) at 4 oC. The column was pre-equilibrated with buffer C (50 mM 
Tris pH 8.0, 50 mM NaCl, 1 mM DTT). Concentrated protein sample was 
injected into the pre-equilibrated column at a flow rate of 2 ml/minute with 2 ml 
fractions collected. Total volume of an elution buffer was approximately 120 ml. 
The eluted protein was analyzed by SDS-PAGE. 
 
2.5.3.4 Ammonium Sulphate Precipitation 
  
The appropriate volume of solid ammonium sulphate was added to PP2AA 
protein sample to get the desired concentration and the sample was incubated 
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at 4 °C for 30 minutes with constant rolling. The protein sample was then 
centrifuged at 20000 g for 15 minutes to pellet out the ammonium sulphate - 
precipitated protein. The supernatant was mixed with additional solid 
ammonium sulphate to make up the next concentration and the sample was 
again centrifuged after the incubation. All pellets from different fractions were 
dissolved in buffer C (50 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT) for further 
analysis by SDS-PAGE electrophoresis. Fraction containing PP2AA protein was 
dialyzed in buffer C at 4 oC overnight. 
 
2.5.4 PP2AC 
 
2.5.4.1 Ethanol Precipitation Method  
 
High Five cells expressing PP2AC stored at -80 oC were resuspended in buffer 
D (20 mM Tris pH 7.5, 2 mM EGTA, 0.5 mM DTT and 0.1 mM PMSF) and 
disrupted using a homogenizer. After centrifugation at 20000 g for 20 min at 4 
oC, five volumes of 99% ethanol were added to the protein mixture and 
centrifuged immediately at 4250 g for 15 minutes at 4 oC. The pellet was 
resuspended in buffer D and homogenized for three times; this was followed by 
centrifugation at 20000 g for 20 min at 4 oC. The supernatant containing PP2AC 
was dialyzed in buffer A (50 mM Tris pH 8.0, 1 mM DTT) for further purification. 
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2.5.4.2 Size Exclusion Chromatography for the assembly of PP2A
 
 
The assembly of PP2AC and PP2AA was carried out using Hi Load 16/60 
Superdex 200 Prep Grade column (GE Healthcare) and ÄKTA FPLC system 
(Amersham Biosciences) at 4 oC. The column was pre-equilibrated with buffer 
C (50 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT). The PP2AC was mixed in the 
molar ratio 1:1 with PP2AA. The protein mixture was concentrated using a 
concentrator with 10,000 Da cut-off membrane and the protein mixture (5 ml) 
was injected onto the pre-equilibrated column at a flow rate of 2 ml per minute 
with 2 ml fractions collected. Total volume of an elution buffer was 
approximately 120 ml. Eluted proteins were examined by SDS-PAGE analysis 
and the immunoblotting. 
 
2.6 Quantification of Protein Concentration 
 
2.6.1 BioRad Protein Assay  
 
Protein concentration was determined using the BioRad (BioRad) protein assay 
kit following the manufactures protocol. 
 
The Coomassie Brilliant Blue G-250 dye will change colour when it associates 
with the residues tryptophan, tyrosine, arginine, histidine and phenylalanine. 
Free dye in solution has absorption maxima at 470 and 650 nm, but when 
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bound to protein the absorption maximum is at 595 nm. The colour change can 
therefore be quantified at 595 nm with a spectrophotometer and a protein 
concentration could be determined from the linear dependence of the 595nm 
absorbance on the concentration of BSA that is used as a protein standard. A 
range of different BSA concentrations was used in order to generate the 
standard reference curve. 
 
2.6.2 Absorbance Spectra 
 
UV-visible absorbance spectra of the proteins were measured in a 1 ml quartz 
cuvette using BioSpec-1601E UV-Visible spectrometer (Shimadzu). Molar 
extinction coefficients were calculated based on the amino acid sequence of 
the various constructs along with their corresponding molecular weight (Da) 
using the program Expasy ProtParam. Protein concentration was calculated 
using the Beer-Lambert Law: 
                          
           A280 = ε280 × C × L                           (2.2) 
                  A280  = the absorbance of the protein at 280 nm 
            ε280  = the molar extinction coefficient at 280 nm (M-1cm-1) 
               C = the protein concentration (M) 
               L = the path length (cm) 
 
2.7 Biophysical Analysis 
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2.7.1 Circular Dichroism (CD) 
  
Circular dichroism (CD) spectroscopy measures differences of that a substance 
exhibits in the absorption of left-handed circular polarized light versus 
right-handed circular polarized light. This is a sensitive method for determining 
the extent of protein ‘foldedness’, and for characterizing a protein secondary 
structure. CD spectroscopy is also powerful in studying the conformational 
stability of a protein under different thermal and pH conditions. 
 
Secondary structure can be analyzed using CD spectroscopy in the Far Ultra 
Violet (UV) spectral region (190-260 nm). At these wavelengths, the signal 
arises when the peptide bond is located in a regular and folded environment. 
Different secondary structures would give varying characteristic shapes and 
magnitude of CD spectrums [237].  
 
Pure 1 mg/ml of protein was prepared for Far-UV CD spectra using Aviv 202SF 
spectropolarimeter (Aviv Instruments Inc.) connected to a thermostated water 
bath at 25 oC. Spectra were recorded between 190 nm and 300 nm in a 0.1 cm 
path length quartz cuvette, with 0.2 nm increments and subtracted from buffer 
scans. The data is represented as delta epsilons (∆ε) calculated from the 
following equation: 
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        ∆ε = (θobs × 0.1 × MRW) / l × c × 3298                 (2.3) 
               θobs= observed ellipticity (millidegrees)  
                MRW = protein mean weight / number of residues 
                  l = optical path length (cm) 
                 c = protein concentration (mg/ml)  
 
2.7.2 Isothermal Titration Calorimetry (ITC) 
 
Isothermal Titration Calorimetry (ITC) is a thermodynamic method for 
measuring the energetics of biochemical reactions or molecular interactions. 
For ITC experiments, two binding partners in the same buffer are placed in the 
injection syringe and the ITC sample cell respectively. The ITC sample cell is 
kept at a small temperature difference compared to a reference cell filled with 
water.  
 
When a protein sample in syringe is injected into the sample cell, the interaction 
of two proteins will generate or absorb heat. If this interaction is exothermic, the 
ITC uses less energy to heat the sample cell. On the contrary, if the interaction 
is endothermic, the ITC uses more energy to heat the sample cell in order to 
maintain the temperatures between the sample and the reference cell equal. 
The enthalpy changes of the system can be measured through the heat 
absorbed or generated by a system at constant pressure. To understand how 
ITC can be used to measure the enthalpy of a binding process through heat 
generation or absorbance, the equation of enthalpy evolved from the First Law 
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of Thermodynamics is applied as follows: 
                                                       
                         ∆H = qp                               (2.4) 
Where ∆H is the change of enthalpy of binding reaction and q is the heat 
transferred to the system at constant pressure.  
 
ITC directly measures this heat and determines association constants (Ka = 102 
- 109 M-1), reaction stoichiometry (n), and enthalpy of binding (∆Hb). In addition, 
through binding constants, ITC can indirectly calculate the value of free energy 
and entropy of binding reaction, thereby provide a complete thermodynamic 
profile of the molecular interaction in a single experiment [238;239]. The 
temperature dependence of the ∆Hb, measured by performing the titration at 
varying temperatures, will provide the information of heat capacity change (∆Cp) 
which describes conformational changes, hydrogen bonding, hydrophobic 
interactions, and electrostatic interactions in molecular interactions.  
 
The binding measurements were performed in reaction buffer (50 mM Tris pH 
8.0, 50 mM NaCl, 1 mM DTT) using a VP-ITC titration calorimeter (MicroCal, 
LLC) with a reaction cell volume of 1.4 ml at different temperatures (10, 15, 20, 
or 25 °C). Before running experiment, all protein samples were dialyzed in the 
same buffer and adjusted to the same pH value. In addition, all samples and 
solutions, as well as the buffer for heat dilution, were degassed and filtered just 
before loading into the calorimeter. 1.4 ml of target protein in the reaction cell 
was titrated by a 300 µl of analyte. At least 20 consecutive injections of 15 µl at 
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2 second/µl were applied at 4 or 5 minutes intervals, while stirring the reaction 
solution at 300 rpm constant speed. For heat dilution of the target protein, 1.4 
ml of the reaction buffer alone in the reaction cell was titrated by a 300 µl of 
analyte and this value was subtracted from the measured heats of binding. 
Titration curves were analyzed with the Origin program provided by MicroCal, 
LLC, using a one-site binding model to fit the curves. 
 
2.7.3 Differential Scanning Calorimetry (DSC) 
 
Differential scanning calorimetry can be used to directly measure the differential 
power required to maintain the temperature of a sample at the same value as 
the solvent in a reference cell when the overall temperature of the system is 
increased or decreased at a fixed scan rate. In addition, DSC may also provide 
useful information for protein-ligand binding or protein-protein interaction which 
may affect thermal transitions.  
 
The output from DSC experiment is a thermogram showing the excess heat 
capacity (CP) as a function of temperature. The data is represented by the 
following formula [240]: 
                                    
          dQP/dt X 1/σM = CP                                  (2.5) 
             QP = the heat absorbed at constant pressure 
               t = time 
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              σ = the scan rate (dT/dt)  
              T = temperature 
             M = the number of moles of sample in the sample cell 
 
The CP simply reflects the difference in heat capacity between the protein and 
the solvent, usually water, it has displaced. Since water has a high heat 
capacity compared to proteins, the apparent CP in this region will normally be 
negative. The thermogram for a simple globular protein contains three regions: 
the pre-transition baseline, the endothermic unfolding transition, and the 
post-transition baseline. The pre-transition baseline represents a slightly 
positive slope, indicating a gradual increase in heat capacity with temperature. 
In a single cooperative unfolding process, the CP increases as more heat 
energy is taken up in denaturing the protein, followed by reaching a peak at 
approximately the mid-point (Tm) temperature of the process, before dropping 
down to the high temperature baseline.  The post-transition baseline, showing 
the relative heat capacity of an unfolded polypeptide, is usually found at a 
higher level and has a lesser slope than the pre-transition baseline [241]. 
 
The calorimetric enthalpy (∆Hcal) is the total integrated area under the 
thermogram peak which represents the total heat energy uptake by the sample 
undergoing the transition and the van’t Hoff Enthalpy (∆HVH) is an independent 
estimate of the enthalpy of the transition, based on an assumed model, a 
simple two-state model. The value of ∆Hcal and ∆HVH should be similar in DSC 
experiment and could be revealing about factors such as the purity and 
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concentration of the sample in addition to providing information about the 
reversibility of the process [241]. 
 
The differential scanning calorimeter VP-DSC (Microcal, LLC) with cell volume 
of 500 µl was used for DSC analysis. Samples were prepared using a 25 µM 
target protein in the buffer containing 25 mM Tris, pH 8.0, 50 mM NaCl, also 
used as a reference buffer. All experiments were calibrated to the baseline 
obtained by scanning the reference buffer. All protein samples and solutions, as 
well as the reference buffer, were degassed and filtered just before loading onto 
the calorimeter. Scanning was performed at 1 °C/min between 10 and 80 °C 
and with filtering period of 16 sec. The calorimetric enthalpy change (∆Hcal), 
determined by numerical integration of the area of the heat absorption peak to 
the area of calibration peak, was calculated using Microcal Origin software 
supplied with the instrument.  
 
2.7.4 Surface Plasmon Resonance (SPR) 
 
Surface Plasmon Resonance (SPR) occurs at metal surfaces (gold or silver) 
when an incident light beam strikes the surface at a particular angle. Depending 
on the thickness of a molecular layer at the metal surface, the intensity of the 
reflected light will change. In biomedical applications, the sensitivity of SPR to 
the refractive index of the medium next to the metal surface makes it possible to 
measure accurately the adsorption of molecules on the metal surface and their 
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interactions with ligand or proteins [242]. 
 
In SPR biosensors, like the BIAcore, monochromatic light with a broad 
distribution of incident angles is used and the reflected light reaches the 
detector at different points, depending on the angle of reflection. The detector 
continuously records the position of reduced light intensity and calculates the 
SPR angle of reflected light. The change in SPR angle θ of reflected light at a 
given wavelength is directly related by constants c1 and c2 to both the change in 
refractive index n at the surface and the change in thickness d of the layer, 
according to the formula [242-244]: 
                                           
                          ∆θ(λ) = c1∆n + c2 ∆d                           (2.6) 
                    ∆d = the change in protein thicken 
                    ∆n = refractive index change  
(according to the Lorentz-Lorenz relation) 
The output of the SPR angle change is resonance units (RU). 1000 RU is 
correspondent to an angle change of 0.1 degree which is produced for most 
proteins by the binding on the sensing layer of approximately 1 ng/mm2. 
 
Real-time biomolecular interaction measurements were performed on a 
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BIAcore™ X-100 (BIAcore Life Sciences). A Ni-NTA sensorchip (BIAcore Life 
Sciences) which immobilized Ni2+ - nitrilotriacetic acid (NTA) was used. The 
PP2AA was analyzed for its capacity to bind free PME1 protein when PP2AA is 
immobilized to the sensor chip. For this purpose, 0.5 mM NiCl2 was injected at 
10 µl per minute for 1 min onto the agarose coated chip, which was followed by 
the injection of 50 nM histidine-tagged PP2AA in the buffer containing 10 mM 
HEPES, pH 7.8, 150 mM NaCl, 50 µM EDTA, and 0.005% surfactant P20 at the 
same rate. The association with analyte (PME1 or LCMT1 variants) was 
allowed to occur during 60 sec before the flow was switched to analyte-free 
buffer for dissociation measurement. The chip was regenerated with buffer 
containing 0.35 M EDTA.  
 
2.7.5 Thermofluor  
  
Thermoflour method was used as a high-throughput approach to efficiently 
identify optimal buffer condition or potential ligand for protein crystallization. 
Folded and unfolded protein can be distinguished through exposure to 
hydrophobic fluoroprobe which is quenched in an aqueous solution (of a folded 
protein) but associate with the exposed hydrophobic portion of an un-folded 
protein and generate fluorescence. Thermally induced unfolding would lead to 
a sharp decrease in quenching and readily detected fluorescence emission 
[245].  
 
Thermofluor method was set up using a 96-well PCR plate (BioRad). Each well 
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contained 5 µl of 50 µM protein, 45 µl of test buffer and 0.025 µl of 300X Sypro 
Orange (Molecular Probes). The plates were sealed using Optical-Quality 
Sealing Tape (BioRad) and analyzed in iCycler iQ Real Time PCR Detection 
System (BioRad) from 20 oC to 95 oC in increments of 0.5 oC.  
 
2.7.6 X-ray Crystallography 
 
X-ray crystallography is the most successful method for the determination of 
protein structure. The protein must be crystallized for application of X-ray 
diffraction to a macromolecule. The crystals do not grow from a saturated 
solution. The system must be in a supersaturated state to provide the 
thermodynamic driving force for crystallization. The natural inclination of any 
system proceeding toward equilibrium is to maximize the entropy by freeing 
individual constituents from physical and chemical constraints; however, the 
formation of chemical bonds and interactions that generally provide negative 
free energy usually minimize the free energy of the system. 
 
The high-quality relatively large crystal is necessary for a high resolution X-ray 
diffraction study. However, the crystallization step is also the primary obstacle in 
X-ray crystallography. Systematic search of protein crystallization condition is 
important for scanning the ranges of the individual parameters that impinge 
upon crystal formation. Commonly a set or multiple sets of these factors are 
found via high throughput pre-screening method that would yield some kind of 
crystals and then the variables are optimized to obtain the best possible crystals 
 123 
for X-ray analysis.   
 
2.7.6.1 Pre-screening Crystallization Condition of Proteins 
 
Following large scale purification, proteins were concentrated to at least 10 
mg/ml concentration and subjected to crystallization trials using sitting drop 
vapor diffusion method with commercial screening suites including: Index 
(Hampton Research), PGA Screen (Molecular Dimensions), PEG Suite 
(Qiagen), JBScreen PEG/Salt (JENA Bioscience), JCSG (Qiagen), JBScreen 
Classic II (JENA Bioscience) and Nextal Cryo Suite (Qiagen). TTP LabTech’s 
mosquito which provides accurate sample placement for drop dispensing was 
used for automated high throughput pre-screening and 0.1 µl of proteins and 
0.1 or 0.2 µl reservoir buffer sitting drops were set up in 96 well plates (Qiagen). 
All crystallization trays were incubated at 20 oC.  
 
2.7.6.2 X-ray Diffraction and Data Collection 
 
The crystal that was used to obtain the X-ray diffraction data was grown from 
the solution containing pentaerytrhritol ethoxylate and the crystal was flash 
frozen directly in a cold nitrogen stream. The X-ray diffraction data were 
collected on 300 mm Saturn 944+ CCD detector with AFC-11 4-axis partial χ 
goniometer with Rigaku MicroMax-007 HF rotating anode X-ray generator 
equipped with Varimax VHF optics. 180° of data was collected over 0.5° 
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oscillations and diffraction images were scaled, data merged and indexed using 
the program d*TREK [246].  
 
2.7.6.3 Optimization of Protein Crystals 
  
High resolution of diffraction pattern is highly desirable for X-ray crystallography 
structure determination. Therefore, the crystal quality is an important issue in 
X-ray crystallography. Diffraction pattern depends on unit cell type and unit the 
cell size. Unit cell size also depends on the protein size, the tightness of the 
packing of the protein and the symmetry. In addition, uniformity of the unit cells 
within the crystal lattice is also important.  
 
For improvement of the quality of crystal and the diffraction pattern, several 
methods including dehydration, annealing, additive screening and seeding 
method were used. 
 
2.7.6.3.1 Dehydration Method 
  
Crystal dehydration is usually applied to remove the excess solvent content, to 
tighten the packing of the protein molecules and to reduce the size of the 
solvent channels. It sometimes improves crystal order and diffraction resolution 
at room temperature, especially for crystals with large initial solvent contents. 
Protein crystals sometime undergo structural rearrangements after dehydrating 
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and yield alternative crystal packing that may be difficult to achieve directly 
during crystal growth. Of course, dehydration often severely degrades 
diffraction properties, but original crystal order can usually be fully recovered 
just by re-hydrating [247;248]. 
 
To achieve the dehydration of protein crystals, four protocols are used and 
tested. In method I, protein crystals are gradually transferred to increasing 
concentration of ammonium sulphate (1.6 M, 1.8 M and 2.0 M) and exposed to 
air.  In method II, 1.8 M ammonium sulphate solution was added to 
crystallization drop which was exposed to air. In method III, crystals were 
transferred to 1.8 M ammonium sulphate buffer and equilibrated over reservoir. 
In method IV, cover slip with protein crystals was transferred to reservoirs 
containing serial increase of ammonium sulphate solution. These methods 
were shown in Figure 2-3. All crystals were tested at room temperature (20 °C) 
or low temperature (-173 °C) by diffraction screening.  
 
MicroRT™ capillary system (MiTeGen) was also used for protein crystal 
dehydration and room temperature diffraction screening.  The method is 
based on the fact that saturated solutions of salts will maintain a fixed relative 
humidity that depends on the salt in an enclosed container at constant 
temperature. Protein crystals usually have relative humidities of 95-98%, so a 
good set of humidities to test is 93%, 86%, 79%, 75%, and 68% which are 
corresponding to a series of saturated salt solutions including potassium nitrate, 
potassium chloride, ammonium sulphate, sodium chloride, and cupric chloride. 
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Each saturated salt solution (30 µl) was injected into the MicroRT capillary, 
made of clear plastic that gives less background scatter than regular quartz 
X-ray capillaries tube, using a pipette with a gel-loading tip. The crystals were 
mounted on a goniometer base and covered by capillary with different salt 
solutions for X-ray diffraction at room temperature.  
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1.6 M (NH4)2SO4
1.8 M (NH4)2SO4 2.0 M (NH4)2SO4
1.8 M (NH4)2SO4
1.8 M (NH4)2SO4 1.8 M (NH4)2SO4
1.7 M (NH4)2SO4 1.8 M (NH4)2SO4 2.0 M (NH4)2SO4
50 µl 5 minseach
10 mins
12 hours 
8 hours each
I
II
III
IV
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. Four Methods for Dehydration of LCMT120-334 Protein Crystals.
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2.7.6.3.2 Annealing Method 
  
Flash cooling step can dramatically increase the mosaicity and crystal 
annealing sometimes will reduce the mosaicity of crystals without affecting 
molecular structure. Two annealing method protocols were tested. In method 
one, the crystals were frozen in a cryostream, brought back to the 
cryoprotectant solution at room temperature for 3 minutes, and re-frozen. In 
method two, the cold stream for crystals was blocked for 3 second and the 
crystal is then re-cooled. Both methods are shown in Figure 2-4 [249]. 
Cryo-protectant
200 µl
Cryostream
Cryostream
Method One
Method Two
 
 
Figure 2-4. Two Methods for Crystal Annealing of LCMT120-334 Protein 
Crystals. 
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2.7.6.3.3 Additive Screening Method 
  
Additive Screen (Hampton Research) and the Opti-Salt Suite (Qiagen) were 
used in screening for crystallization additives. In Additive Screen (Hampton 
Research), two separate methods were used for volatile and non-volatile 
additives. When non-volatile additives were tested, 1 ml of hit crystallization 
reagent was added directly into the reservoir and sample drop was set up using 
1 µl of protein sample, 0.8 µl of reservoir solution and 0.2 µl non-volatile 
additives. Volatile additives were screen by mixing 100 µl of additive with 900 µl 
of hit crystallization reagent that were then added into the reservoir and 1 µl of 
protein sample was mixed with 1 µl of reservoir solution for the sample drop.  
 
In Opti-Salt Suite (Qiagen), the reservoir solution was set up by mixing hit 
crystallization reagent in a ratio of 9:1 with Opti-Salt solutions. The sample drop 
was set up by mixing reservoir solution in a ratio of 1:1 or 2:1 with the protein 
sample. 
  
2.7.6.3.4 Seeding Method 
 
Preparation of the seed stock was carried out by placing the seed crystal in the 
microcentrifuge tube containing 50 µl of reservoir solution together with seed 
bead and the microcentrifuge tube was vortexed for 90 sec. Seed stock was 
diluted in the ratio of 1:10 with the reservoir solution for storage.  
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The Additive Screen HT (Hampton Research) and Seeding method were used 
together for large screening for optimal crystallization conditions. The reservoir 
condition were set up by mixing hit crystallization condition in a ratio of 9:1 with 
additives and the sitting drop was set up by mixing seed stock, reservoir 
solution with additives and the protein sample in a ratio of 1:2:1. High 
throughput screening was accomplished by using TTP LabTech’s mosquito. 
 
2.7.6.4 Structure Determination and Refinement 
 
The structure of human LCMT1 was determined by the molecular replacement 
method using the programs Phaser and Molrep from CCP4 v6.1.3 Suite 
[250;251] (Collaborative Computational Project, Number 4, 1994) and a 
homology model for the core structure of LCMT1 that was based on the 
coordinates of S. cerevisiae protein phosphatase methyltransferase 1 (PDB: 
1RJG) [223] as the starting model.  The initial model covered ~75 % of the 
amino acid residues present in the polypeptide chain used to obtain crystals.  
The electron density for the cofactor not included in the molecular replacement 
model was clearly visible in the initial maps, providing confirmation of the 
molecular replacement solution.  Structure refinement was carried out using 
the maximum likelihood restrained method with simple scaling in 
REFMAC5/CCP4 [252] as well as solvent flattening and density modification 
routines implemented in CCP4.  Real space refinement/manual fitting of the 
electron density map and model building were carried out in Coot 0.6.1 [253]. 
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The final model of LCMT1 includes residues 29-232, EG dipeptide linker, and 
residues 259-334.  In addition, a single molecule of AdoMet and a glycerol 
molecule are included in the model. The model was validated using Coot, 
PROCHECK [254] and MolProbity [255].  No Ramachandran outliers were 
detected and the model generated a good MolProbity score of 2.1 with 
hydrogen atoms added prior to the analysis.  MolProbity was very valuable in 
identifying significant number of poor rotamers, in particular those of Leu 
residues that were subsequently corrected such that the final model contains 
only 4 % of poor rotamers, many of which were constrained by the 
intramolecular interactions with other residues in the structure.  While the core 
of the structure fitted well into the electron density, there were regions that 
exhibited high level of disorder, in particular a large loop region (residues 
303-313) and the C-terminal end (residues 325-334). Atomic coordinates for 
LCMT1 structure were deposited to Protein Data Bank (www.pdb.org) [256], 
PDBID 3O7W.   
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After many years of investigation it is now clear that the methylation state of the 
catalytic subunit provides a key mechanism for the assembly of a PP2A 
holoenzyme; however, the discrepancies in literature with respect to the 
relationship between the methylation state and the type of the regulatory 
subunit (B, B’ or B’”) found within the heterotrimeric complex emphasizes the 
need for further investigations of this phenomena. Although the major 
participants in methylation of PP2A, PME1 and LCMT1, are well recognized, at 
the time of starting the work for this dissertation the structure of human LCMT1 
and PME1 had not been determined. And although, the structure of 
PME1-PP2A complex was solved in 2008 [221], there is uncertainty regarding 
the full extent of PME1 and PP2A interaction, as large segments of 
polypeptides from both PME1 and PP2AA were truncated in the reported 
complex structure.   
 
The initial objective of this project was to generate a panel of soluble PME1 and 
LCMT1 protein constructs so that suitable candidates could be used for 
structure analysis and mechanistic studies. This chapter describes molecular 
cloning of the full length PME1, LCMT1 and truncated PME1 and LCMT1 genes 
in the expression vector pET30a-TEV/pGEX2T1/pET442b to generate DNA 
constructs encoding for protein variants with an N-terminal histidine tag or 
glutathione-s-transferase fusion proteins for the protein expression in E.coli 
cells. This chapter also includes the results of over-expression of cloned 
constructs, purification of each cloned construct, initial characterisation of the 
soluble proteins using biophysical instrumentation and high throughput 
screening of crystallization condition.  
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3.1 Human Leucine Carboxyl Methyltransferase 
 
3.1.1 Construct Design 
 
3.1.1.1 Bioinformatics Analysis of LCMT1 
 
Proteins commonly contain flexible regions serving as linkers between 
structurally autonomous domains that could interfere with the production of a 
soluble protein. Based on the information from sequence alignments and 
secondary structure predictions, optimal DNA constructs that encode for 
structurally independent domains could be predicted and designed.  
 
LCMT1 was predicted to contain leucine carboxyl methyltransferase domain 
(residues 24-322) using the Simple Modular Architecture Research Tool 
(SMART) [227]. This tool uses multiple sequence alignments to identify and 
annotate protein domains within the target sequence. The secondary structure 
of LCMT1 was also predicted using PSIPRED secondary structure prediction 
protocol (BCB, UCL) for construct design (Figure 3-1) [228;229]. In addition, the 
crystal structure of protein phosphatase methyltransferase 1 from 
Saccharomyces cerevisiae that was previously solved and that shares 28% 
sequence identity with human’s LCMT1 [223] was used to carry out secondary 
structure alignment with the predicted secondary structure of human LCMT1.  
Based on the combined information from these comparisons, the expression 
constructs could be design to keep the core domain of the protein and to 
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potentially remove the putative flexible segments. Therefore, several residues 
preceding the first α helix of LCMT1 including Met1, Glu7, Ser9, Thr16 and 
Asp20 were chosen as an alternative N- terminus of protein products and 
residues following the last β strand of LCMT1 (Thr321 and Tyr334) were 
selected as the alternative C-terminus of the engineered proteins. In addition, it 
was considered that, based on the sequence alignment, the similarity of 
secondary structure of LCMT1 and PPM1 become more significant after the 
residue 61 of LCMT1 and thus, Arg61 of LCMT1 was also chosen as a potential 
candidate residue for the N-terminus.
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Figure 3-1. Comparison of the Secondary Structure Prediction of LCMT1 
and the Secondary Structure of PPM1. The domain recognition (yellow 
region) and secondary structure prediction were accomplished respectively by 
simple modular architecture research tool [227] and psipred secondary 
structure prediction (BCB, UCL) [228,229]. The primary sequences of human 
LCMT1 and yeast PPM1 aligned through ClustalW (EMBL-EBI) [257] exhibit 
28% sequence similarity. However, the secondary structure arrangements of 
LCMT1 and PPM1 are highly conserved. Residues shown in red and residues 
shown in green are chosen as alternative N-termini and C-termini respectively. 
The residues 234 to 267 of PPM1 protein in PDB file (1RJD) [223] were not 
observed in the electron density maps due to high flexibility of this region. 
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3.1.1.2 Limited Proteolysis of LCMT1 
            
In order to facilitate crystallization and improve solubility of LCMT1, the limited 
proteolysis method was applied for detecting any putative flexible segments 
and internal loops of LCMT1. After the incubation of 1 mg of the full length 
LCMT1 with 1 µg of trypsin for 10, 30, 60, 120, 240, 480 minutes, a stable 
fragment of LCMT1 was generated and further analyzed by SDS-PAGE. The 
result shows that the molecular weight of this segment is about 30 kDa (Figure 
3-2a). To characterize the first residue and molecular weight of this target 
segment, the samples were sent to Protein & Nucleic Acid Chemistry Facility 
(PNAC) of Cambridge University for the N-terminal protein sequence analysis 
and to the Institute of Structural and Molecular Biology (ISMB) for Mass 
Spectrometry analysis respectively. The protein sequencing result showed that 
the first six residues in the N-terminus are E7SSITS12 (where superscript 7 and 
12 denote the residue number in the amino acid sequence) while the molecular 
weight of this target segment is 26.8 kDa, as verified by Mass Spectroscopy. 
These two analyses and the prediction of trypsin digestion site of LCMT1 
suggested that the residue at the C-terminus of the fragment could be Arg236. 
In addition, sequence alignment of yeast PPM1 and Human LCMT1 by 
ClustalW [257], indicates that the residue Arg236 of human LCMT1 
corresponds to the residue Arg242 at the flexible region in the PPM1 structure 
(Figure 3-2b). The combination of the prediction of secondary structure and the 
result of sequence alignment suggest that the protein sequence from Asn232 to 
Ser260 of human LCMT1 may be also a flexible segment (Figure 3-2b). 
Therefore, based on this information and the limited proteolysis studies, three 
 138 
LCMT1 constructs were designed and generated. LCMT17-334 contains 
residues 7-232, a small linker EG, and residues 259-334, whereas LCMT17-232 
protein variant only includes residues 7-232. LCMT120-334, with a truncation of 
the N-terminal 20 amino acids of LCMT1,
 
previously formed weakly diffracting. 
Therefore, LCMT1SD20-334 DNA expression construct was also designed to 
include DNA sequence coding for residues 20-232, a small EG dipeptide linker, 
followed by residues 259-334. 
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Figure 3-2. The Limited Proteolysis Analysis of LCMT1. (a) 1 mg of LCMT1 
was incubated with 1 µg of trypsin and the digestion reaction was stopped at 
several time points (10, 30, 60, 120, 240, and 480 minutes). The results of 10 % 
acrylamide SDS-PAGE gel show more and more truncated segment of LCMT1 
was generated with time. (b) The target trypsin cutting site (Arg236) was 
situated in the flexible region of human LCMT1 correspondent to the missing 
site in the structure of yeast PPM1 (PDB: 1RJG) [223]. 
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3.1.2 Molecular Cloning and Protein Expression 
 
The primer design for all LCMT1 variants and the conditions of PCR reactions 
were described in section 2.2.5. The PCR products were digested and cloned 
into pET30aTEV vector. The purification of DNA from agarose gel and ligation 
of plasmid and insertion were both described in sections 2.2.4.3, 2.2.5.2, and 
2.2.5.3. All constructs were initially transformed into E. coli DH5a cells, a host 
without the T7 genes, thus eliminating plasmid instability due to the production 
of a cloned protein potentially toxic to the host cells. The detail of transformation 
was described in section 2.2.5.3. All clones were verified through DNA 
sequencing via Eurofins MWG.  
 
The pET30a-TEV vector contains a kanamycin resistance gene. Within the pET 
expression systems, T7 RNA polymerase produced from an engineered E. coli 
strain will transcribe the recombinant gene. This polymerase is under control of 
a lac operon and expression of T7 polymerase gene is suppressed by the 
binding of lac repressor protein to the lac promoter. The addition of 
isopropyl-β-D-thiogalactopyranoside (IPTG), the analog of allolactose, will 
activate the T7 polymerase gene by dissociating lac repressor protein from the 
lac promoter.  
 
For protein expression, LCMT17-334, LCMT17-232 and LCMT1SD20-334 were 
transformed to E. coli BL21 (DE3) pLysS cells, whereas other LCMT1 
constructs were co-transformed with pBADESL plasmid that contains the 
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GroES and GroEL coding region, to E. coli BL21 (DE3) or E. coli C41 (DE3) 
cells. Previously, it was shown that GroEL/ES mediate LCMT1’s folding and 
improve the production of LCMT1 [234]. The recombinant proteins contain an 
N-terminal six histdine tag and a tobacoo etch virus (TEV) protease cleavage 
site for removal of the tags and redundant amino acids. After removing histdine 
tag, only an additional glycine and alanine residues remained at the N-terminus 
of each LCMT1 variant.  
 
Small scale expression tests were carried out in 100 ml cultures that were 
grown to an optical density (OD600nm) of 0.6. The expression of the proteins was 
induced using IPTG to a final concentration of 1 mM. Several hours after the 
induction of protein expression un-induced and the induced cell cultures were 
individually sonicated and subjected to SDS-PAGE analysis to confirm protein 
expression as described in section 2.2.6.1. Only LCMT161-334 in E. coli BL21 
(DE3), LCMT120-334 in E. coli C41 (DE3), LCMT17-334 and LCMT1SD20-334 in E. 
coli BL21 (DE3) pLysS and LCMT11-334 in E. coli C41 (DE3) cells yielded 
soluble target protein at 37 oC.  
 
3.1.3 Purification of LCMT1 for Protein Crystallization 
         
Proteins cloned into the pET30aTEV vector carry the histidine tag sequence, a 
segment of six consecutive histidine residues that are expressed at the 
N-terminus of the proteins. The histdine tag binds to divalent cations, e.g. (Ni2+, 
Co2+), immobilised on tetra-dentate chelating adsorbent resin. Here, we used 
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the resin of Ni2+ Sepharose 6 (GE Healthcare), composed of highly cross-linked 
6% spherical agarose that contains a proprietary chelator and comes 
pre-charged with nickel.  
 
Before metal affinity chromatography, all E. coli cells were lysed through 
sonication. The cell lysate was centrifuged and then the soluble fraction was 
incubated with Ni Sepharose 6 which trapped all LCMT1 proteins with an 
N-terminal histidine tag. Any non-specifically bound of other proteins were 
removed by washing with 20 mM imidazole. All LCMT1 proteins were 
harvested by elution with 250 mM imidazole, which displaces the tagged 
proteins from the Ni Sepharose 6 beads. 
 
All LCMT1 proteins were dialyzed in the presence of TEV protease, containing 
a non-cleavable N-terminal histidine tag, in order to cleave the histidine tag 
from all LCMT1 proteins. After TEV digestion, only an additional glycine and 
alanine residues remain at the N-terminus of each variant.  To remove the 
cleaved histidine tag, un-cleaved protein and TEV protease, the solution was 
passed back over Ni-NTA resin and the unbound cleaved protein collected. The 
nitrilo-tri-acetic acid (NTA) occupies four of the six ligand binding sites in the 
coordination sphere of the nickel ion, leaving two sites free to interact with the 
histidine tag, which binds with high affinity to the histidine tagged proteins.  
 
Each LCMT1 variant was discussed in the following sections while the details of 
the purification methods were described in section 2.5.1. Total amount of 
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soluble protein obtained from 1 litre of E. coli cells for each of the LCMT1 
proteins was estimated using UV-visible absorbance spectra or BioRad protein 
assay as described in section 2.6.  
 
Before setting crystallisation trays using TTP LabTech’s mosquito and 
commercial screening kits, 20-30 mg/ml of protein was mixed with the ligand 
S-adenosylmethionine (Sigma) in a 1:1 molar ratio. 672 conditions were used 
for LCMT1 variant crystal screening as described in section 2.7.6.1. Only 
LCMT120-334 and LCMT1SD20-334 protein could be crystallized. The protein 
production and crystallization condition of each LCMT1 variant were described 
and summarized in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 144 
 
Table 3-1. The Protein Production and Crystallization Condition of Each LCMT1 Construct. 
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Figure 3-3. Purification and Crystallization of Truncated LCMT1 (residues 20-334). (a) 10% acrylamide SDS-PAGE analysis of 
the LCMT1 isolation with Coomassie Blue staining. The arrow denotes the recombinant LCMT1 protein at each purification step. (b) 
Small crystals of LCMT1 were formed in 0.1 M sodium citrate (pH5.6), 2% PEG400 and 1.8 M ammonium sulfate. 
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Figure 3-4. Purification and Gel Filtration of Truncated LCMT1 (residues 61-334). (a) 10 % acrylamide SDS-PAGE analysis of 
the LCMT1 isolation with Coomassie Blue staining. The arrow denotes the recombinant LCMT1 protein. Relatively high yield of 
purified protein - 10 mg of LCMT161-334 protein/L cells was obtained. However, this form of the N-terminally truncated protein was 
poorly soluble and it precipitated in a buffer containing glycerol (20 %) and a high salt concentration (500 mM). (b) Based on the 
calibration equation of the size exclusion chromatography Superose 6 column (separation range : 5 to 5000 kDa) (GE Healthcare), 
the LCMT161-334 (31 kDa) eluted at a high molecular weight of 773 kDa indicating that the N-terminal deletion of the polypeptide 
sequence resulted in an aggregated form of the protein.
(a)                                        (b) 
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Figure 3-5. Purification of Full Length LCMT1 and PME1. Full length 
LCMT1 and PME1 were further purified using gel filtration column (Hi Load 
16/60 Superdex 200 Prep Grade, GE Healthcare). The 10% acrylamide 
SDS-PAGE gel was visualized using Coomassie Blue staining method and 
showed the purified full length PME1 and LCMT1 after size exclusion 
chromatography column. 
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Figure 3-6. 10% Acrylamide SDS-PAGE Analyses of LCMT17-334 and LCMT1SD20-334 Purification. Soluble LCMT17-334 and 
LCMT1SD20-334 protein could be obtained after large scale protein purification. 
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Figure 3-7. The Protein Crystals of LCMT1SD20-334. In the initial screen of seven hundred crystallization conditions with the 
LCMT1SD20-334 protein about hundred conditions produced crystals. The successful crystallization conditions contained a range of 
different precipitants including PEG 3350, PEG 5000, PEG 8000, ammonium sulfate, or Jeffamine ED-2001.
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3.2 Protein Phosphatase Methylesterase 1 
 
3.2.1 Gene Annotation and Construct Design 
          
The protein construct deign of PME1 was carried out for two purposes, to 
generate the protein suitable for X-ray crystallography and to generate the 
protein for thermodynamic studies. To target the suitable domain or segment for 
protein crystallization, several bioinformatic websites or softwares were used to 
assist in gene construct design. According to 3D-PSSM fold recognition and 
Pfam domain prediction server [219,220], PME1 contains an esterase domain 
(residue position from 47 - 238) thought to catalyze hydrolysis of the 
carboxylmethylester of Leu309 from PP2A. With reference to protein sequence 
alignment by ClustalW [257], PME1 shares a consensus sequence 
IMLIGHSMGG with lysophospholipase [(I/V/R/F)X(L/V)(L/I/Y/F/A)GHSXGG] 
containing Ser-Asp(Glu)-His triad (Fig 3-8a). The secondary structure of PME1 
was also predicted using PSIPRED secondary structure prediction protocol 
(BCB, UCL) [228,229] to find the suitable region of PME1 for constructs design 
(Fig 3-8b). Based on this prediction, there is a large flexible region in front of the 
residue Asp55 which I postulated may interfere with protein solubility or 
crystallization. For the protein constructs design, the residues Glu51, Met53, 
Val56, Asp65, and Ser88 were chosen as alternative N-termini, whereas the 
residues His370, Val382 and Cys386 were selected as alternative C-termini. 
 
To clarify the interaction between PP2A and PME1 via thermodynamic studies, 
 151 
PME139-376, the same construct of PME1 used by a group in Princeton 
University, was also made to compare with the full length PME1 in biophysical 
analysis [221]. In addition, to study the effect of protein engineering and the role 
of the specific polypeptide segment (residues 237-283) of PME1, additional two 
protein variants, PME1_GE239-283 and PME1_ET239-283, were generated and 
purified. 
 
3.2.2 Molecular Cloning and Protein Expression 
            
The PCR reactions were described in section 2.2.5.1. All PCR products were 
digested and cloned into pET30aTEV vector except PME1_GE239-283 and 
PME1_ET239-283 which were cloned into pGEX4T2 and pET442b vector 
respectively. The purification of DNA from agarose gel, ligation of plasmid and 
insertion, and transformation were all referred to in sections 2.2.4.3, 2.2.5.2, 
and 2.2.5.3. 
 
100 ml of LB mediums were also prepared for each PME1 construct and grown 
to an optical density (OD600nm) of 0.6. All samples were sonicated and subjected 
to SDS-PAGE analysis to confirm protein expression as described in section 
2.2.6. Judged by SDS-PAGE analysis, small scale expression tests of each 
PME1 construct reveal that PME124-382 in E. coli Rosetta (DE3) pLysS, 
PME126-382 in E. coli Rosetta (DE3) pLysS, PME139-376 in E. coli BL21 (DE3) 
pLysS, PME1_ET239-283 in E. coli BL21 (DE3) pLysS, PME1_GE239-283 in E. coli 
BL21 (DE3) pLysS and the full length PME1 in E. coli BL21 (DE3) could 
express soluble protein at 30 oC. 
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(b) 
 
PME1 
 
1   msaleksmhlgrlpsrpplpgsggsqsgakmrmgpgrkrdfspvpwsqyfesmedveven 60 
    ----HHHH----------------------------------------------SSSSS- 
 
61  etgkdtfrvyksgsegpvllllhggghsalswavftaaiisrvqcrivaldlrshgetkv 120 
    ----SSSSSS-------SSSSS------HHHHHHHHHHHHHH---SSSSS---------- 
 
121 knpedlsaetmakdvgnvveamygdlpppimlighsmggaiavhtassnlvpsllglcmi 180 
     -------HHHHHHHHHHHHHHH-------SSSSSS-HHHHHHHHHHHH------SSSSSS 
 
181 dvvegtamdalnsmqnflrgrpktfkslenaiewsvksgqirnlesarvsmvgqvkqceg 240 
     -------------HHHHHHH----HHHHHHHHHHHHH------HHHH----HHHH----- 
 
241 itspegsksivegiieeeeedeegsesiskrkkeddmetkkdhpytwrielaktekywdg 300 
     -----------HHHH-------HHHHHHHH------HHHHH---------HHHHHHHHHH 
 
301 wfrglsnlflscpipkllllagvdrldkdltigqmqgkfqmqvlpqcghavhedapdkva 360 
     HH-------------SSSSS--------HHHHHHH----SSSSS-------HHHHHHHHH 
 
361 eavatflirhrfaepiggfqcvfpgc 386 
     HHHHHHHHH----------------- 
          (PSIPRED) 
Figure 3-8. Gene Annotation of PME1. (a) Sequence alignment of PME1 and 
several lipases was produced by 3D-PSSM fold recognition server [219]. PME1 
shares a Ser-Asp(Glu)-His triad (Ser156, His349, and Asp181) with lipases and 
was classed as a serine hydrolase. (b) According to the domain (yellow region) 
and secondary structure prediction of PME1 by simple modular architecture 
research tool and psipred (BCB, UCL) [228;229], residues in red and residues 
in green are chosen as the alternative N and C termini of protein constructs. 
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3.2.3 Purification of PME1 for Protein Crystallization 
  
3.2.3.1 PME124-382 & PME126-382 
       
Following large-scale protein purification protocol as described in section 2.5.1, 
2 mg of purified protein was obtained from 1 L cells (Figure 3-9a). In order to 
identify the optimal buffer condition for the crystallization of PME124-382, 
thermoflour method was utilized using a 96-well PCR plate (BioRad) with 52 
different test buffers at the range of temperatures from 20 oC to 95 oC. The 
profile shows that PME124-382 is more stable at a high pH (>7.5) and in the 
presence of sodium phosphate (Figure 3-9b).  
 
Different concentrations of PME124-382 and PME126-382 proteins (5, 10, 15, 20 
mg/ml) were used to set up crystallization trails at different temperature (15 or 
20 °C) using hanging drop and sitting drop methods. Although different 
commercial crystallization screening kits and additive screening kits were used 
to test these truncated proteins, no crystal was observed. In addition, 
co-crystallization of PME1 with okadaic acid was attempted but no crystals 
were obtained from these experiments. 
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(a)
 
(b) 
 
Figure 3-9. Purification and Thermoflour Analysis of PME124-382 and 
PME126-382. (a) The 10% SDS-PAGE analysis of the PME124-382 and PME126-382 
stained by Coomassie Blue. The arrow denotes the recombinant PME124-382 
and PME126-382 protein after the large scale purification. (b) Thermofluor 
analysis of buffer conditions. PME124-382 is more stable at higher pH and in the 
presence of sodium phosphate.  
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3.2.3.2 PME11-386 
            
2 mg of protein was obtained from 1 L cells after the schedule of purification as 
described in section 2.5.1 (Figure 3-5). Purified protein was concentrated to 20 
mg/ml and subjected to a series of sparse matrix crystallisation screens using 
TTP LabTech’s mosquito. However, no hits were obtained for the full length 
PME1. 
 
3.2.4 Purification of PME1 for Thermodynamic Studies 
 
3.2.4.1 PME139-376 
          
2.5 mg of protein could be harvested from 1 L cells after large scale purification 
as described in section 2.5.1 (Figure 3-10a). 
 
3.2.4.2 PME1_ET239-283 & PME1_GE239-283 
         
For the PME1_GE239-283 protein (31.6 kDa) with glutathione-s-transferase tag 
(GST tag), the Glutathione Sepharose™ 4 Fast Flow beads (GE Healthcare) 
column was used for the initial purification of PME1_GE239-283. To improve the 
protein solubility and stability, the GST tag (27.7 kDa) was retained on the 
protein. 2.5 mg of PME_GE239 protein was purified from 1 L of E. coli cell 
cultures (Figure 3-10b). The schedule of purification was described in section 
2.5.2.1.
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It was previously reported that NusA protein [258], 65.4 kDa, is superior in 
improving protein solubility compared to other protein tags, such as maltose 
binding protein (MBP) or glutathione-s-transferase (GST), used to generate 
fusion proteins. However, there is no commercial resin for NusA tag fusion 
protein purification. Therefore, NusA tag was linked six histidine tag at the 
N-terminus in order to facilitate protein purification. Ni Sepharose 6 beads were 
therefore utilized for purification of PME1_ET239-283, (64.7 kDa). After further 
purification as described in section 2.5.2.2, 3 mg of PME1_ET239-283 protein was 
purified from 1 L of cell cultures (Figure 3-10c). 
 
Calibration of the size exclusion chromatography column (Hi Load 16/60 
Superdex 200 Prep Grade, GE Healthcare) using both low and high molecular 
weight standards (LMW and HMW Calibration Kit GE Healthcare) (Figure 
3-11a), confirmed that native glutathione-s-transferase and NusA protein form 
dimer and tetramer molecule respectively. However, both PME1 fusion proteins 
described here, PME1_GE239-283 (GST tag) and PME1_ET239-283 (NusA tag), 
were tetrameric in solution (Figure 3-11b) suggesting that the specific PME1 
protein segment favours oligomerisation. 
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Figure 3-10. 10% Acrylamide SDS-PAGE Analyses of the Purification of PME139-376, PME1_GE239-283 and PME1_ET239-376. (a) 
The arrow denotes the recombinant PME139-376 after large scale purification including Ni-Sepharose 6, removal of the histidine tag, 
and size exclusion chromatography. (b) GST tag and PME1_GE239-283 were both purified using Glutathione Sepharose™ 4 Fast Flow 
beads. (c) NusA and PME1_ET239-376, containing six histidine tag, were purified using Ni2+ beads, anion exchange and size exclusion 
chromatography. 
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Figure 3-11. Size Exclusion Chromatography Analysis of GST, NusA, 
PME1_GE239-283 and PME1_ET239-283. (a) Multiple proteins from LMW and 
HMW calibration kits (GE Healthcare) were applied to Hi Load 16/60 Superdex 
200 Prep Grade column (GE Healthcare). The Kav value (Ve-Vo/Vt-Vo, Vo= void 
volume, Vt = total column volume, Ve = elution volume) and log molecular 
weight values were calculated for calibration curve. (b) Based on the calibration 
curve, GST (27 kDa) and PME1_GE239-283 (31.6 kDa) proteins were eluted at 55 
kDa and 126 kDa region respectively, whereas NusA (65 kDa) and 
PME1_ET239-283 (64.7 kDa) were both eluted at approximately 260 kDa region. 
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3.3 Initial Analysis of PME1 and LCMT1 Variants  
 
3.3.1 Analytical Size Exclusion Chromatography  
  
In addition to LCMT161-334 protein discussed in section 3.1.3, PME1 and 
LCMT1 variants, including LCMT120-334 (36.7 kDa), LCMT17-334 (35.2 kDa), 
LCMT1SD20-334 (33.8 kDa), PME124-382 (39.7 kDa) and PME126-382 (39.6 kDa), 
were all analyzed using high resolution size exclusion column, Superdex 200 
10/300GL (separation range: 10 - 600 kDa) (GE Healthcare) prior to 
crystallization trials. Calibration of this column was carried out using the LMW 
Calibration Kit (GE Healthcare) (Figure 3-12a).  
 
Based on the calibration curve and trend equation, LCMT120-334, LCMT17-334, 
LCMT1SD20-334, PME124-382 and PME126-382 were eluted in region of 30 - 44 kDa, 
thus demonstrated a monomeric form of the proteins (Figure 3-12b).  
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Figure 3-12. Analytic Superdex 200 10/300 GL Column Analysis of LCMT1 
and PME1 Variants. (a) The column was calibrated with LMW Calibration Kit 
(GE Healthcare). To obtain the trend equation, the Kav value (Ve-Vo/Vt-Vo, Vo= 
void volume, Vt = total column volume, Ve = elution volume) and log molecular 
weights were calculated and the calibration curve generated.  (b) PME1 and 
LCMT1 variants were eluted at region 30 - 44 kDa were the monomeric forms of 
the proteins would be expected to elute. 
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3.3.2 Circular Dichroism Spectroscopy Analysis 
 
In order to ensure that PME1 and LCMT1 variants for setting crystal tray are 
well folded, LCMT120-334 (36.7 kDa), LCMT17-334 (35.2 kDa), LCMT1SD20-334 
(33.8 kDa), LCMT161-334 (31.7 kDa), and PME124-382 (39.7 kDa) were analyzed 
using circular dichroism (CD) spectroscopy. All data were interpreted through 
CDtool program (Birkbeck College).  
 
Based on the curves of CD wavelength scans, all LCMT1 and PME1 variants 
appear to be well folded. Two negative peaks (208 and 222 nm) and one 
positive peak (195 nm) demonstrate that LCMT1 and PME1 variants are 
mixture of α-helix and β-sheet (Figure 3-13).  
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Figure 3-13. Circular Dichroism Analysis of PME1 and LCMT1 Variants. 1 
mg/ml of LCMT120-334 (green), LCMT17-334 (blue), LCMT161-334 (cyan) and 
PME124-382 (red) were analyzed via CD spectrum wavelength scan. All LCMT1 
and PME1 variants contain a mixture of α-helices and β-sheets. Truncation of 
residues 233-258 (LCMT17-334) or the N-terminal 20 residues (LCMT120-334) in 
LCMT1 may not influence the core structure of LCMT1, as the spectra shared a 
similar signal curve; however, truncation of the N-terminal 60 residues of 
LCMT1 may affect the folding of the core structure. 
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3.4 Summary 
 
Although the full-length human LCMT1 can be expressed in and purified from E. 
coli, no crystals were obtained of this form of the protein and further gene 
constructs for LCMT1 were designed. Amino acid sequence alignment with S. 
cerevisiae PPM1 using ClustalW [257] together with a comparison of human 
LCMT1 secondary structure prediction obtained by PSIPRED [228,229] and the 
secondary structure from the crystal structure of yeast PPM1 [223] were 
suggesting secondary structure conservation starting from the residue Asp 20 
of LCMT1. Therefore, several residues preceding the first predicted α helix of 
LCMT1 including Arg6, Glu7, Ser9, Thr16 and Asp20 were chosen as a 
potential starting N-terminal residue of the protein products while the residues 
following the last predicted β strand of LCMT1 (Thr321 and Aspr329) were 
selected as alternative C-termini of the protein products to be generated for 
crystallization studies.  Table 3-2 gives the summary of the protein products 
generated and their solubility properties; superscript denotes starting and 
ending residue in the full-length LCMT1 sequence. Truncation at the residue 
Thr321 at the C-terminus of LCMT1 rendered the resulting proteins insoluble.  
Yields of soluble proteins generated from other gene constructs were relatively 
low and their levels were enhanced through co-expression with chaperonin 
molecules (GroES/GroEL) [234].  LCMT120-334 was the only protein product 
that was crystalized in complex with the co-factor, S-adenosylmethionine from 
crystallization conditions of 0.1 M sodium citrate (pH5.6), 2% PEG400 and 1.8 
M ammonium sulfate at 22 oC.  
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Limited proteolysis method was also utilized in order to detect any flexible 
segments and internal loops of human LCMT1 and to potentially identify stable 
protein domain. SDS-PAGE analysis showed that limited proteolysis of LCMT1 
resulted in a single stable polypeptide band with migration properties 
corresponding to the molecular weight of approximately 27 kDa. N-terminal 
protein sequencing, mass spectrometry analysis and the prediction of trypsin 
digestion sites of LCMT1 suggested that the C-terminal residue of the main 
proteolytic product could be Arg236. Arg236 of human LCMT1 corresponds to 
the residue Arg242 in the previously reported flexible region of the S. cerevisiae 
PPM1 structure.  
 
Three LCMT1 constructs were designed: LCMT17-334 containing residues 7-232, 
a small linker EG, and residues 259-334; LCMT17-232 construct including 
residues 7-232 only; and the LCMT1SD20-334 construct including residues 
20-232, a small linker EG, and residues 259-334. Similar strategy of excision of 
the flexible region has been previously employed in generating a suitable 
protein for crystallization of human PP2A methylesterase [221]. LCMT17-232 did 
not yield soluble protein. In contrast, both protein products that lacked a 
putative flexible region were soluble and the levels of soluble protein 
expression were significantly higher than previously obtained such that we 
were able to purify about 8 mg of protein per liter of cells in the absence of any 
chaperonin molecules. In the initial screen of seven hundred crystallization 
conditions with the LCMT1SD20-334 protein more than hundred conditions 
produced crystals. The successful crystallization conditions contained a range 
of different precipitants including PEG 3350, PEG 5000, PEG 8000, ammonium 
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sulfate, or Jeffamine ED-2001. 
 
For protein crystallization, PME1 constructs were also designed based on the 
secondary structure prediction. PME1 variants (PME124-382 and PME126-382) 
could be successfully expressed and purified. Thermofluor analysis of various 
buffer conditions identified alkaline pH and sodium phosphate salt as favouring 
stability of PME124-382 protein, however this finding id not help in identifying 
crystallization conditions for human PME1. 
 
In addition to constructs for protein crystallization, three PME1 constructs, 
PME139-376, PME1_GE239-283, and PME1_ET239-283, were also designed for 
isothermal titration calorimetry analysis discussed in chapter five. The residues 
239 to 283 of PME1, containing a stretch of acidic amino acids, that were 
excised from the protein used to generate reported crystals of PME1 [221] were 
generated as NusA or GST C-terminal fusion proteins. All protein constructs 
were successfully purified. 
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+a = The protein forms soluble aggregation 
Table 3-2. LCMT1 Constructs. 
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Chapter Four 
 
Heterologous Expression of 
PP2AA and PP2AC in Insect Cell 
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Following the publication of the crystal structure of PP2AD complex with 
okadaic acid in 2006 [18] the crystal structures of some other proteins that form 
complexes with PP2A were reported in 2007, such as PP2AD complex with B’ 
subunit [17;19] or B subunit [24], and PP2AA with SV40 small T antigen [217]. 
Previous studies also demonstrate that SV40 small T antigen could tightly 
associate with PP2A [216] and the interaction between PME1 and PP2A was 
also observed in vivo [63]. Therefore, it might be possible to obtain crystals of 
PME1-PP2A or LCMT1-PP2A complexes. In an attempt to co-crystallize PME1 
or LCMT1 with PP2AA or PP2AC or PP2AD, purified PP2AA and PP2AC proteins 
were needed..  
 
It was previously reported that PP2AA could be expressed in E. coli cells [12;17], 
whereas PP2AC could only be obtained from insect cells using baculovirus 
expression system [17;19;259]. This chapter includes the results from cloning 
of full length PP2AA gene in the expression vector pET28a to obtain 
N-terminally his-tagged protein in E. coli cells and the cloning of the full length 
PP2AC gene in the baculovirus expression vectors pEastBacHTa (Invitrogen) 
and pBAC4x-1 (Novagen) for the use in insect cells. In addition, full length 
PP2AA and PP2AC genes were cloned together into pBAC4x-1 for 
co-expression in insect cells. This chapter also describes the results of the 
over-expression of cloned constructs, as well as purification and assembly of 
PP2AA and PP2AC. 
  
4.1 The Scaffolding Subunit of PP2A (PP2AA) 
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4.1.1 Molecular Cloning, Expression and Purification of 
PP2AA 
 
Following PCR protocol as described in section 2.2.5.1 the PCR products were 
cloned into a pET28a expression plasmid as described in sections 2.2.5.2 and 
2.2.5.3. The recombinant protein included an N-terminal six histidine tag to aid 
protein purification and a thrombin protease cleavage site for removal of the 
tags. After the confirmation of the sequencing result and the small scale protein 
expression test (see section 2.2.6.1), a large scale expression and purification 
of PP2AA were carried out as described in sections 2.2.6.4 and 2.5.3. Routinely, 
about 15 mg of PP2AA was purified from 6 L culture of E. coli BL21 (DE3) plysS 
cells.The N-terminal 6 histidine tag of was not removed, as protein digestion of 
PP2AA by thrombin protease was nonspecific. Further purification of PP2AA 
was achieved through anion exchange column (Q FF, GE Healthcare) and size 
exclusion chromatography (Superdex 200) as described in sections 2.5.3.2 and 
2.5.3.3. 
 
At this stage it was expected that protein will be sufficiently pure as previously 
published protocol was followed; however, some contaminating proteins were 
observed (Figure 4-1) on SDS-PAGE gels. Therefore, to obtain pure PP2AA, 
the ammonium sulphate precipitation and a protein purification using 
hydrophobic interaction column were tested. 
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Figure 4-1. 10% Acrylamide SDS-PAGE Analyses of PP2AA Purification by 
Former Studies. PP2AA was applied to Ni Sepharose 6 (GE Healthcare), anion 
exchange column (Q FF, GE Healthcare, eluted on a linear gradient between 
120 and 400 mM NaCl) (lane A) and finally size exclusion chromatography 
column (Hi Load 16/60 Superdex 200 Prep Grade, GE Healthcare, eluted at  
65-70 kDa region) (lane B). Peak fractions were loaded onto a SDS-PAGE gel 
stained by Coomassie Blue. 
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Figure 4-2a shows the results of ammonium sulphate precipitation of PP2AA 
protein that was previously purified by Ni Sepharose 6 Fast Flow (GE 
Healthcare) and anion exchange chromatography. Protein fraction containing 
PP2AA was applied to 20% to 40 % ammonium sulphate solution and incubated 
at 4 oC for 15 minutes as described in section 2.5.3.4.  
 
The result of the SDS-PAGE analysis suggested an enhancement in purity of 
the protein and therefore the ammonium sulphate precipitation step was 
included in the purification protocol. Finally, the protein was dialyzed in buffer, 
25 mM Tris (pH 8.0), 50 mM NaCl and 2 mM BME for overnight at 4 oC. The 
total protein amount of PP2AA obtained after above purification was about 1 mg 
from 1 litre of cell culture (Figure 4-2b). 
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Figure 4-2. The Ammonium Sulphate Precipitation of PP2AA. (a) The 10% acrylamide SDS-PAGE analysis visualized by 
Coomassie Blue staining showed that 40% ammonium sulphate solution was successful in removing contaminating proteins. (b) New 
PP2AA purification protocol and the 10% acrylamide SDS-PAGE analysis of the purified PP2AA after the final dialysis step. 
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4.2 The Catalytic Subunit of PP2A (PP2AC)  
 
4.2.1 Molecular Cloning and Viral Expression of PP2AC 
 
4.2.1.1 Bac-to-Bac Expression System (Invitrogen) 
   
Following PCR reactions as described in section 2.2.5.1 desired PCR fragment 
was cloned into the pFastBacHTa plasmid (Invitrogen) such that expressed 
protein would contain an N-terminal six histidine tag and a TEV cleavage site as 
described in section 2.3.2.1.  In additionspecific D88N mutation was 
introduced in the active site [235] using site-directed mutagenesis kit 
QuikChange (Stratagene). To obtain bacmids of this mutant, the plasmid was 
transformed to E. coli DH10Bac cells containing the bacmid with a mini-attTn7 
target site and the helper plasmid. The mini-Tn7 site of the pFastBacHTa donor 
plasmid could transpose to the mini-attTn7 target site on the bacmid in the 
presence of transposition proteins produced by the helper plasmid. For further 
transfection, the bacmids were verified by PCR analysis and 1% agarose gel 
electrophoresis.   
 
After amplification of virus, recombinant virus was quantified using FastPlax 
Titer Kit (Novagen) which can efficiently detect the GP64 envelope fusion 
protein of sf9 cells (Novagen) after 8-24 hours post-infection by virus. It was 
estimated that the concentration of viral stock was about 3 × 108 pfu/ml.  
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Although sf9 cells perform well in cell transfection and viral titer, the doubling 
time (72 hours) and protein production of sf9 cells are not as convenient as that 
of High Five cells (Invitrogen). The doubling time of High Five cells is usually 18 
hours and the protein production of High Five cells are usually 5 to 10 fold 
higher than that of sf9 cells. Therefore, High Five cells were chosen as more 
suitable for protein expression.  
 
For small scale expression test, High Five cells in EX-405 cell medium (Sigma) 
at a density of 2 × 106 cells/ml were infected with recombinant virus from the 
stock at multiplicity of infection (MOI) of 3 and 6 for 24, 48 and 72 hours. The 
result of this test suggested that the optimal infection was achieved with 
multiplicity of infection of 3 for 48 hours (Figure 4-3a).  
 
4.2.1.2 BacMagic Transfection System (Novagen) 
 
In BacMagic system, PCR was carried out using primers designed to introduce 
the restriction site BamHI (GGATCC), start codon (ATG), and un-cleavable 8 
histdine tag at the 5’ end of the PCR fragments and a SphI (GCATGC) 
restriction site and stop codon at the 3’ end. The PCR reaction was described in 
section 2.2.5.1 and target sequence was observed and verified on a 1 % 
agarose gel stained with ethidium bromide. PP2Ac with D88N mutation was 
cloned into the pBAC4x-1 plasmid (Novagen) as described in section 2.3.3.1 
[235]. For transfection, 100 ng of BacMagic DNA and 500 ng of recombinant 
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plasmid were co-transfected to Spodoptera frugiperda (Sf9) cells (Novagen). 
The BacMagic DNA is an AcNPV genome containing incomplete essential open 
reading frame (ORF) and a bacterial artificial chromosome (BAC) in place of the 
polyhedrin coding region. The target gene was cloned into the transfer vector 
containing parts of baculovirus DNA sequence and polyhedrin promoter. After 
homologous recombination of the transfer plasmid and BacMagic DNA in insect 
cells, the function of the virus ORF1629 was restored and the BAC was 
replaced by the target gene.  
 
After amplification of virus, the FastPlax Titer Kit (Novagen) was used for 
efficient titer of viral inoculum. High Five cells (Invitrogen) was also used for 
small scale of expression test. It was found that the optimal condition were 
infection of a 50 ml culture at 2 × 106 cells/ml at MOI of 3 for 48 hours or at MOI 
of 7 for 36 hours (Figure 4-3b). 
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Figure 4-3. Transfection tests for PP2A C subunit. (a) After virus was successfully generated using bac-to-bac transfection system 
(Invitrogen), High Five insect cells were infected at varying MOI and time intervals. The western blot, using anti-His-tag-antibodies 
(Clontech), results showed that the optimal infection of cells was at MOI of 3 for 48 hours. (b) Sf9 cells were also transfected by using 
BacMagic transfect kit (Novagen). To find the ideal condition of infection, Sf9 insect cells were infected at varying MOI and time 
intervals. The western blot indicates that the optimal condition is MOI of 3 for 48 hours or at MOI of 7 for 36 hours.  
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4.2.2 Solublization of PP2AC 
 
The recombinant PP2AC proteins from pFastBacHTa expression construct 
contain cleavable N-terminal six histidine tag followed by un-cleavable eight 
histidine residues tag whereas proteins expressed from pBAC4x-1 construct 
only contain un-cleavable eight histidine residues tag at the N-terminus. The 
histidine tag binds to divalent cations immobilised on a metal chelation resin. 
The large scale purification of PP2AC from 1 litre insect cells using Ni-NTA 
(Qiagen) demonstrated a low production of soluble PP2AC which cannot be 
detected by Coomassie Blue staining in SDS-PAGE. However, a significant 
amount of PP2AC was observed in insoluble form (Figure 4-4); therefore, the 
solubility of PP2AC was considered to be a major problem for PP2AC 
purification. To solubilise PP2AC, several detergents (Elugent detergent, 
Zwittergent detergent and MEGA-8) and non-detergents (EGTA, NDSB-211, 
Dodecanoylsucrose, Arginine, and Ethylene Glycol) were individually 
supplemented to the sonication buffer (20 mM Tris pH 8.0, 150 mM NaCl, 1 % 
Triton X-100 and 1 mM DTT) with the final concentration of detergent in buffer 
based on the critical micelle concentration (CMC). Each sample pellet from 10 
ml cells was re-suspended in each testing buffer on ice. After incubation on ice 
for 20 minutes, each sample was spun and the supernatant and pellet was 
analyzed using electrophoresis. This analysis showed that most of detergents 
and non-detergents could be helpful to solubilise PP2AC. While all of the 
additives appeared to have increased the solubility of the expressed protein, no 
additive was significantly superior and therefore, 5 mM EGTA was chosen to be 
included in further purification (Figure 4-5).  
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Figure 4-4. The Metal Affinity Purification of PP2AC from One Litre of Insect Cells. The sample from each step in Ni-NTA beads 
(Qiagen) purification was loaded onto 10 % acrylamide SDS-PAGE gel and further detected by the western blot method, using 
anti-His-tag-antibodies (Clontech). A low production of soluble PP2AC can only be observed (left picture) due to a majority of PP2AC 
protein associated with cell debris as shown by 10 % acrylamide SDS-PAGE analysis visualized by Coomassie Blue staining (right 
picture). 
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Figure 4-5. Solubilisation of PP2AC subunit.  Various detergents and non-detergents used to improve the solubility of PP2AC 
subunit analyzed by 10 % acrylamide SDS-PAGE. The gel was detected by western blot using anti-His-tag-antibodies (Clontech). 
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4.2.3 Purification of PP2AC 
 
4.2.3.1 Published Methods for PP2AC Purification 
 
Various strategies were implemented in an attempt to purifiy PP2AC; however, 
none of them was successful in obtaining purified PP2AC. The methods used 
and the results that were obtained are summerised below:  
1. PP2AC was initially purified using Ni-NTA beads (Qiagen) and then passed 
through ion exchange (DEAE and Q FF, GE Healthcare) and size exclusion 
chromatography (Hi Load 16/60 Superdex 200 Prep Grade) columns 
(Figure 4-6a). The SDS-PAGE analysis of the sample that was purified via 
this protocol clearly shows PP2AC is not sufficiently pure (1-3) [17;19].  
2. PP2AC was also purified using Ni-NTA beads and followed by precipitation 
by increasing concentrations of ammonium sulphate, 20%, 30% and 40% 
(Figure 4-6b). The western blot indicates that most of PP2AC precipitates at 
20% and 30% ammonium sulphate solution similarly to other 
contamination.  
3. PP2AC subunit was first purified from the cell-lysate using Ni-NTA beads 
and the eluted fraction was the loaded on a hydrophobic interaction column 
(HIC) (e.g. Phenyl HP, GE Healthcare) (Figure 4-6c). In hydrophobic 
interaction chromatography, proteins are separated based on their different 
surface hydrophobic interactions with column resin that contains 
hydrophobic groups attached (e.g. phenyl-, octyl-, and butyl- groups). The 
surface hydrophobic characteristics of proteins are dominated by their 
amino acid side chains (e.g. Trp > ILE/Phe > Tyr > Leu > Val > Met).The 
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interaction between proteins and a HIC column is significantly influenced by 
the salt types and concentrations in running buffer. In contrast to ion 
exchange chromatography, a high salt concentration will enhance the 
interaction whereas low salt concentration will weaken the interaction. 
Amongst available hydrophobic interaction active groups, the strongest one 
is octyl- group followed by phenyl- group and then butyl- group. PP2AC was 
successfully purified using hydrophobic interaction column, HiTrap Phenyl 
HP; however, I was unable to repeat this result.  
4. Cell lysate was applied to 55% ammonium sulphate solution and the 
precipitate was resuspended in a Tris buffer (20 mM Tris pH 8.0, 150 mM 
NaCl, 5mM EGTA and 1 mM DTT) and adjusted to 80% ethanol by quickly 
adding 5 volume of 95 % ethanol with 1 mM PMSF. The mixture was 
immediately centrifuged at 4200 g for 5 minutes and the pellet was 
extracted in a Tris buffer (20 mM Tris pH 8.0, 150 mM NaCl, 5 mM EGTA 
and 1 mM DTT) and centrifuged again for 5 minutes at 4200 g. The 
supernatant was subsequently precipitated by 65 % ammonium sulphate 
[259;260]. Unfortunately, in contrast to the published report PP2AC cannot 
be easily re-dissolved after ethanol precipitation.   
 
Main problems encountered in purification of PP2AC were low levels of protein 
production and a low efficiency of histdine tag binding to Ni-NTA beads. In 
order to improve his tag binding efficiency, each dialysis buffer (20 mM Tris pH 
8.0, 150 mM NaCl, and 1 mM DTT) was prepared with different type of salt 
ions at a range of concentrations. Usually, increasing ionic strength of a buffer 
composition aids in the removal of the non-specifically bound proteins to 
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Ni-NTA.  
 
Effect of various salt concentrations in the Ni-NTA wash buffer was evaluated 
by dialysis of cell lysates from 10 ml cell cultures in each buffer and the lysates 
were then passed over Ni-NTA beads. The western blot analysis of these 
experiments confirmed that in this case, increased salt concentration does not 
result in a decreased amount of non-specifically bound proteins to the Ni-NTA 
resin (Figure 4-7).  
 
4.2.3.2 Additional Methods Used for PP2AC Purification 
 
Dr. Ikehara’s group [259] used modified ethanol precipitation to purify PP2AC 
protein and according to their published protocol, ammonium sulphate 
precipitation preceded ethanol precipitation [259]. In our experience, while this 
procedure precipitated PP2AC the protein could not be re-dissolved in original 
buffer as suggested. Thus, ethanol precipitation step at that stage was 
abandoned from our experiments. 
 
In a final attempt to improve purity of PP2AC, proteins from the insect cell lysate 
were ethanol precipitated directly without initial ammonium sulphate addition 
and a Tris buffer (20 mM Tris pH 7.5, 2 mM EGTA, 0.5 mM DTT and 0.1 mM 
PMSF) was used to re-dissolve PP2AC using homogenizer. Subsequently, the 
protein sample was dialyzed in 50 mM Tris pH 8.0, 1 mM DTT at 4 oC overnight 
and then subjected to Ni-NTA purification (Qiagen). Purification details are 
described in section 2.5.4. The western blot and SDS-PAGE results showed a 
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significant increase in PP2AC purification when this method was used, 
however the efficiency of histidine-tagged PP2AC binding to Ni-NTA (Figure 4-8) 
was still very poor. PP2Ac was not detected in the elution fractions or on the 
resin either by mouse anti-histidine tag monoclonal antibody (Clontech) or 
mouse anti-PP2AC antibody (BD Biosciences) respectively. It is possible that 
the histidine tag is obstructed through an interaction with the rest of the PP2AC 
molecule and thus unavailable for binding to Ni resin. 
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Figure 4-6. Purification of PP2AC. (a) High Five insect cell lysate was applied to Ni-NTA (Qiagen) (lane E1, E4 and beads) and anion 
exchange column (Q FF, GE Healthcare, eluted on a linear gradient between 250 and 400 mM NaCl) (lane FT, E8-11, E12-15, and 
E16-20). Peak fractions were loaded onto a 10 % acrylamide SDS-PAGE gel stained by silver stain method (ProteoSilver Kits, Sigma). 
(b) High Five insect cell lysate was applied to Ni-NTA beads and followed by precipitation by increasing concentrations of ammonium 
sulphate, 20%, 30% and 40%. Supernatant of each fraction (20%, 30% and 40%) was loaded onto a 10 % acrylamide SDS-PAGE gel. 
PP2AC can be detected by the western blot method, using anti-His-tag-antibodies (Clontech). (c) High Five insect cell lysate was 
applied to Ni-NTA (Qiagen) (lane E1, E4 and beads) and HIC column (Phenyl HP, GE Healthcare, eluted on flow through fractions) 
(lane FT). Peak fractions were loaded onto a 10 % acrylamide SDS-PAGE gel stained by silver stain method (ProteoSilver Kits, Sigma) 
(right picture) and also detected by the western blot method, using anti-His-tag-antibodies (Clontech) (left picture). PP2AC was 
successfully purified using phenyl HP column; however, the result was not repeated. 
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Figure 4-7. Low Efficiency of His-tag Binding to Ni-NTA. High Five insect 
cell lysate was dialyzed and passed over Ni-NTA beads using different type of 
salt ions at a range of concentrations. Each sample was loaded onto 10% 
acrylamide SDS-PAGE gel and detected by the western blot method, using 
anti-His-tag-antibodies (Clontech). The result showed that lysis buffer (20 mM 
Tris pH 8.0, 150 mM NaCl, and 1 mM DTT) supplemented with different types of 
salts did not improve the efficiency of his tag binding to Ni-NTA.  
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Figure 4-8. Purification of PP2AC by Ethanol Precipitation. The sample from each step in ethanol precipitation was loaded onto 10 
% acrylamide SDS-PAGE gel and stained by Coomassie Blue. To identify PP2AC, the gel was also detected by the western blot 
method, using mouse anti-PP2AC antibody (BD Biosciences).The western blot (left) and SDS-PAGE (right) analysis of the steps in 
protein purification showed that ethanol precipitation surprisingly improved the purity of PP2AC. However, efficiency of his-tag binding 
to Ni-NTA resin remained low. 
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4.3  Co-expression of PP2AA and PP2AC 
 
The pBAC4x-1 plasmid contains four multiple cloning sites; therefore, PP2AC 
and PP2AA could be both cloned into this vector and co-expressed in insect 
cells using BacMagic Transfection System (Novagen).  Co-expessing the two 
proteins might have an impact on soluble yields of PP2AC, as through 
protein-protein interaction between A and C subunit, the stability and folding of 
the C subunit might be improved.   
 
Specific primers and the PCR reaction conditions were described in section 
2.2.5.1. After the PCR products were verified PP2AA was cloned into the 
second multiple cloning site of pBAC4x-1 plasmid (Novagen) which already 
contained PP2AC gene in the first multiple cloning site (For details see section 
2.3.3.2. 100 ng of BacMagic DNA and 500 ng of recombinant plasmid were 
co-transfected to Spodoptera frugiperda (Sf9) cells. After amplification of virus, 
and titer efficiency were determined small scale expression tests using sf9 cells 
were carried out. The western blot analysis of the expression tests showed that 
while PP2AA is found in soluble form in the cell lysates, unfortunately, in 
contrast to our expectations, majority of PP2AC was found in the fraction with 
the cell debris (Figure 4-9). Furthermore, the results suggest that co-expression 
of PP2AA and PP2AC did not assist in solubilisation of PP2AC but that the yields 
of expression of PP2AA in this system were relatively high. When High Five 
cells were used for co-expression of PP2AA and PP2AC, significant cell death 
and diminished levels of PP2AA were observed.  
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Figure 4-9. Co-expression of PP2AA and PP2AC in Sf9 Cells. Each sample 
was loaded onto 10 % acrylamide SDS-PAGE gel and stained by Coomassie 
Blue. The SDS-PAGE showed that co-expression of PP2AA and PP2AC in sf9 
cells resulted in PP2AC subunit found only in an insoluble form. 
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4.4  Assembly of PP2AA and PP2AC 
 
To obtain PP2A AC complex, partially purified PP2AC was mixed with 100 µg 
purified PP2AA and applied to the size exclusion column (Hi Load 16/60 
Superdex 200 Prep Grade, GE Healthcare). Samples from each of the fractions 
collected were analyzed using SDS-PAGE electrophoresis and the western blot 
analysis, using mouse anti-PP2AC antibody (BD Biosciences). There were two 
main peaks in the gel filtration elution profile. Based on the calibration of Hi 
Load 16/60 Superdex 200 Prep Grade column (GE Healthcare), the first peak 
(fraction 38, ∼200 kDa) could be interpreted as containing dimeric PP2A AC 
complex that in a 1:1 stoichiometry would have a molecular weight of 104.1 kDa 
while I would suggest that the second peak (fraction 47, ∼65 kDa), contains 
monomeric form of PP2AA (67.5 kDa) (Figure 4-10). However, to clarify the 
association of PP2AA and PP2AC in gel filtration column, both samples should 
be advanced analyzed through other biophysical instruments such as Mass 
Spectrometry. 
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Figure 4-10. Assembly of PP2AA and PP2AC in Superdex 200 Column. Multiple proteins from LMW and HMW calibration kits (GE 
Healthcare) were applied to Hi Load 16/60 Superdex 200 Prep Grade column (GE Healthcare). The Kav value (Ve-Vo/Vt-Vo, Vo= void 
volume, Vt = total column volume, Ve = elution volume) and log molecular weight values were calculated for calibration curve. Based 
on the calibration curve, two peaks were observed at 200 kDa and 65 kDa region respectively. The first peak (fraction 38) could be 
interpreted as containing dimeric PP2A AC complex (~104 kDa) or oligomeric PP2AC while the second peak (fraction 47) could 
contain monomeric form of PP2AA (67.5 kDa). However, to identity the proteins both samples should be further analyzed. The 
fractions of gel filtration were verified using 10 % acrylamide SDS-PAGE gel. To identify PP2AC, the gel was also detected by the 
western blot analysis, using mouse anti-PP2AC antibody (BD Biosciences).  
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4.5  Summary 
      
The full-length A subunit of PP2A
 
was successfully expressed in an E. coli 
expression system, whereas PP2AC was expressed using baculovirus 
expression system. The purification procedure of PP2AA, including Ni 
sepharose 6, anion exchange chromatography (Q FF), size exclusion 
chromatography and 40% ammonium sulphate precipitation, was used to 
reproducibly obtain mg quantities of the protein with high level of purity (>99 
%). Purification of the C subunit was less successful.  The best purification 
protocol for PP2AC incorporated ethanol precipitation step that was originally 
reported in purification of the phosphatase from animal tissues [261;262]. 
However, the efficiency of histidine tag binding to Ni-NTA was persistently low 
and precluded obtaining a protein of the desired purity.  
  
Although PP2AA and PP2AC were both expressed in insect cells using 
BacMagic transfection system, co-expression of PP2AA and PP2AC, in 
contrast to what was expected, decreased the solubility of PP2AC.  
  
Finally, to obtain PP2AD, PP2AA and PP2AC were mixed, assembled and 
partially purified using size exclusion chromatography.  
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Chapter Five 
 
 
Biophysical Studies of PP2AA and 
PME1 Interaction 
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The structure of PME1-PP2A complex was solved in 2008 and demonstrated 
that the association of PME1 with PP2AC will activate PME1 and lead to the 
inactivation of PP2A [221]. Based on the X-ray crystal structure, this study 
implied that PME1 only interacts with PP2AC but not PP2AA subunit. However, 
neither PME1 nor PP2AA used to form the molecular complex structure were 
not in their native form. PP2AA protein construct used in the study had HEAT 
repeats 2-10 deleted while PME139-376 protein construct contained only 
residues 39-238, a small tri-peptide linker EGK, and residues 284-376 at the 
C-terminus. Although the authors insist that deletion of HEAT repeats 2-10 from 
the PP2AA molecule has no detectable impact on the interaction between 
PME1 and the PP2A core enzyme, in the absence of any supporting data, it 
was suggested that the HEAT repeats 2-10 were very important for PP2AA 
interaction with B and B’ subunits [19,24]. It was previously reported that PP2AA 
HEAT repeats 2, 4 and 5 are involved in PR61-PP2AA interaction, while HEAT 
repeats 3 to 7 are engaged in PR55-PP2AA interaction. In addition, not only 
regulatory subunits but also small T antigen was shown to interact with the 
intra-loops of HEAT repeats 3-7 of PP2AA.  Although no structural similarity 
was found among PR61, SV40 small T antigen and PME1, PR61 and SV40 
small T antigen interact with PP2AA at similar HEAT repeats region [217].  
To evaluate putative association of full the length PME1/LCMT1 molecules and 
PME139-376 with PP2AA, isothermal titration calorimetry (ITC), differential 
scanning calorimetry (DSC) and surface plasmon resonance (SPR) techniques 
were used. In addition, as it was previously reported that PME1 is a 
PMSF-resistant, okadaic acid-sensitive PP2A methylesterase in vivo [60,63], 
association of okadaic acid with PME1 was tested in vitro.  
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This chapter focuses on thermodynamic studies of PME1/LCMT1 and PP2AA 
interaction using ITC and DSC. This chapter also includes SPR experiments to 
confirm the observations from ITC measurements. Finally, the interaction 
between PME1 and okadaic acid was analyzed using ITC method. 
 
5.1  Analysis of PME1/LCMT1 and PP2AA Interaction  
 
5.1.1 Thermodynamic Studies 
 
Isothermal Titration Calorimetry (ITC) is a thermodynamic technique for 
monitoring the energetics of biochemical reactions or molecular interactions 
including ligand-binding reactions, enzyme-substrate interactions, and 
interactions among components of multi-molecular complexes. By monitoring 
directly the energy required to maintain temperature of the sample cell during 
several ligand injections allows for the calculation of free energy, enthalpy of 
binding (∆Hb), entropy (∆S), binding constants (Kb), and reaction stoichiometry 
(n) of binding from one single experiment, thereby providing a complete 
thermodynamic profile of the molecular interaction in a single experiment. In 
addition, unlike NMR or SPR method, the reaction can be measured without 
immobilization or labelling of the binding partners. Today’s ITC instrument, 
VP-ITC titration calorimeter (MicroCal, LLC), is so sensitive that can detect very 
weak association (Ka = 100 M-1). Therefore, it’s a suitable biophysical 
instrument to investigate the interaction between PME1/LCMT1 and PP2A. 
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5.1.1.1 Does PME1/LCMT1 Interact with PP2AA? 
 
In order to obtain an optimal binding curve, relative concentrations of binding 
partners should be first considered. The c value in the following formula is used 
for the estimation of required protein concentrations.  
 
           c = Ka × [M] × n                      (5.1) 
 
Here, Ka is the binding constant, [M] is the concentration of the macromolecule 
in the sample cell, and n is the stoichiometry of the binding reaction. The 
optimal c value is between 10 and 100 in ITC experiments. The concentration 
of the binding partner in the syringe is estimated as follows: 
 
                  Binding partner concentration = 10 × [M] × n            (5.2) 
 
Where n is the stoichiometry of the binding reaction, and [M] is the molar 
concentration of the binding material in the sample cell.  
 
All sample proteins were dialyzed in the same buffer for heat dilution 
experiments. In addition, all samples were filtered and degassed before setting 
up an ITC experiment. To measure the interaction between PP2AA and the full 
length LCMT1/PME1, 10 µM of the full length PP2AA was prepared for ITC 
analysis with 100 µM concentration of full length LCMT1/PME1 and the 
experiment was initially carried out at 10 °C. The result suggests that LCMT1 
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may not associate with PP2AA because of irregular heat change; however, 
PME1 may interact with PP2AA due to the regular heat signal (Figure 5-1). This 
result did not support the three dimensional arrangement in PME1-PP2A 
structure. To obtain the thermodynamic parameters, additional ITC experiments 
were carried out for analysis of the full length PME1 and PP2AA interaction.  
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Figure 5-1. Structure of PME1-PP2A Complex and ITC Analysis of the Interaction between PP2AA and PME1/LCMT1. (a) 
PME1-PP2A structure suggests that PME1 only interacts with C subunit but not A subunit of PP2A. (b) 10 µM of PP2AA was titrated 
by 100 µM PME1 or LCMT1 using ITC. The result shows that PME1 may associate with PP2AA due to regular heat change; however, 
LCMT1 may not bind PP2AA subunit because of irregular heat change.  
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5.1.1.2 Thermodynamic Parameters of PME1-PP2AA Interaction 
 
To obtain best Ka fit, the titration curve should exhibit sigmoidal shape and 
clearly reach saturation at the end of the titration. The sigmoidal region of the 
binding reaction should contain at least five data points. However, the first data 
from ITC experiment did not show clear sigmoidal curve nor reach the 
saturation baseline. Therefore, increasing the concentration of protein in the 
syringe and modifying the titrating schedules were both tested in order to obtain 
stronger signals. ITC experiments were carried out using the titration of 10 µM 
of PP2AA with 5 x 7-µl, 5 x 10-µl, and 9 x 15-µl injections of PME1 (300 µM) at 
10, 15, 20 °C. Depending of the titration conditions the dissociation constant 
was estimated to be between 10 and 20 µM. In addition, it was apparent that 
the value of the dissociation constant (Kd) slightly decreases as temperature 
raises. However, because the protein concentration of PP2AA in the cell was 10 
µM and very near the estimated value of the Kd, the accuracy in determination 
of the association constant might be diminished (Figure 5-2). Therefore, in 
further experiments, the concentration of PP2AA was increased. 
 
The titration of 30 µM of PP2AA with 19 x 15 - µl injections of PME1 (295 µM) at 
15 °C and the titration of 25 µM of PP2AA with 19 x 15 - µl injections of PME1 
(250 µM) at 10, 20, 25 °C, respectively were performed.  ITC curve fitting 
analysis using one set of sites model, shows that this reaction is exothermic 
and the stoichiometry (n) indicates that single PME1 molecule may interact with 
one molecule of PP2AA subunit. These experiments also suggested that there 
was a slight decrease in dissociation constant (Kd) value when temperature of 
the reaction is increased (Figure 5-3). To find out the relationship between 
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temperature and dissociation constant, all ITC data generated at different 
temperatures are compared and analyzed (Table 5-1). When the temperature 
reaches 10, 15, 20, or 25 °C, the value of Kd is calculated as 20, 12, 10, or 6 µM 
respectively. This observation implies that PME1 may ‘prefer’ to interact with 
PP2AA at higher temperatures. In addition, data clearly showed that in these 
experiments it’s difficult to reach curve saturation levels due to low value of Ka 
in combination with relatively low, although maximum practically achievable 
levels of protein concentration.  
The binding reaction can be represented as follow: 
 
             PME1 + PP2AA  <=> PME1-PP2AA                                 (5.3) 
 
It is assumed that there is only one binding site
 
for PME1 per PP2AA. The 
association constant is defined as  
 
      Ka = [PME1-PP2AA] / [PME1][PP2AA]                   (5.4) 
 
and the dissociation constant is  
 
                 Kd = [PME1][PP2AA] / [PME1-PP2AA]                   (5.5) 
 
where [PP2AA]T = [PME1-PP2AA] + [PP2AA] is the total concentration of PP2AA. 
The fractional saturation (F) of PP2AA sites is 
 
   F = [PME1-PP2AA] / [PP2AA]T = [PME1] / Kd + [PME1]        (5.6) 
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The mathematical relationship between the bound and the free PME1 
concentrations will be a rectangular hyperbola. Half saturation occurs when 
[PME1] is equal to Kd. [PME1] = 9 × Kd gives only 0.9 saturation. The 0.99 
saturation will be reached only when the concentration of PME1 is equal to 99 
Kd.  
 
Based on this formula, if Kd is small (∼ nM), even small concentrations of free 
protein will give F = ∼1. The dissociation constant of PME1 and PP2AA binding 
reaction is about 6 to 20 µM. Therefore, the final concentration of PME1 in 
sample cell should be at least 600 µM to reach 99 % saturating curve at 25 °C. 
It also means that the concentration of PME1 in the syringe should be about 3 
mM due to the volume of sample cell of 1.4 ml being about 4.7 times larger than 
the volume of the syringe. However, it’s impossible to obtain 3 mM PME1 
because of the precipitation of PME1 at concentrations approaching mM range.  
 
It could be considered to measure PME1 and PP2AA binding reaction at higher 
temperatures in an attempt to obtain saturation of reaction. But unfortunately, 
when temperature reaches 30 °C, PP2AA will start to unfold, judged by the 
differential scanning calorimetry data (see 5.2.1). It will be difficult to estimate 
the percentage of well-folded protein in ITC experiments. Therefore, it’s not 
suitable to measure the binding reaction of PME1 and PP2AA at temperatures 
above 30 °C and further experiments were carried out at the best possible 
optimal conditions. 
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Table 5-1. ITC Analysis of the Interaction between PP2AA and the Full Length PME1.  
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Figure 5-2. ITC Titration Data Describing the Formation of PME1-PP2AA Complex at Different Temperatures. Titrations were 
performed in 25 mM Tris (pH 8.0), 50 mM NaCl and 2 mM BME buffer. Raw data show the titration of 10 µM of PP2AA with 5 7- µl, 5 
10 - µl and 9 15 - µl injections of PME1 (300 µM). The solid smooth line represents the best fit of the experimental data to a single 
binding site model.   
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Figure 5-3. ITC Titration Data Describing the Formation of PME1-PP2AA Complex at Different Temperatures. Titrations were 
performed in 25 mM Tris (pH 8.0), 50 mM NaCl and 2 mM BME buffer. Raw data show the titration of 25 µM of PP2AA with 19 15 - µl 
injections of PME1 (250 µM). The solid smooth line represents the best fit of the experimental data to a single binding site model.
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5.1.2 Surface Plasmon Resonance Analysis 
 
Surface plasmon resonance is used to measure the changes in refractive index 
occurring at the metal surface upon association between the two partners [263]. 
To confirm the association of PME1 and PP2AA, BIAcore™ X-100 with NTA 
sensor chip (GE Healthcare) was used [264].  
 
BIAcore™ X-100 can detect real-time binding signal enabling kinetic 
characterization, association constant determination and detection of weak and 
transient binding events. For protein-protein interaction, the sensitivity of 
association rate constant (kon) and dissociation rate constant (koff) are 103 - 107 
M-1s-1 and 10-5 - 10-1 s-1 respectively. Therefore, the sensitivity of dissociation 
constant determination (Kd) is 100 µM - 1 pM. Sensor chip NTA is used for 
immobilization of histidine tagged analytes. The matrix, carboxymethylated 
dextran, is pre-immobilized with nitrilotriacetic acid (NTA) which will chelate Ni2+ 
to trap molecules containing histidine tag. This method not only controls steric 
orientation of the immobilized interaction partner for optimum site exposure but 
also can be easily regenerated by injection of EDTA to remove metal ions.  
 
30 µM of PME1 (42 kDa) and 50 nM of PP2AA (67 kDa) were prepared for 
Biacore analysis and 30 µM of LCMT1, which has similar molecular weight (38 
kDa) and no interaction with PP2AA judged by ITC experiment, was used in a 
control experiment. The binding partner immobilized on the chelating NTA chip 
was 50 nM PP2AA and the association with analyte (PME1 or LCMT1) was 
allowed to occur during 60 sec before dissociation step. The output signal of 
Biacore is measured in resonance units (RU) proportional to a change in mass 
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of the immobilized protein. The sensorgram clearly shows that PME1 but not 
LCMT1 will interact with PP2AA (Figure 5-4). 
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Figure 5-4. BIAcore Analysis of the Interaction between PP2AA and PME1/LCMT1. Sensorgram showing the evolution of 
resonance units versus time during association and dissociation measurements performed in BIAcore instrument. The binding 
partner immobilized on the chip is PP2AA and the association is individually measured in the presence of 30 µM PME1 (42kDa) or 30 
µM LCMT1 (38kDa). The association time is 60 seconds before the flow is changed to analyte-free buffer for dissociation 
measurements.   
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5.2  Interpretation of Positive Heat Capacity Change  
 
The heat capacity (Cp), first described in details by Joseph Black, Scottish 
chemist (1728-1799), is defined as the heat taken up or released per unit 
change in temperature from a material at constant pressure. This heat capacity 
is readily measure and it can be used to calculate changes in the enthalpy. The 
formula can be expressed as follows: 
 
             H(T2) = H(T1) + Cp × (T2 – T1),                          (5.7) 
 
where T1 is the temperature of the system in state 1 and H(T2) is the enthalpy of 
the system in state 2. Another way of writing equation (5.7) is  
 
                 ∆H = Cp × ∆T,                                          (5.8) 
 
where ∆H = H(T2) - H(T1) and ∆T = T2 – T1. The equation (5.8) can be also 
written as follows: 
 
                  Cp = ∆H/∆T,                                           (5.9) 
 
such that the heat capacity at the constant pressure can be determined from a 
plot of H versus T in the interval ∆T. When Cp is constant throughout the 
temperature range, H versus T will be constant. For many molecules including 
proteins, Cp is effectively constant over small range of temperature in the 
absence of a change of phase. 
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For proteins, the heat capacity (Cp) is contributed by the covalent, non- 
covalent interaction, hydration and the state of protonation terms of charged 
residues. The burial of polar and non-polar residues in the protein is indeed 
accompanied by the heat capacity changes that have an opposite sign, 
negative for non-polar groups and positive for polar groups.  The equation 
describing this relationship was proposed by Makhatadze and Privalov (1995) 
as follows: 
 
  ∆Cp = 2.14 ∆ASAnon-polar – 0.88 ∆ASApolar,                  (5.10) 
 
where ∆Cp is heat capacity change, ∆ASAnon-polar is water accessible surface 
area for non-polar groups, and ∆ASApolar is water accessible surface area for 
polar groups [265]. 
 
Most of the protein-protein/DNA/ligand interactions have a negative heat 
capacity change due to a hydrophobic effect, the removal of non-polar 
molecules from water [266-268]. However, in our case, a positive heat capacity 
change is observed in the thermodynamic parameters (Figure 5-5). A positive 
heat capacity change normally occurs as the protein is unfolding [269-272]. 
With regard to purified proteins in solution, both folded and unfolded states 
have their own enthalpy respectively. The heat capacity change between folded 
and unfolded state at constant pressure is Cpunfold - Cpfold = ∆Cp,d where Cpunfold 
is the heat capacity of the unfolded state and Cpfold is that of folded state. For 
the enthalpy difference between the folded and unfolded states of a protein, this 
equation can also be written as follows: 
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           ∆Hd°(T2) = ∆Hd°(T1) + ∆Cp,d × (T2-T1),                    (5.11) 
               ∆Hd°= enthalpy of denaturation 
where heat capacity change is temperature independent. 
 
In contrast to most of the protein-protein interactions or protein folding process, 
positive ∆Cp,d is related to the increase in hydrophobic surface contact with the 
solvent. The side chains of hydrophobic core are largely sequestered from the 
solvent in the folded state. Does it mean that PME1 or PP2AA is unfolding 
during the ITC experiment? To characterize the melting temperature and 
unfolding procedure of full length PME1 and PP2AA, the differential scanning 
calorimeter VP-DSC (Microcal, LLC) was used. 
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Figure 5-5. Heat Capacity of PME1-PP2AA Interaction. The positive heat capacity change could be observed in PME1 (250 µM) - 
PP2AA (25 µM) interaction. 
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5.2.1 The Melting Temperature Scan of PME1 and PP2AA 
 
Measuring of ∆H and melting temperature (Tm) can be done with differential 
scanning calorimetry (DSC), which measures heat absorbed as a function of 
temperature. Based on the DSC thermograms, it could be concluded that 
melting process of PP2AA corresponds to a two-state and irreversible transition 
model.         
   
       PP2AA, fold    =>    PP2AA, unfold                        (5.12) 
 
The PP2AA started to unfold, when temperature reached 30 oC and the melting 
temperature is about 54.1 oC. In contrast to PP2AA, the melting curve for PME1 
only fits a non-two-state and irreversible transition model with the melting 
temperature of 57.7 oC. These data indicate that in the process of unfolding 
PME1 goes through a distinct intermediate state. 
 
    PME1fold   =>   PME1I   =>  PME1unfold                      (5.13) 
 
Unlike PP2AA, PME1 was more stable and started to transition at 53 oC. Both 
proteins are well folded below 30 oC. Furthermore the measurement of 25 µM of 
PP2AA and PME1 mixture in DSC experiment revealed that PME1-PP2AA 
complex starts to melt after 42 oC (Figure 5-6) with the melting temperature of 
PME1 and PP2AA complex reaching only 54 oC.  In other words no significant 
additional stabilization of the proteins was observed upon complex formation, 
compared to the melting temperatures of the individual components.  
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All ITC measurements of PME1 and PP2AA interaction were performed 
between 10 and 25 oC. Therefore, PME1 and PP2AA are both unlikely to unfold 
in ITC experiments. Thus, not unfolding but another factor dominates PME1 
and PP2AA interaction that contributes to the observed positive heat capacity 
change.  
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Figure 5-6. Differential Scanning Calorimetry of PME1, PP2AA, and PME1-PP2AA Complex. DSC transitions for 50 µM of 
PP2AA (green), PME1 (red) and PME1-PP2AA complex (blue) in Tris buffer (25 mM Tris, 50 mM NaCl, pH 8.0) represents the melting 
temperature (Tm) of each protein and indicates all samples for ITC experiment are stable below 30 °C.
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5.2.2 The Theory of Positive Heat Capacity Change 
 
There are very few examples for positive heat capacity change such as the 
formation of the phosphofructokinase tetramer [272], the interaction of the brain 
natruretic peptide with heparin [273], and eIF4E binding to mRNA 5’cap [274].  
These studies demonstrated that dehydration of polar molecules will lead to 
positive heat capacity change and suggest that PME1 may interact with PP2AA 
via a polar region. To find out the targeted region for PME1 to interact with 
PP2AA, the sequence of full length PME1 and PME139-376 were compared using 
ClustalW2 (EMBL-EBI) [257]. The sequence alignment of full length PME1 and 
PME139-376 shows that there are three main segments that have been truncated. 
The distribution of polar and non-polar residues are equal in the truncated 
N-terminal segment (residues 1-38) and the C-terminal segment (residues 
376-386); however, the middle polypeptide segment (residues 239-282) 
contains almost 77% polar residues that might potentially be forming PP2AA 
subunit interaction surface (Figure 5-7). This interpretation would be in an 
agreement with an apparent lack interaction of PME139-376 and PP2AA in the 
three-dimensional structure of the complex. But does PME139-376 really have no 
site of interaction with PP2AA? To answer this question, PME139-376 construct 
was required for isothermal titration calorimetry experiments. 
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Figure 5-7. Comparison of PME1 and PME139-376 Protein Sequences. The multiple sequence alignment of full length PME1 and 
PME139-376 by ClustalW2 (EMBL-EBI) [257] shows that the sequence segment containing residue 242 to 283 includes 77% polar 
residues (green) and 23% non-polar residues (red). 
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5.3  Interaction of PME139-376 and PP2AA   
 
5.3.1 Does PME139-376 Interact with PP2AA? 
 
As the Isothermal titration calorimetry and BIAcore results of full length PME1 
and PP2AA interaction seem to be inconsistent with the crystal structure of the 
PME139-376-PP2AA complex solved in 2008 a construct of PME1 (PME139-376), 
composed of residues 39-238, a small linker EGK, and residues 284-376 was 
constructed and used in ITC analysis [223]. The measurements was taken by 
titrating 10 µM of PP2AA with 5 7- µl, 5 10 - µl and 9 15 - µl injections of 
PME11-386/PME139-376 (300 µM). Even though the thermodynamic parameters 
of the association between full length PME1 and PP2AA were previously 
obtained, the raw data from this experiment suggested that PME139-376 has lost 
the capacity to interact with PP2AA (Figure 5-8). This finding is consistent with 
the reported three-dimensional X-ray crystal structure of PME139-376-PP2A 
complex, where PME139-376 indeed exhibited no interaction with PP2AA. The 
results of the ITC experiment also suggest that the middle polar amino acid 
segment (residues 239-282) of PME1 may play an important role in 
PME1-PP2AA interaction. 
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Figure 5-8. ITC Analysis for PME11-386-PP2AA or PME139-376-PP2AA interaction. 10 µM of PP2AA was respectively titrated with 5 
7- µl, 5 10 - µl and 9 15 - µl injections of 300 µM PME139-376 (right figure) or full length PME1 (left figure) at 10 °C. The result suggests 
no interaction between PME139-376 and PP2AA due to the truncation of the putative PP2AA interacting region..
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5.3.2 Electrostatic Interactions 
 
The truncated sequence (residues 239-283) of PME1 not only includes several 
charged residues, but also contains a highly polar region. Is it possible that 
PME1 interacts with PP2AA via electrostatics? To further understand the 
electrostatic interaction of PP2AA and PME1, a 25 µM sample of PP2AA was 
titrated with 19 15 - µl injections of PME1 (250 µM) under a range of sodium 
chloride (50, 100, 150, and 500 mM) and magnesium chloride (100 µM) in 
buffer, 25 mM Tris, pH 8.0, and 1 mM β-mercaptoethanol (Table 5-2). The raw 
data demonstrated that increasing salt concentration may neutralize the 
charges in the segment, residue 239 to residue 283, and interfere with the 
association of PME1 and PP2AA through electrostatic interaction. This 
bservation further supports our explanation regarding a loss in capacity of 
PME139-376 to interact with PP2AA (Figure 5-9). Finally, these results are 
consistent with of the proposed interpretation for the observed positive heat 
capacity change of PME1 and PP2AA interaction. 
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Table 5-2. The Analysis of PP2AA- PME1 Interaction in Different Salt Conditions Using ITC Instrument. 
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Figure 5-9. The Electrostatic Interaction of PME1-PP2AA Complex. The figure shows the titration of 25 µM of PP2AA with 19 15 - 
µl injections of PME1 (250 µM) at different sodium chloride concentration, 50, 100 and 150 mM and indicates that increasing salt 
concentration will interfere with the association of PME1 and PP2AA through electrostatic type of interactions. 
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5.3.3 The Putative Site of PME1 for PME1-PP2AA Interaction 
 
Based on the previous experiments, the polar segment (residues 239 to 283) of 
PME1 may play an important role in dominating PP2AA and PME1 interaction. 
Truncation of this segment from PME1 will completely abolish the interaction 
between PME1 and PP2AA. PP2AA was shown to interact with other proteins 
such as regulatory subunits and small T antigen. Do these proteins also contain 
the similar segment in their protein sequence? The sequence of PME1 was 
compared with PR61, PR55, and SV40 small T antigen respectively via 
pairwise sequencing alignment using blastp (NCBI) [275] and ClaustalW 
(EMBL-EBI) [257]. Unfortunately, there is no similarity among these proteins. In 
addition, highly polar region segment was not observed in PR55, PR61, or 
small T antigen interacting with PP2AA. Although these proteins all interact with 
PP2AA at similar region (HEAT repeats 2 to 7), the participating residues from 
the interacting proteins are very different and it will be difficult to postulate a 
common mode of interaction. 
 
The next question that was investigated was whether the specific polar amino 
acid segment (residues 239 to 283) was sufficient for the interaction with PP2AA 
to occur even within the context of a different protein (not PME1).  Will the 
protein with the same polypeptide segment engineered be able to associate 
withPP2AA? To improve the solubility of the polypeptide, 
glutathione-s-transferase and NusA fusion proteins were created incorporating 
this segment at the C-terminus. PME1_ET239-283 containing NusA sequence 
and PME1_GE239-283 including GST tag were made and successfully expressed. 
In addition, native GST tag and NusA protein were also expressed and purified 
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to be used in the control ITC experiments. 
 
In order to ensure that glutathione-S-transferase and NusA protein will not 
interact with PP2AA, 100 µM of glutathione-S-transferase and NusA protein 
were titrated with with 19 15 - µl injections into the cell containing 10 µM of 
PP2AA at 10 °C. The ITC signal showed that there was no interaction between 
native GST or NusA protein and PP2AA due to non-significant heat change 
(Figure 5-10a).  
 
PME1_GE239-283 and PME1_ET239-283 were also prepared for ITC experiment. 
150 µM of PME1_GE239-283 and PME1_ET239-283 were used to titrate 20 µM 
PP2AA at 10 °C. Unfortunately, no significant heat change signal could be 
observed in these ITC measurements either (Figure 5-10b). Three explanations 
for the observed lack of interaction could be put forward. First, the residues 239 
to 283 of PME1 may not be the only target site in PME1 and PP2AA interaction. 
Second, the residues 239 to 283 are situated in the middle of PME1 
polypeptide chain, whereas in PME1_GE239-283 and PME1_ET239-283 they were 
connected with the C terminus of glutathione-S-transferase or NusA protein. 
The specific protein topology context within the PME1 may thus be required for 
the formation of the appropriate binding surface and influence the interaction. 
Finally, native glutathione-S-transferase will form dimer (55.4 kDa) and NusA 
protein is normally a tetramer (260 kDa). However, when these two proteins 
were fused with residues 239 to 283 of PME1, PME1_GE239-283 formed 
tetramer (126 kDa) while PME1_ET239-283 still kept original tetrameric form (258 
kDa) based on the calibration results of the size exclusion chromatography, Hi 
Load 16/60 Superdex 200 Prep Grade column (GE Healthcare).  Interestingly 
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addition of the polar polypeptide segment seems to have induced further 
oligomerisation of the glutathione-S-transferase.  
 
Although, the experiments described here clearly showed that PME1 polar 
residues segment 239-283 is necessary for PP2AA interaction, current data 
does not show that the specific polypeptide region is sufficient for the reaction 
to occur. Perhaps the only way to show details of PME1-PP2A interaction would 
be by determining the structure of a full length PME1-PP2A complex.
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Figure 5-10. The ITC Analysis for PME1_GE239-283 /PME1_ET239-283 and PP2AA Interactions. (a) The ITC analysis showed that 
there is no interaction between either NusA or GST protein and PP2AA. (b) No significant heat change was detected in 
PME1_GE239-283 /PME1_ET239-283 and PP2AA experiments, suggesting lack of interaction between these molecules. 
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5.4  A Potential Inhibitor of PME1  
  
The okadaic acid, a toxin found in bivalves, causes diarrhetic shellfish 
poisoning. The molecular formula of okadaic acid is C44H68O13, a derivative of a 
C38 fatty acid [276]. In addition, okadaic acid is a strong inhibitor of PP1, PP2A, 
and PP2B. The inhibitory effect of okadaic acid is strongest for PP2A, followed 
by PP1, and then PP2B.  In vitro, PP2A is inhibited by okadaic acid at a 
concentration of 1–2 nM and the dissociation constant of the inhibition on 
protein serine / threonine phosphatase 2A is about 30 pM. Therefore, okadaic 
acid was a potential tumor promoter through inhibiting PP2A and PP1 
[101;277].  
 
Previous studies suggested that PME1 is an okadaic acid-sensitive 
methylesterase in vivo. Thus, PME1 may associate with okadaic acid. If it’s true, 
okadaic acid would be a good ligand for co-crystallization with PME1. In order 
to determine the thermodynamic parameters of PME1-okadaic acid interaction, 
10 µM of PME1 was prepared for ITC analysis with 19 15 - µl injections of 100 
µM okadaic acid at 10 °C. However, there is no significant heat change in 
PME1-okadaic acid experiment suggesting that okadaic acid is not PME1 
ligand (Figure 5-11). This data is not consistent with the results of an in vivo 
study reported by Stock’s group [278]. Previously, it was shown that okadaic 
acid interferes with the demethylation of PP2A and the author proposed that 
okadaic acid may be an inhibitor of PME1. Most likely, PME1 not only 
associates with the C terminus of PP2AC but also interacts with the active site of 
PP2AC at the same time and thus it may compete for binding with the okadaic 
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acid. This suggestion is supported by the structure of PME1-PP2A complex. 
The details of PME1 and PP2AC interaction were described in chapter one 
(1.2.1). The binding affinity of okadaic acid for PP2AC is rather high and it either 
competes PME1 out or it may act as an allosteric inhibitor of PP2AC and PME1 
interaction.  
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Figure 5-11. Isothermal Titration Calorimeter (ITC) Analysis of PME1 Binding Ability to Okadaic Acid. 300 µl of okadaic acid 
(100 µM) was prepared for the binding reaction with 1.4 ml PME1 (10 µM). The titration protocol included 19 15 µl injections.This 
analysis demonstrated that PME1 does not directly interact with okadaic acid.  
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5.5 Summary  
 
The results of ITC and BIAcore experiments both support the thesis that PME1 
but not LCMT1 can interact with PP2AA. This result is not consistent with the 
reported crystal structure of PME139-376-PP2AHEAT1,11-15 complex showing that 
PME1 only associates with PP2AC. In addition, a positive heat capacity change 
suggested a highly polar region of dehydration during PME1-PP2AA interaction. 
This region was determined to include polar amino acids segment of residues 
239 to 283 of PME1.  This segment was omitted in the protein used to obtain 
the crystal structure of PME139-376-PP2AHEAT1, 11-15 complex.  
 
The analysis of PME139-376-PP2AA interaction using ITC equipment also 
supported the hypothesis that PME139-376 lost its ability to associate with PP2AA. 
Increasing ionic strength of ITC buffer interferes with the association of PME1 
with PP2AA due to the neutralization of electrostatic interactions through the 
highly polar region, residues 239 to 283. 
 
Finally, although PME1 was demonstrated an okadaic acid sensitive protein in 
vivo, no interaction was observed between PME1 and okadaic acid in ITC 
analysis.  
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Chapter Six 
 
X-ray Crystallography of LCMT1 
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Although the structure of Saccharomyces cerevisiae protein phosphatase 
methyltransferase 1 (PPM1) was solved in 2004 [223], the structure of human 
leucine carboxyl methyltransferase 1 (LCMT1) is still unknown. Based on the 
PSIPRED secondary structure prediction [228,229], several constructs, 
including LCMT161-334, LCMT11-321, LCMT19-321, LCMT116-321, and LCMT120-321, 
of LCMT1 are accomplished and expressed in E. coli cells. Unfortunately, only 
LCMT161-334 could express soluble proteins. In addition, only the LCMT120-334 
construct, made by Dr. Roger Geroge in our group, could express soluble 
protein and form crystals [234]. However, the resolution of the LCMT120-334 
protein crystals (7 Å) is not suitable for structure determination. Several 
methods were also used for the refinement of crystals from LCMT120-334 
construct. Recently, new constructs, LCMT17-232, LCMT17-334 and 
LCMT1SD20-334, were designed based on limited proteolysis method. The 
LCMT17-334 and LCMT1SD20-334 construct could express large amount of soluble 
protein (6 mg per Liter cells). 
 
In addition, LCMT1SD20-334 construct protein can form crystals. The 2 Å 
resolution of LCMT1SD20-334 crystal enabled solution of the structure of human 
LCMT1. This chapter includes the development of LCMT120-334 and 
LCMT1SD20-334 crystals and the improvement of crystal quality of LCMT120-334. In 
addition, a model of LCMT1 was generated using the bioinformatic program, 
Modeller 9v2 [231], for molecular replacement. Finally, the structure of human 
LCMT1 was determined and compared with yeast PPM1. This structure 
suggested the potential mode of interaction between PP2A and LCMT1. 
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6.1 Molecular Modelling  
 
Based on  the secondary structure comparison of LCMT1 and PPM1 as 
described in chapter three, the structure of PPM1 and LCMT1 are most likely 
very similar. In order to understand the catalytic mechanism and predict the 
structure of human LCMT1, a full length model was generated using the 
program Modeller (Figure 6-1a) [231]. The yeast protein phosphatase 
methyltransferase 1 (PPM1) was used as a template. In addition, the generated 
model of LCMT1 could be used for the molecular replacement methods of 
phase determination. The model was analyzed using PROCHECK [232] and a 
summary of the data obtained from PROCHECK is shown in Figure 6-1b.  
 
Figure 6-1. The Model of Human LCMT1. (a) The overall structure of LCMT1 
and PPM1 (PDB: 1RJG) [223] are very similar. (b) The model was further 
assessed using PROCHECK [232].
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6.2  The Refinement of LCMT120-334 Crystals 
 
The crystallization conditions for LCMT120-334, mixed with the ligand 
S-adenosylhomocysteine (Sigma) in a 1:1 molar ratio, were screened using 
commercial screen kit by vapour diffusion hanging drop or sitting drop method. 
Some irregular small crystals could be found in conditions containing 
ammonium sulphate and PEG as describe in section 3.1.3. This condition was 
similar to those previously reported by Dr. Roger Geroge in our laboratory [234]. 
Therefore, this crystallization conditions were further refined. Some methods 
used for improvement of crystal diffraction quality and the refinement of 
crystallization conditions, such as dehydration, annealing and seeding are 
discussed in the following sections. 
 
6.2.1  The Optimal Condition for LCMT120-334 Crystals 
 
The original condition for LCMT120-334 crystallization is 0.1 M Na-citrate (pH 5.6), 
2 M ammonium sulphate, 0.38 M Na-K tartrate, 2 % PEG 400, 4 % acetone and 
5 mM DTT at 22 oC. However, the crystals from this condition were not only 
small but also irregular and weakly diffracting. To refine the condition, the pH 
value, type of buffer, and the concentration of other components were all 
slightly adjusted. Based on manual hanging drop screening, the optimal pH 
range for LCMT120-334 was about pH 6.0 to pH 6.3. Protein was more likely to 
precipitate at pH value above 6.3 or below 6.  The pH range is more important 
than the type of buffer. Protein was also crystallized in MES, MOPS, and 
phosphate buffer in different pH range. A lot of small and irregular crystals 
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(about 0.02 mm) will be easily formed within 24 hours when higher 
concentration of the main precipitant, ammonium sulphate (1.8-2.0 M) was 
used. When the concentration of ammonium sulphate is slightly lowered (about 
1.6 M -1.4M), the size of protein crystal will reach 0.6 mm and the crystals were 
well developed after 72 hours (Figure 6-2). Potassium sodium tartrate, PEG 
400, and acetone very slightly impacted the size of crystals. Increasing the 
concentration of these precipitants will lead to the precipitation of protein. 
Therefore, the optimal crystallization condition for LCMT120-334 is 0.1 M sodium 
citrate (pH 6.3), 1.6 M ammonium sulphate, 0.38 M potassium sodium tartrate, 
2 % PEG 400, and 4 % acetone at room temperature. Unfortunately even 
though the crystal size could reach 0.7-0.8 mm, maximum x-ray diffraction 
resolution for these crystals is only 7 to 7.5 Å. Synchrotron radiation increased 
the resolution only to maximum of 6.5 Å. 
 
6.2.2  Additive Screening Method for New Crystal Form 
 
To improve the quality of crystal, Additive Screen Kit (Hampton Research) and 
the Opti-Salt Suite (Qiagen) were used for additive screening. 0.1 M sodium 
citrate (pH 6.3), 1.6 M ammonium sulphate, and 2 % PEG 400 were all kept in 
crystallization reagent for mixing with additives as described in section 2.7.6.3.3. 
Unfortunately, only similar protein crystals were observed in additive condition, 
potassium sodium tartrate.  
 
6.2.3  Dehydration of Crystals 
 
The unit cell size may be related to the low resolution of LCMT120-334 crystals. A 
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lot of factors such as protein size, the tightness of the protein packing, protein 
number in asymmetric unit will determine the unite cell size. Therefore, 
dehydration of crystals could remove the excess solvent content, tighten 
packing of the protein molecules and reduce the size of the solvent channel. 
Four methods were employed for LCMT120-334 protein crystals dehydration as 
described in section 2.7.6.3.1. Due to the high concentration of salt in 
crystallization reagent, salt crystallized in very short time and reagent condition 
also changed rapidly. Therefore, the LCMT120-334 crystals were seriously 
damaged in method I and II. In method III, although the reagent was not 
exposed to air, directly transferring crystals to higher concentration of 
precipitants resulted in crystal damage. Finally, LCMT120-334 crystals were 
tested in the last method, method IV, and analyzed using low temperature x-ray 
diffraction (-173 oC). The resolution of crystals was slightly improved but not 
very significantly (Figure 6-3).   
 
In addition, MicroRT™ Capillaries (MiTeGen) were used for salt dehydration of 
LCMT120-334 crystals as described is section 2.7.6.3.1. Each capillary was filled 
with each kind of salt resulting in different relative humidity. For dehydrating the 
protein crystal, the crystal was serially transferred to each capillary for 30 
minutes at room temperature to decrease the relative humidity. Each protein 
crystal was applied to low or room temperature x-ray diffraction. The increased 
mosaicity of diffraction patterns showed that protein crystals were seriously 
impaired through this method (Figure 6-4).  
 
Thus, the dehydration method did not significantly improve the resolution of 
LCMT120-334 crystals and, the protein packing may not be a reason for low 
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diffraction resolution of crystals.  
 
6.2.4  Annealing Method 
 
The uniformity of the unit cells also plays an important role in scattering pattern. 
Disordered unit cell will increase mosaicity and reduce the diffraction resolution. 
Sometimes, crystal annealing method can reduce disorder induced by flash 
cooling. The methods were described in section 2.7.6.3.2. Unfortunately, both 
methods did not improve the resolution of the crystals (Figure 6-5). The 
uniformity of unit cell may not be related to the low resolution problem in 
LCMT120-334 crystals.  
 
6.2.5  Seeding Method 
 
All x-ray diffraction experiments showed that there were always very few 
scattering spots in each diffraction pattern. It may suggest very few unit cells or 
very large unit cell size in one crystal. The low resolution of the data may be a 
consequence of a large size of the unit cell which contains a lot of molecules in 
one asymmetric unit. Therefore, finding a new crystal form may be the only way 
to solve the problem. To achieve this purpose, a seeding method and 
generation of new protein constructs were both tested in search for a new 
crystal form of LCMT1. 
 
To optimize the quality of crystal, seed bead kit (Hampton Research) was used 
in generating seeds of protein crystals. Seeding will assist crystals to form in the 
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metastable zone which provides reproducibility and improvement of a 
crystallization experiment. In addition, by placing a seed or solution of seeds in 
a drop can help crystals, which cannot spontaneously nucleate, to grow from 
seeds and by performing serial dilutions from a concentrated seed stock, one 
can control the number of crystals grown in the drop. The detail of seeding 
method for LCMT120-334 was described in 2.7.6.3.4. Although a lot of crystals 
were formed in different conditions, no new crystal form was observed in the 
screening tray. The hexagon crystals were also analyzed through x-ray 
diffraction; however, no breakthrough was observed in these experiments. 
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Figure 6-2. The Development of LCMT120-334 Protein Crystals. The 
crystallization condition of LCMT120-334 was refined and optimized. The 
diameter of largest protein crystal can reach 0.6 to 0.7 mm. However, the 
resolution of these crystals was not significantly improved. 
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Figure 6-3. The Dehydration Method of LCMT120-334 Crystals through 
Increasing Precipitants. The protein crystals were dehydrated and 
equilibrated over reservoir containing serial increase of concentration of 
precipitant, ammonium sulphate. The x-ray diffraction analysis showed that the 
resolution of protein crystals was not significantly improved. 
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Figure 6-4. The Salt Dehydration Method of LCMT120-334 Protein Crystals. 
The protein crystal was serial situated in each capillary, containing different 
types of salt, for 30 minutes; thus, the relative humidity was serially decreased 
to dehydrate the protein crystal. Here, when the relative humidity reached 82%, 
the protein crystals were starting to crack. Therefore, the potassium chloride 
was used for crystal dehydration. The left and right figure showed the x-ray 
diffraction of crystals at room and cold temperature respectively. Unfortunately, 
both results are not satisfactory. 
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Figure 6-5. Two Anneal Methods for Crystals. Two methods were applied for 
LCMT1 crystal annealing. The method one (up left corner figure) seriously 
damaged the crystals. In method two (down left corner figure), the diffraction 
pattern showed that annealing of crystals did not improve the resolution. 
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6.3  New Constructs  
 
6.3.1  Crystallization of New Construct Protein   
 
The new constructs were designed based on the limited proteolysis method 
and well expressed in E. coli cells as described in section 3.1.1.2 and 3.1.3 The 
LCMT17-334 protein was also set up in crystal trays using the sitting drop method 
through high throughput screening. However, only phase separation could be 
observed in some conditions of screening kits, ammonium sulphate suite and 
PEG suite (Qiagen), which is similar with the condition for LCMT120-334 protein 
crystallization. The LCMT120-334 crystallization buffer was also used and 
adjusted for LCMT17-334 protein. Unfortunately, no crystal was formed in these 
conditions.  
 
LCMT120-334 was not very soluble but could form crystals, whereas LCMT17-334 
was very soluble but no protein crystallization occurred. Combining both 
characters in one construct may be helpful for protein solubility and crystal 
growth. LCMT1SD20-334 was designed based on these two constructs. Like 
LCMT17-334, large amount of LCMT1SD20-334 protein could be harvested from E. 
coli cells. As prediction, this protein could successfully form crystals in several 
conditions with different precipitants (PEG 3350, PEG 5000, PEG 8000, 
ammonium sulfate, or Jeffamine ED-2001) (Fig 3-7). The resolution of crystals 
(1.7 to 2 Å) was also greatly improved. The pentaerythritol ethoxylate was a 
good cryoprotectant for low temperature X-ray diffraction. The crystal from the 
condition, 0.05 M Bis-Tris pH 6.5, 0.05 M ammonium sulfate and 30% 
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pentaerythritol ethoxylate, was chosen for X-ray data collection. 
 
6.3.2  Structure Determination 
  
The images from charged-coupled device (CCD) detectors were processed 
using the program, d*TREK (Rigaku) [246]. A list of Bragg reflections contains 
their Miller indices (h, k, l), the integrated intensities I (hkl), and standard 
deviations, sigma (I). The summary of data collection was list in Table 6.1.  
 
The crystal structure of the human LCMT1 was determined through molecular 
replacement program, Phaser/CCP4 suite [233]. The homology model for the 
core structure of LCMT1 as the starting model was described in section 6.1.  
The initial model covered ~75 % of the amino acid residues, including residues 
62-108, residues 114-137, residues 157-231 and residues 258-321, present in 
the polypeptide chain used to obtain crystals. 
 
After molecular replacement, the structure was refined using RefMac/CCP4 
suite [233]. The final refinement statistics are also listed in Table 6.1.    
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             LCMT1SD20-334 
Data 
Space group 
Unit cells (Å) (a, b, c) 
Resolution ( Å)  
Measured reflections 
Unique reflections 
Completeness (%) 
Rmerge 
I/σ (I) 
                                                                   
Refinement Statistics 
 Resolution Range 
 Rcryst 
 Rfree 
 Mean B factors (Å2)  
 Water molecules 
 r.m.s.d.bond length (Å)  
 r.m.s.d. bond angles (°) 
 Ramachandran plot (%) 
(Favored, allowed, disallowed) 
 
                            
               P212121 
               49.09, 63.30, 81.8  
               17.53-2.0 (2.07-2.0)  
               76195 (4418) 
               17062 (1587) 
               96 (91.2) 
               0.057 (0.335) 
               17.5 (2.2) 
 
               17.53-2.0 (2.07-2.0) 
               0.20 
               0.26 
               32.8 
               138 
               0.016 
               1.6 
               (98.6, 100, 0) 
†Rmerge= ∑h∑i | Ih,i - <Ih> | / ∑h∑i <Ih> where Ih,i is the ith used observation for unique 
hkl h, and  <Ih> is the mean intensity for unique hkl h. ‡ With respect to Engh and 
Hubber parameters (Engh & Hubber, 1991). 
 
 
Table 6.1 Data Collection and Refinement Statistics 
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6.4  The Crystal Structure of Human LCMT1 
 
6.4.1  The Overall Structure of Human LCMT1 
 
Human LCMT1 belongs to the Class I AdoMet-dependent MTase family, a 
member of the FAD/NAD(P) binding Rossmann fold superfamily (Figure 6-6a) 
[279]. The main structural feature of LCMT1 is a seven-stranded β-sheet 
flanked by α-helices, with the core β-strands arranged in the following order, β3, 
β2, β1, β4, β5, β7, and β6. The strands (β1 to β5 and β6) surrounded by the six 
α-helices (αZ and αA to αE) are parallel, whereas β7 is anti-parallel (Figure 
6-6a). In addition to the core domain, several insertions were observed in the 
human LCMT1 structure. Structural insertions in members of the Rossmann 
fold superfamily contain substrate recognition motifs and variations in these 
insertions amongst the methyltransferases are associated with their observed 
differences in substrate specificities [280]. Even orthologous proteins from 
different species exhibit significant differences in these embellishments to the 
core protein fold. Based on the spatial arrangement around the central β-sheet 
in human LCMT1, variations to the core topology can be grouped into three 
regions: the β3-β2 region, the β1-β4-β5 region and the β7-β6 region. In the 
β3-β2 region, helix α3 and strand βA join helix αB to αC to pack against strands 
β3 and β2. Although, other proteins might have embellishments at this site, 
their structures differ significantly.  For example, in the structure of the 
bacterial protein methyltransferase CheR, there is a small subdomain at this 
position, which serves as a point of the attachment to its membrane associated 
substrate [281]. In the β1-β4-β5 region, helices α4, α1 and α2 are placed at the 
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C-terminal edge of the central β-sheet, near the entrance to the enzyme active 
site.  Location of the N-terminal helices α1 and α2 is similar to the location of 
the N-terminal regions in other methyltransferases, where they have been 
implicated in substrate recognition [281].   In the β7-β6 region, three helices, 
α5, α6 and α7, create a topological insertion arranged in a triangular fashion, 
while packing against helix αZ through hydrophobic interactions. Helices α1, α5, 
α6 and α7, as well as the associated connecting loops, are all in the vicinity of 
helix αZ such that they completely bury the N-terminal end of the helix αZ inside 
the hydrophobic core of the protein (Figure 6-6b). The role of the described 
topological additions and insertions to the Rossmann fold is dual: it is both 
structural, in providing the stabilizing hydrophobic environment for the central 
β-sheet, and functional, in creating the platform for the site of the specific 
interactions with the substrate, in this case the PP2A molecule.  The crystal 
structure of human LCMT1 is missing a 26-residues long polypeptide fragment 
that would represent the fourth site of the topological insertions, located 
between strand β5 and the helix αE and this part of the structure would also be 
placed at the C-terminal edge of the central β-sheet thus forming the entrance 
to the active site together with other described inserted structural elements 
(Figure 6-7). The corresponding region in the yeast structure, labeled αY in 
Figure 6-7, exhibited great flexibility and it is tempting to postulate that this 
domain acts as a lid for the active site that enables substrate interaction and 
that might become ordered upon binding of PP2A. Superimposition of PPM1 
structure including that region on the structure of LCMT1 indicates that the 
region could not be accommodated within the same crystal form of LCMT1, as it 
would interfere with crystal packing, which might explain the difficulty in 
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crystallizing the full-length form of the protein.   
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Figure 6-6. The Overall Structure of LCMT1. (a) Topology diagram of human leucine carboxyl methyltransferase 1. (b) The core 
structure of LCMT1 containing a seven-stranded β sheet (β3, β2, β1, β4, β5, β7, and β6) flanked by six α-helices (αZ and αA to αE) 
belongs to the Class I AdoMet-dependent methyltransferase 1 family. The colours of secondary structure elements are represented 
as follows: the core structure of methyltransferases, green; insertions in the β3-β2 region, yellow; the insertion in the β1-β4-β5 region, 
cyan; the insertion in the β7-β6 region, pink. A ribbon diagram of LCMT1 generated with PyMOL viewer (DeLano Scientific LLC). The 
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same colour scheme was used as in Fig. 1A. (c) Detailed view of the structural embellishments to the core methyltransferase domain: 
region β3-β2 (α3 and βA), β1-β4-β5 (α1, α2 and α4), and β7-β6 (α5, α6, α7 and α8). 
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Figure 6-7. Comparison of Human LCMT1 and Yeast PPM1. The sequence 
alignment, based on the superimposition of yeast PPM1 and human LCMT1 
structure, is shown on the top of the figure. The secondary structure elements 
of human LCMT1 and yeast PPM1 are indicated above the aligned sequences. 
The colour assignment for the secondary structure of human LCMT1 is the 
same as in Fig.1. Dashed lines coloured black and red represent gaps in the 
sequence alignment or protein loops, respectively. The amino acid residues 
coloured in blue are associated with AdoMet. The Saccharomyces cerevisiae 
PPM1(1RJD) (orange) and human LCMT1 (green) structures were 
superimposed using Coot 0.6.1. Helix αY in the yeast PPM1 structure is absent 
from the LCMT1 structure and it was replaced by the EG dipeptide. 
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6.4.2  Comparison of Human LCMT1 with Yeast PPM1 
 
The molecular replacement method was utilized to solve the crystal structure of 
human LCMT1 using the crystal structure of yeast PPM1 (PDB id 1RJG) [223] 
to generate a starting model for the rotation/translation function searches. Initial 
attempts to solve the structure with a PPM1-based homology model of LCMT1 
failed and the successful solution was obtained only with a greatly stripped 
model of LCMT1. Specifically, the successful molecular replacement model 
contained the core structure corresponding to the residues 61-321 with all 
loop/insertion regions removed. The omitted residues were subsequently built 
into the electron density maps during the process of model building and 
refinement.  The superimposition of the structures of human LCMT1 and S. 
cerevisiae PPM1 (1RJD), using the program Coot 0.6.1 [253], shows that the 
core regions of the two proteins are very similar, with a root mean square 
distance of 1.3 Å for 231 Ca-atoms of the aligned residues despite a relatively 
low sequence identity for the overlapping sequence (~30 %) (Figure 6-7).  As 
expected, the structures exhibit main differences within the associated variable 
segment. For example, in the β1-β4-β5 region of the human LCMT1 core 
structure, a short helix α2 is flanked by two flexible long loops, whereas in the 
same area of yeast PPM1, this part is replaced by a long α helix with a sharp 
kink in the middle giving the appearance of two helices (Figure 6-7). In contrast, 
helix α1 within this insertion is strongly conserved in its topology and sequence 
between LCMT1 and PPM1, most likely due to the direct participation of this 
helix in the formation of the AdoMet binding site.  Additional variations include 
conformational differences of the α3-loop-βA connection between the helix αB 
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and strand β3, significant differences in lengths and relative orientation of the 
C-terminal helices α5, α6, and α7, and the presence of an additional single 
helical turn α8 at the C-terminal end of LCMT1 (Figure 6-7). Clearly, the 
structural differences reflect species-specific determinants of protein-protein 
interactions with the respective partner substrates or potential regulatory 
proteins. 
 
6.4.3  S-adenosylmethionine Binding Site 
 
An initial electron density map, following the successful molecular replacement 
solution, was examined for any un-modeled electron density within the core of 
the LCMT1 structure and we could clearly identify the position and 
conformation of the AdoMet molecule that was included in the crystallization 
(Figure 6-8a). The cofactor adopts an extended conformation that is commonly 
found in AdoMet-dependent methyltransferases and the superimposition of 
AdoMet binding sites of human LCMT1 and that of yeast PPM1 shows that 
residues interacting with AdoMet are highly conserved between two proteins 
(Figure 6-8b). The adenine ring of the bound AdoMet is sandwiched between 
hydrophobic residues Phe123 and Leu172 in LCMT1, while the equivalent 
residues in the PPM1 structure are Tyr129 and Leu176. Similarly, as it is the 
case in many other nucleotide-binding proteins, hydroxyl oxygen atoms from 
the ribose moiety are positioned in the active site through interaction with the 
acidic residue, Asp122 in LCMT1, specifically. At the other end of the AdoMet 
molecule, the carboxylate group is engaged in an ionic interaction with the 
conserved residues Lys37 (α1) and Arg73 (αZ) while the amino group forms 
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hydrogen bonds with the backbone carbonyl oxygen from Gly98 (β1-αA 
connection) and Glu198 (β4) (Figure 6-8b). However, further away from the 
zone of direct interaction with AdoMet but lining the cavity that creates the 
binding pocket for the cofactor, there are some significant differences such as 
the presence of Ile126 in LCMT1 in place of Ser132 in PPM1, Val200 in LCMT1 
instead of Leu203 in PPM1, or Arg173 at the top of the adenine ring in LCMT1, 
compared to Asn177 at the equivalent position of PPM1. 
 
In the structure of human LCMT1 presented here, AdoMet does not appear fully 
buried into the active site with the side of the cofactor containing the activated 
methyl group being relatively exposed – AdoMet has a contact area of 17 Å2 as 
calculated by AreaMol/CCP4 [233]. In contrast, in the structure of yeast PPM1 
(1RJD), AdoMet is covered by the beginning of the N-terminal helix α1, which is 
partially unraveled in the structure of LCMT1.  Although the full-length LCMT1 
protein contains an additional 20 residues at the N-terminus, the sequence 
content of that N-terminal segment, dominated by Ser and Cys residues, would 
suggest that the region is unstructured, at least in the absence of substrate, and, 
thus, we do not anticipate that the N-terminal residues would be occluding 
AdoMet in the context of the full-length protein. Partially exposed AdoMet and 
the surrounding funnel shaped opening indicate an entry site for the carboxyl 
terminal motif of the PP2A catalytic subunit (T304PDYFL309) which is methylated 
by LCMT1 on the terminal carboxyl group to form an alpha-leucine ester 
modification (Figure 6-8c).  Examination of a molecular surface of PPM1 
identifies a deep and narrow grove that leads toward the only exposed side of 
the cofactor – an activated methyl group of the bound AdoMet molecule (Figure 
 257 
6-9a).  The equivalent orientation of the human LCMT1 molecular surface 
reveals a similar groove, strongly suggesting that an extended form of the 
PP2AC C-terminus might approach AdoMet through that site. 
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Figure 6-8. Active Site of Human LCMT1. (a) The electron density of AdoMet 
can be clearly observed in the sigma-weighted (2mFo-DFc, αc) electron density 
map calculated with the initial model after the molecular replacement solution 
was obtained.  The model at that stage included only 75 % of the residues and 
no AdoMet. The map is shown at a level of 1.0 σ (0.33e/Å3) with the final refined 
coordinates for LCMT1 overlaid. (b) Superimposition of the human LCMT1 
(green) and yeast PPM1 (orange) structures shows conservation of the AdoMet 
binding site. Several hydrogen bonds between AdoMet and human LCMT1 
residues are indicated in dashed lines. Residue numbers corresponding to 
PPM1 are shown in brackets. (c) The putative PP2A binding site is indicated on 
the superimposed structures of human LCMT1 and yeast PPM1. The site of 
excision of residues 232 to 259 and replacement by EG linker in human LCMT1 
is also indicated.  
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Figure 6-9. Model of the protein-protein interaction with PP2A. (a) 
Qualitative representation of the surface electrostatic potential of LCMT1 was 
generated in PyMOL viewer (DeLano Scientific LLC). Molecular surfaces of 
yeast PPM1 (left) and human LCMT1 (right) shown in the equivalent 
orientations reveal narrow grooves providing access to the cofactor.  AdoMet 
is shown as van der Waals spheres representation with atoms of carbon, 
sulphur, oxygen and nitrogen coloured green, yellow, red and blue respectively.  
In both images an activated methyl group bound to the sulphur atom is visible.  
Above the active sites in both molecules, there are areas of positively charged 
surface (blue region) suggesting an additional site of association with PP2A. (b) 
Areas of negative surface potential of PP2AD (red) that might be involved in 
binding LCMT1. (c) Isothermal titration calorimetry experiments revealed no 
effective binding between PP2AA subunit and LCMT1. 
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6.4.4  Putative Mode of PP2A Interaction with LCMT1 
 
Over the past several years, the structures of several proteins forming 
complexes with PP2A have been determined, including the structure of the 
holoenzyme with the B’ (PR61) [17,19] or B (PR55) subunits [24], the structure 
of SV40 small-T antigen in complex with the PP2A scaffolding subunit (PP2AA) 
[217] and methylesterase PME1 with the PP2A
 
core enzyme (PP2AD) [221], 
and these structures can provide some clues regarding LCMT1 interaction with 
PP2A. While B’ (PR61), B (PR55) and SV40 small-T antigen associate with 
both catalytic PP2AC and scaffolding PP2AA subunits, PME1 was observed to 
interact only with PP2AC. The PP2AA subunit, which is composed of HEAT 
repeats, uses different sets of these repeats for intermolecular interactions with 
various partners, such that HEAT repeats 2, 4 and 5 are involved in the 
PR61-PP2AA interaction, whereas HEAT repeats 3 to 7 are associated with the 
PR55-PP2AA interaction. The SV40 small-T antigen, on the other hand, 
interacts with the intra-HEAT-repeat loops of HEAT repeats 3-7 of the PP2AA 
subunit. The association of PP2AC with various regulatory proteins is even 
more diverse, due to the different functions that these proteins perform.    
 
Although it is the C-terminal carboxyl group of the PP2AC subunit that is 
methylated, the substrate for the LCMT1 enzyme is a PP2AD core enzyme – a 
complex between the A and C subunits.  Furthermore, LCMT1 does not exhibit 
any activity towards the synthetic peptide corresponding to the conserved 
C-terminal motif of the PP2AC, suggesting that LCMT1 would also need to 
recognize other molecular features of PP2A in addition to Leu309.  LCMT1 
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might use protein/protein interactions to orient its active site appropriately 
towards the C-terminus of PP2AC which, otherwise, would be a poor substrate 
and this mode of interaction might involve recognition of specific surfaces on 
the A subunit or a direct interaction with the C subunit at a site additional to that 
of the C-terminus, in a fashion similar to that seen for the methylesterase PME1 
[221].  Qualitative examination of the electrostatic surface potential of LCMT1 
reveals a positively charged area of the protein (Figure 6-9a) just above the 
deep groove leading to the cofactor. This surface is formed by the helices α2, 
αB and the flexible loop linking α2 to αZ of human LCMT1. Examination of the 
electrostatic surface potential of the core PP2AD enzyme reveals two 
complementary negatively charged regions, one on the C subunit and another 
formed by the C-terminus of PP2AC and the N-terminal HEAT repeats of the A 
subunit, suggesting that either of these regions might be involved in 
protein/protein interaction with LCMT1 (Figure 6-9b).  However, isothermal 
titration calorimetry experiments with 100 µM full length LCMT1 did not detect 
any association between LCMT1 and PP2AA as no significant heat change was 
observed (Figure 6-9c). Thus, we would suggest that either the binding 
constant for PP2AA is very low, contrary to what would be expected for the 
proposed charge-charge surface interaction, or that LCMT1 might only 
associate with PP2AC. Further verification of this model is needed. 
 
6.5  Summary 
 
LCMT120-334 was the only protein product that was crystalized in complex with 
the co-factor, S-adenosylmethionine from the optimized crystallization 
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conditions of 0.1 M Na-citrate (pH 6.5), 1.6 M ammonium sulphate, 0.38 M 
Na-K tartrate, 2 % PEG 400, 4 % acetone and 5 mM DTT at 22 oC. However, 
these crystals diffracted only to 7 Å and were not suitable for structure 
determination. Several methods were used to improve diffraction quality of the 
crystals including additive screening method (Hampton Research), dehydration 
using MicroRT™ Capillaries (MiTeGen), crystal annealing and seeding method 
(Hampton Research) but neither method was successful in improving 
diffraction pattern suggesting that additional protein constructs would need to 
be considered for crystallization in order to obtain a different crystal form.  
 
New constructs were designed based on secondary structure prediction and 
limited proteolysis. The crystals from the variant LCMT1SD20-334 protein were 
also successfully developed in various precipitant buffers. A single crystal from 
one of the conditions (0.05 ammonium sulphate, 0.05 M Bis-Tris chloride pH 
6.5, 30 % pentaerythritol ethoxylate) was used to collect diffraction data that 
were used to solve the structure.  
 
Crystal structure of human LCMT1 exhibits strong conservation of the core of 
the globular structure including the AdoMet binding site.  Unique structural 
elements that represent variation to the common topology are most likely 
involved in protein/protein interactions with its substrate – the catalytic subunit 
of the key cellular phosphatase PP2A. LCMT1 is involved in regulation of 
methylation-dependent PP2A holoenzyme assembly however the full 
implications of this modification are not well understood.  The crystal structure 
of LCMT1 could be exploited for the development of the specific inhibitors that 
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would be used as molecular tools for investigation of PP2A methylation in vivo. 
The truncated form of enzyme that we described here is very soluble and 
crystallized under a range of conditions thus it would provide an excellent 
platform for the crystallographic studies of the putative inhibitors. 
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Chapter Seven 
 
Conclusions and Discussion 
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Protein phosphatase 2A is an important protein involved in several essential 
cellular mechanisms that has been a subject of investigation for many years 
[10,74,75]. Cancers and Alzheimer’s disease were related to de-regulation of 
PP2A [96-100]. In addition, two main modes of regulation of PP2A, 
phosphorylation and methylation, were studied for almost two decades. 
Phosphorylation at Tyr307 of PP2AC leads to the inactivation of PP2A [50-53]; 
however, the role of methylation and demethylation, carried out by LCMT1 and 
PME1 respectively, at Leu309 of PP2AC was debated for several years. More 
recently, it was demonstrated that the methylation state of the catalytic subunit 
is a key mechanism for the assembly of a PP2A holoenzyme [72]. 
 
Tight binding of PME1 to PP2A was demonstrated in vivo several years ago 
together with the role of PME1 in de-methylation and stabilization of PP2AC [63]. 
Recently, the three-dimensional structure of PME1 and PP2A was determined 
suggesting that in the trimeric complex of PP2AA, PP2AC and PME1, as 
expected, PP2AC is in contact with the methylesterase but there  was no 
interaction observed between PP2AA and PME1 [221]. In contrast, our SPR 
and ITC studies showed direct association of PP2AA with PME1 and the 
thermodynamic parameters of this interaction were obtained. To gain an insight 
into the molecular characteristics of PME1 interaction with PP2AA, ITC 
experiments were carried out at different temperatures and saline buffers. 
Positive heat capacity change suggests that interaction between PME1 and 
PP2AA is via polar residues. Increasing the concentration of salt interferes with 
the electrostatic nature of interaction between PME1 and PP2AA. Finally, the 
truncated PME1, PME139-376, loses its ability to associate with PP2AA due to the 
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deletion of an important amino acid segment (residues 239-282)  that is most 
likely required for interaction.  
 
In the crystallographic structure of PME1-PP2A complex, a large space 
between truncated PME1 and PP2AA can be clearly observed and, in the 
context of a complex that would be formed between the full-length PME1 and 
PP2AA, it might accommodate the truncated polypeptide segment (residues 
239-282) of PME1. To support this assumption, the structure of PP2A–PR61 
[17,19], SV40 small t antigen-PP2AA [217] and PP2A-PME1 complex [221] 
were superimposed and analyzed (Fig 7-1). Although no structural similarity 
was found among PR61, SV40 small t antigen and PME1, PR61 and SV40 
small t antigen interact with PP2AA at similar HEAT repeats region. HEAT 
repeats 2, 4 and 5 are involved in PR61-PP2A interaction and SV40 small t 
antigen interacts with the intra-loops of HEAT repeats 3-7 of PP2AA.  HEAT 
repeats 3 to 7 are positioned beneath the proposed space for the truncated 
segment (residues 239-282) of PME1. Additionally, the superimposition shows 
that this space bellow the residues 238 and 283 of PME1 is occupied by two α 
helices of PR61 in a structure of a complex of PP2A with PR61. Secondary 
structure prediction of PME1 using PSIPRED indicates that the truncated 
segment (residues 239-282) of PME1 is composed of two α helices connected 
by a loop. Thus I would propose that HEAT repeats 3 to 7 of PP2AA are not only 
the target for PR61 and SV 40 small t antigen, but also the site of PP2AA 
interaction with for PME1.  
 
It would be necessary to determine the three-dimensional structure of the full 
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length PME1 in a complex with PP2A in order to fully describe molecular basis 
of their interaction. Further efforts will be made to isolate full length 
PME1-PP2AA complex for crystallization studies. Data described in this thesis 
imply that PME1 which can interact individually with either PP2AA or PP2AC 
may play additional role in the mechanism of PP2A regulation.  
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Figure 7-1. The superimposition and comparison of PP2A complexes. The 
structure of PP2A–PR61 (PDB: 2NYM), SV40 small t antigen-PP2AA (PDB: 
2PKG) and PP2A-PME1 (PDB: 3C5W) complex were superimposed using 
CCP4mg program. PR61 and SV40 small t antigen interact with PP2AA at 
similar region, HEAT repeats 3 to 7. A large space (black square) observed 
beneath the residues cys238 and lys283 may be occupied by the missing 
polypeptide segment (residues 239-282) in a complex between the full-length 
PME1 and PP2A. Hence, PME1 may also interact with PP2AA at HEAT repeats 
3 to 7.   
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High resolution diffracting crystals of human LCMT1 crystals were generated. 
The crystal structure of human PP2A LCMT1 exhibits strong conservation of 
the core of the globular structure including the AdoMet binding site.  Unique 
structural elements that represent variation to the common topology are most 
likely involved in protein/protein interactions with its substrate – the catalytic 
subunit of the key cellular phosphatase PP2A. The crystal structure of LCMT1 
could be exploited for the development of the specific inhibitors that would be 
used as molecular tools for investigation of PP2A methylation in vivo. The 
truncated form of the enzyme that we described here is very soluble and 
crystallized under a range of conditions thus it would provide an excellent 
platform for the crystallographic studies of the putative inhibitors.  Furthermore 
inhibition of LCMT1 might have therapeutic potential in cancer, as it was shown 
that LCMT1 is required for cell cycle progression and cell survival. 
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